EP3868878A2 - Protein degradation inducing tag and usage thereof - Google Patents
Protein degradation inducing tag and usage thereof Download PDFInfo
- Publication number
- EP3868878A2 EP3868878A2 EP20215603.0A EP20215603A EP3868878A2 EP 3868878 A2 EP3868878 A2 EP 3868878A2 EP 20215603 A EP20215603 A EP 20215603A EP 3868878 A2 EP3868878 A2 EP 3868878A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein
- degradation
- degradation inducing
- tmp
- cikd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001939 inductive effect Effects 0.000 title claims abstract description 484
- 230000017854 proteolysis Effects 0.000 title claims abstract description 477
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 428
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 426
- 239000004365 Protease Substances 0.000 claims abstract description 257
- 108091005804 Peptidases Proteins 0.000 claims abstract description 207
- 230000015556 catabolic process Effects 0.000 claims abstract description 140
- 238000006731 degradation reaction Methods 0.000 claims abstract description 140
- 238000000034 method Methods 0.000 claims abstract description 133
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 80
- 230000034512 ubiquitination Effects 0.000 claims abstract description 11
- 238000010798 ubiquitination Methods 0.000 claims abstract description 11
- 230000000593 degrading effect Effects 0.000 claims abstract description 8
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 14
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 148
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 148
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 37
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 32
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 30
- 239000004615 ingredient Substances 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 230000036953 caspase-like activity Effects 0.000 claims description 11
- 230000037012 chymotrypsin-like activity Effects 0.000 claims description 11
- 230000001810 trypsinlike Effects 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 9
- 241000894006 Bacteria Species 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 241000206602 Eukaryota Species 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 229930014626 natural product Natural products 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 235000012041 food component Nutrition 0.000 claims description 2
- 239000005417 food ingredient Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 229940070376 protein Drugs 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 225
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 203
- 102000035195 Peptidases Human genes 0.000 description 193
- 235000019419 proteases Nutrition 0.000 description 171
- 235000018102 proteins Nutrition 0.000 description 147
- 239000000243 solution Substances 0.000 description 138
- 229960001467 bortezomib Drugs 0.000 description 102
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 102
- 241000588724 Escherichia coli Species 0.000 description 85
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 80
- 108020001096 dihydrofolate reductase Proteins 0.000 description 80
- 201000010099 disease Diseases 0.000 description 66
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 66
- 239000012528 membrane Substances 0.000 description 55
- 108010088842 Fibrinolysin Proteins 0.000 description 53
- 229940012957 plasmin Drugs 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 48
- 108090000190 Thrombin Proteins 0.000 description 48
- 229960004072 thrombin Drugs 0.000 description 48
- 108090000317 Chymotrypsin Proteins 0.000 description 46
- 229960002376 chymotrypsin Drugs 0.000 description 46
- 239000013612 plasmid Substances 0.000 description 46
- 239000000126 substance Substances 0.000 description 45
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 43
- 108090000526 Papain Proteins 0.000 description 42
- 238000001962 electrophoresis Methods 0.000 description 42
- 235000019834 papain Nutrition 0.000 description 42
- 229940055729 papain Drugs 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 41
- 239000003112 inhibitor Substances 0.000 description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
- 108090000631 Trypsin Proteins 0.000 description 35
- 102000004142 Trypsin Human genes 0.000 description 35
- 239000012588 trypsin Substances 0.000 description 35
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 33
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 32
- 108090000712 Cathepsin B Proteins 0.000 description 32
- 102000004225 Cathepsin B Human genes 0.000 description 32
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 32
- 229940079156 Proteasome inhibitor Drugs 0.000 description 32
- 239000003207 proteasome inhibitor Substances 0.000 description 32
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- 239000002609 medium Substances 0.000 description 30
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 29
- 108060005987 Kallikrein Proteins 0.000 description 28
- 102000001399 Kallikrein Human genes 0.000 description 28
- 238000012216 screening Methods 0.000 description 28
- 238000001262 western blot Methods 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 238000011156 evaluation Methods 0.000 description 26
- 239000002953 phosphate buffered saline Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 108010067372 Pancreatic elastase Proteins 0.000 description 24
- 102000016387 Pancreatic elastase Human genes 0.000 description 24
- 235000020183 skimmed milk Nutrition 0.000 description 23
- 230000015572 biosynthetic process Effects 0.000 description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 21
- 235000019833 protease Nutrition 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 21
- 238000002849 thermal shift Methods 0.000 description 21
- 0 CC(C)C[C@@](*)NC(CNC(C1=C(*)C#CCC(*)=C1)=[U])=O Chemical compound CC(C)C[C@@](*)NC(CNC(C1=C(*)C#CCC(*)=C1)=[U])=O 0.000 description 20
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 20
- 239000000872 buffer Substances 0.000 description 20
- 239000005090 green fluorescent protein Substances 0.000 description 20
- 102000005367 Carboxypeptidases Human genes 0.000 description 19
- 108010006303 Carboxypeptidases Proteins 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 101000588067 Homo sapiens Metaxin-1 Proteins 0.000 description 18
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 18
- 229930182816 L-glutamine Natural products 0.000 description 18
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 108090000270 Ficain Proteins 0.000 description 17
- 108010059712 Pronase Proteins 0.000 description 17
- 235000019836 ficin Nutrition 0.000 description 17
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 102000005572 Cathepsin A Human genes 0.000 description 15
- 108010059081 Cathepsin A Proteins 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 15
- 229960003648 ixazomib Drugs 0.000 description 15
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- YSOKXDUFQIWMQV-UHFFFAOYSA-N Chymostatin C Natural products CCCCC(NC(=O)CNC(=O)NC(Cc1ccccc1)C(=O)O)C(=O)NC(Cc2ccccc2)(C=O)C3CCNC(=N3)N YSOKXDUFQIWMQV-UHFFFAOYSA-N 0.000 description 14
- 239000004471 Glycine Substances 0.000 description 14
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 239000003656 tris buffered saline Substances 0.000 description 14
- 238000005406 washing Methods 0.000 description 14
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 14
- 108010080937 Carboxypeptidases A Proteins 0.000 description 13
- 102000000496 Carboxypeptidases A Human genes 0.000 description 13
- 235000002597 Solanum melongena Nutrition 0.000 description 13
- 229960005051 fluostigmine Drugs 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 238000000926 separation method Methods 0.000 description 13
- 108010004032 Bromelains Proteins 0.000 description 12
- 108090000087 Carboxypeptidase B Proteins 0.000 description 12
- 102000003670 Carboxypeptidase B Human genes 0.000 description 12
- 108090000258 Cathepsin D Proteins 0.000 description 12
- 102000003908 Cathepsin D Human genes 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 108090000284 Pepsin A Proteins 0.000 description 12
- 102000057297 Pepsin A Human genes 0.000 description 12
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 12
- 235000019835 bromelain Nutrition 0.000 description 12
- 238000010899 nucleation Methods 0.000 description 12
- 229940111202 pepsin Drugs 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 12
- SUGXUUGGLDCZKB-UHFFFAOYSA-N 3,4-dichloroisocoumarin Chemical compound C1=CC=C2C(Cl)=C(Cl)OC(=O)C2=C1 SUGXUUGGLDCZKB-UHFFFAOYSA-N 0.000 description 11
- FMYKJLXRRQTBOR-BZSNNMDCSA-N acetylleucyl-leucyl-norleucinal Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O FMYKJLXRRQTBOR-BZSNNMDCSA-N 0.000 description 11
- 230000003197 catalytic effect Effects 0.000 description 11
- 210000004748 cultured cell Anatomy 0.000 description 11
- 108010007093 dispase Proteins 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 10
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 10
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 10
- 108090000028 Neprilysin Proteins 0.000 description 10
- 102000003729 Neprilysin Human genes 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 108010021843 fluorescent protein 583 Proteins 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 10
- 108010052968 leupeptin Proteins 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000012096 transfection reagent Substances 0.000 description 10
- 108010087765 Antipain Proteins 0.000 description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 9
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 108030000958 Cytosol alanyl aminopeptidases Proteins 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 102000001398 Granzyme Human genes 0.000 description 8
- 108060005986 Granzyme Proteins 0.000 description 8
- 239000002033 PVDF binder Substances 0.000 description 8
- 102100033192 Puromycin-sensitive aminopeptidase Human genes 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 7
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 7
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 108090000848 Ubiquitin Proteins 0.000 description 7
- 102000044159 Ubiquitin Human genes 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 238000010230 functional analysis Methods 0.000 description 7
- 238000003209 gene knockout Methods 0.000 description 7
- 239000012723 sample buffer Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 6
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 6
- CUVGUPIVTLGRGI-UHFFFAOYSA-N 4-(3-phosphonopropyl)piperazine-2-carboxylic acid Chemical compound OC(=O)C1CN(CCCP(O)(O)=O)CCN1 CUVGUPIVTLGRGI-UHFFFAOYSA-N 0.000 description 6
- 229940121926 Calpain inhibitor Drugs 0.000 description 6
- 102100035037 Calpastatin Human genes 0.000 description 6
- 108090000624 Cathepsin L Proteins 0.000 description 6
- 102000004172 Cathepsin L Human genes 0.000 description 6
- 101100278853 Mus musculus Dhfr gene Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 102100032491 Serine protease 1 Human genes 0.000 description 6
- 101710151387 Serine protease 1 Proteins 0.000 description 6
- 108090001109 Thermolysin Proteins 0.000 description 6
- 101710119665 Trypsin-1 Proteins 0.000 description 6
- 108010091545 acetylleucyl-leucyl-norleucinal Proteins 0.000 description 6
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical compound [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 6
- 125000005382 boronyl group Chemical group 0.000 description 6
- 108010079785 calpain inhibitors Proteins 0.000 description 6
- 108010044208 calpastatin Proteins 0.000 description 6
- 108010054847 carboxypeptidase P Proteins 0.000 description 6
- 108090001092 clostripain Proteins 0.000 description 6
- 229910001873 dinitrogen Inorganic materials 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 229940054269 sodium pyruvate Drugs 0.000 description 6
- 229960002385 streptomycin sulfate Drugs 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102000005600 Cathepsins Human genes 0.000 description 5
- 108010084457 Cathepsins Proteins 0.000 description 5
- BEUQWPLRPXILQA-UHFFFAOYSA-N Chymostatin B Natural products CCCC(NC(=O)CNC(=O)NC(Cc1ccccc1)C(=O)O)C(=O)NC(Cc2ccccc2)(C=O)C3CCNC(=N3)N BEUQWPLRPXILQA-UHFFFAOYSA-N 0.000 description 5
- 101710131551 Chymotrypsin-like serine proteinase Proteins 0.000 description 5
- 102100020750 Dipeptidyl peptidase 3 Human genes 0.000 description 5
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 5
- 101000931862 Homo sapiens Dipeptidyl peptidase 3 Proteins 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 5
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 239000013024 dilution buffer Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- HKIPCXRNASWFRU-UHFFFAOYSA-N 1,3-difluoropropan-2-one Chemical compound FCC(=O)CF HKIPCXRNASWFRU-UHFFFAOYSA-N 0.000 description 4
- 229940126695 20S proteasome inhibitor Drugs 0.000 description 4
- MQWCXKGKQLNYQG-UHFFFAOYSA-N 4-methylcyclohexan-1-ol Chemical compound CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 4
- 229940097396 Aminopeptidase inhibitor Drugs 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 4
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 4
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 4
- 102400000925 Opiorphin Human genes 0.000 description 4
- TWWFCOBVAKAKIT-SXYSDOLCSA-N Opiorphin Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)N)CC1=CC=CC=C1 TWWFCOBVAKAKIT-SXYSDOLCSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 231100000676 disease causative agent Toxicity 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 229950000501 gabexate Drugs 0.000 description 4
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 108010074283 glutaminyl-arginyl-phenylalanyl-seryl-arginine Proteins 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 229960003330 pentetic acid Drugs 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- -1 trochiscus Substances 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- XYXYXSKSTZAEJW-VIFPVBQESA-N (2s)-2-(phenylmethoxycarbonylamino)butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 XYXYXSKSTZAEJW-VIFPVBQESA-N 0.000 description 3
- AXTKTZHLZLOIIO-PBEPODTISA-N (4s)-4-[[(2s,3s)-2-acetamido-3-methylpentanoyl]amino]-5-[[(2s,3r)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C=O AXTKTZHLZLOIIO-PBEPODTISA-N 0.000 description 3
- 102100032126 Aminopeptidase B Human genes 0.000 description 3
- XGDFITZJGKUSDK-UDYGKFQRSA-N Bestatin (hydrochloride) Chemical compound Cl.CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 XGDFITZJGKUSDK-UDYGKFQRSA-N 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 102000056189 Neutrophil collagenases Human genes 0.000 description 3
- 108030001564 Neutrophil collagenases Proteins 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 108020004459 Small interfering RNA Proteins 0.000 description 3
- 238000005411 Van der Waals force Methods 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 3
- XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 3
- XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 3
- 108090000449 aminopeptidase B Proteins 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000008004 cell lysis buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 108090000212 dipeptidyl peptidase II Proteins 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 108010091212 pepstatin Proteins 0.000 description 3
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- HBEJJYHFTZDAHZ-QMMMGPOBSA-N tert-butyl (2s)-2-amino-4-methylpentanoate Chemical compound CC(C)C[C@H](N)C(=O)OC(C)(C)C HBEJJYHFTZDAHZ-QMMMGPOBSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GBDUPCKQTDKNLS-PORDUOSCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-3-amino-2-hydroxy-5-methylhexanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid;hydron;chloride Chemical compound Cl.CC(C)C[C@@H](N)[C@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O GBDUPCKQTDKNLS-PORDUOSCSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- WQAVPPWWLLVGFK-VTNASVEKSA-N (2s)-3-(4-methoxyphenyl)-n-[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1=CC(OC)=CC=C1C[C@@H](C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)NC(=O)[C@H](C)NC(=O)CN1CCOCC1 WQAVPPWWLLVGFK-VTNASVEKSA-N 0.000 description 2
- TVTYMGFOGZRIHG-XUXIUFHCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(C)=O TVTYMGFOGZRIHG-XUXIUFHCSA-N 0.000 description 2
- JUWDSDKJBMFLHE-UHFFFAOYSA-N 1-[1-(4-fluorophenyl)-2,5-dimethylpyrrol-3-yl]-2-pyrrolidin-1-ylethanone Chemical compound CC=1N(C=2C=CC(F)=CC=2)C(C)=CC=1C(=O)CN1CCCC1 JUWDSDKJBMFLHE-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 2
- FJPHHBGPPJXISY-UHFFFAOYSA-N 2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCCC(C(O)=O)NC(=O)C(NC(=O)CNC(=O)CN)CC1=CC=C(O)C=C1 FJPHHBGPPJXISY-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
- UMBVAPCONCILTL-MRHIQRDNSA-N Ac-Asp-Glu-Val-Asp-H Chemical compound OC(=O)C[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(C)=O UMBVAPCONCILTL-MRHIQRDNSA-N 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- LZJRNLRASBVRRX-ZDUSSCGKSA-N Boldine Chemical compound CN1CCC2=CC(O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-ZDUSSCGKSA-N 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 108010032088 Calpain Proteins 0.000 description 2
- 102000007590 Calpain Human genes 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000567 Caspase 7 Proteins 0.000 description 2
- 101710090333 Caspase-5 Proteins 0.000 description 2
- 102100038916 Caspase-5 Human genes 0.000 description 2
- 102100038902 Caspase-7 Human genes 0.000 description 2
- 229940123329 Cathepsin B inhibitor Drugs 0.000 description 2
- 108090000267 Cathepsin C Proteins 0.000 description 2
- 102000003902 Cathepsin C Human genes 0.000 description 2
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 description 2
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 description 2
- 102000017284 Collagenase 3 Human genes 0.000 description 2
- 108010028774 Complement C1 Proteins 0.000 description 2
- 108010078044 Complement C1r Proteins 0.000 description 2
- 102100030149 Complement C1r subcomponent Human genes 0.000 description 2
- 102100025406 Complement C1s subcomponent Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108090000059 Complement factor D Proteins 0.000 description 2
- 102100035436 Complement factor D Human genes 0.000 description 2
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010079844 PR-957 Proteins 0.000 description 2
- 101710193050 Papain inhibitor Proteins 0.000 description 2
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 2
- 229940122791 Plasmin inhibitor Drugs 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 108010038177 acetyl-tryptophyl-glutamyl-histidyl-aspartal Proteins 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- CAILNONEKASNSH-UHFFFAOYSA-N benzyl n-[1-[(4-fluoro-3-oxo-1-phenylbutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C=1C=CC=CC=1CC(NC(=O)OCC=1C=CC=CC=1)C(=O)NC(C(=O)CF)CC1=CC=CC=C1 CAILNONEKASNSH-UHFFFAOYSA-N 0.000 description 2
- 108010018550 caspase 13 Proteins 0.000 description 2
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 2
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 2
- HJKBJIYDJLVSAO-UHFFFAOYSA-L clodronic acid disodium salt Chemical class [Na+].[Na+].OP([O-])(=O)C(Cl)(Cl)P(O)([O-])=O HJKBJIYDJLVSAO-UHFFFAOYSA-L 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 2
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000002792 enkephalinase inhibitor Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000003540 gamma secretase inhibitor Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229950002736 marizomib Drugs 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002806 plasmin inhibitor Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 2
- 230000004063 proteosomal degradation Effects 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 108010059339 submandibular proteinase A Proteins 0.000 description 2
- QOISWWBTZMFUEL-NSHDSACASA-N tert-butyl (2s)-2-amino-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)[C@@H](N)CC1=CC=CC=C1 QOISWWBTZMFUEL-NSHDSACASA-N 0.000 description 2
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- KYVJVURXKAZJRK-UHFFFAOYSA-N (+)-laurolitsine Natural products N1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 KYVJVURXKAZJRK-UHFFFAOYSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 1
- RKBKYSFKXFKBBM-QMMMGPOBSA-N (2s)-2,4-diamino-1-piperidin-1-ylbutan-1-one Chemical compound NCC[C@H](N)C(=O)N1CCCCC1 RKBKYSFKXFKBBM-QMMMGPOBSA-N 0.000 description 1
- JMDKBDALNFZTOV-JQWIXIFHSA-N (2s)-2-[[(2s)-2-(phenylmethoxycarbonylamino)propanoyl]amino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1 JMDKBDALNFZTOV-JQWIXIFHSA-N 0.000 description 1
- GBDUPCKQTDKNLS-TXUMRZAQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r,3r)-3-amino-2-hydroxy-5-methylhexanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid;hydrochloride Chemical compound Cl.CC(C)C[C@@H](N)[C@@H](O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC(O)=O GBDUPCKQTDKNLS-TXUMRZAQSA-N 0.000 description 1
- FJPHHBGPPJXISY-KBPBESRZSA-N (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CN)CC1=CC=C(O)C=C1 FJPHHBGPPJXISY-KBPBESRZSA-N 0.000 description 1
- XERVAQYNJKWPRP-CACGZCQESA-N (2s)-n-[(2r)-1-[(2,6-difluorophenyl)methylamino]-4-methyl-1-oxopentan-2-yl]-2-[[2-(6-methoxy-3-oxo-1,2-dihydroinden-1-yl)acetyl]amino]-4-methylpentanamide Chemical compound O=C([C@@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CC1CC(=O)C2=CC=C(C=C21)OC)NCC1=C(F)C=CC=C1F XERVAQYNJKWPRP-CACGZCQESA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- GFARQYQBWJLZMW-JYFOCSDGSA-N (3e,5e)-3,5-bis[(4-nitrophenyl)methylidene]-1-prop-2-enoylpiperidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C(/CN(C\1)C(=O)C=C)C(=O)C/1=C/C1=CC=C([N+]([O-])=O)C=C1 GFARQYQBWJLZMW-JYFOCSDGSA-N 0.000 description 1
- OOGHGBCRVSBUHH-GOYXDOSHSA-N (3s)-3-[[(2s)-2-acetamido-3-methylbutanoyl]amino]-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-carboxy-3-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C=O OOGHGBCRVSBUHH-GOYXDOSHSA-N 0.000 description 1
- MXGWDBFUMHUPTG-SKZNYKRCSA-N (4S,7S,13R,22R)-4-(1H-indol-3-ylmethyl)-7-[(4-methoxy-1H-indol-3-yl)methyl]-13,18,22-trimethyl-16-methylidene-24-thia-3,6,9,12,15,18,21,26-octazabicyclo[21.2.1]hexacosa-1(25),23(26)-diene-2,5,8,11,14,17,20-heptone Chemical compound N([C@H](C(NCC(=O)N[C@H](C)C(=O)NC(=C)C(=O)N(C)CC(=O)N[C@H](C)C=1SC=C(N=1)C(=O)N1)=O)CC2=CNC=3C=CC=C(C2=3)OC)C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 MXGWDBFUMHUPTG-SKZNYKRCSA-N 0.000 description 1
- FOYHOBVZPWIGJM-KCHLEUMXSA-N (4s)-4-[[(2s)-4-methyl-2-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]pentanoyl]amino]-5-[(4-methyl-2-oxochromen-7-yl)amino]-5-oxopentanoic acid Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 FOYHOBVZPWIGJM-KCHLEUMXSA-N 0.000 description 1
- SWDZPNJZKUGIIH-QQTULTPQSA-N (5z)-n-ethyl-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-[4-(morpholin-4-ylmethyl)phenyl]-2h-1,2-oxazole-3-carboxamide Chemical compound O1NC(C(=O)NCC)=C(C=2C=CC(CN3CCOCC3)=CC=2)\C1=C1/C=C(C(C)C)C(O)=CC1=O SWDZPNJZKUGIIH-QQTULTPQSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PPQJCISYYXZCAE-UHFFFAOYSA-N 1,10-phenanthroline;hydrate Chemical compound O.C1=CN=C2C3=NC=CC=C3C=CC2=C1 PPQJCISYYXZCAE-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QVTQYSFCFOGITD-UHFFFAOYSA-N 2,5-dichlorobenzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1Cl QVTQYSFCFOGITD-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- DSGOSRLTVBPLCU-UHFFFAOYSA-N 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol;hydrobromide Chemical compound Br.C1=CC(O)=CC=C1C1C2=CC(O)=C(O)C(Cl)=C2CCNC1 DSGOSRLTVBPLCU-UHFFFAOYSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710142965 Bromelain inhibitor Proteins 0.000 description 1
- BYUCSFWXCMTYOI-ZRDIBKRKSA-N Bromoenol lactone Chemical compound O=C1OC(=C/Br)/CCC1C1=CC=CC2=CC=CC=C12 BYUCSFWXCMTYOI-ZRDIBKRKSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 108010081642 CA 074 methyl ester Proteins 0.000 description 1
- DABFKTHTXOELJF-UHFFFAOYSA-N CCCN(C(C=C1)=O)C1=O Chemical compound CCCN(C(C=C1)=O)C1=O DABFKTHTXOELJF-UHFFFAOYSA-N 0.000 description 1
- UBWWKWFLWOAAAE-VIFPVBQESA-N C[C@@H](CCc1ccccc1)C(N)=O Chemical compound C[C@@H](CCc1ccccc1)C(N)=O UBWWKWFLWOAAAE-VIFPVBQESA-N 0.000 description 1
- NEDLYQXZCPTKOD-QMMMGPOBSA-N C[C@@H](Cc1ccccc1)C(N)=O Chemical compound C[C@@H](Cc1ccccc1)C(N)=O NEDLYQXZCPTKOD-QMMMGPOBSA-N 0.000 description 1
- 101100030889 Caenorhabditis elegans rpt-4 gene Proteins 0.000 description 1
- 101100371648 Caenorhabditis elegans usp-14 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
- 102000003847 Carboxypeptidase B2 Human genes 0.000 description 1
- 101710091846 Carboxypeptidase Y inhibitor Proteins 0.000 description 1
- 229940122728 Caspase 2 inhibitor Drugs 0.000 description 1
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 229940100513 Caspase 8 inhibitor Drugs 0.000 description 1
- 229940122396 Caspase 9 inhibitor Drugs 0.000 description 1
- 229940123169 Caspase inhibitor Drugs 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000004091 Caspase-8 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 229940122524 Cathepsin C inhibitor Drugs 0.000 description 1
- 229940123363 Cathepsin D inhibitor Drugs 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102100025975 Cathepsin G Human genes 0.000 description 1
- 229940094918 Cathepsin L inhibitor Drugs 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 101710185563 Chymotrypsin-2 Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229940122097 Collagenase inhibitor Drugs 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 241000006271 Discosoma sp. Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 229940122586 Enkephalinase inhibitor Drugs 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229940121832 Granzyme B inhibitor Drugs 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 108010049171 IPSI-001 Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DIFKWHRMEGFLSD-UHFFFAOYSA-N JBIR-22 Natural products O=C1C(CC(O)(C(C)C)C(O)=O)N(C)C(=O)C1=C(O)C1C2CCCCC2C=CC1C DIFKWHRMEGFLSD-UHFFFAOYSA-N 0.000 description 1
- 108010056836 L 685458 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000579835 Merops Species 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 108010030545 N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide Proteins 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- HTEOCLJVFCRBQX-KBPBESRZSA-N OC(=O)C[C@H](O)[C@H](CC(C)C)NCC1=CC=CC=C1 Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NCC1=CC=CC=C1 HTEOCLJVFCRBQX-KBPBESRZSA-N 0.000 description 1
- 108010011140 OM99-2 Proteins 0.000 description 1
- 108010064641 ONX 0912 Proteins 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100041010 Proteasome assembly chaperone 3 Human genes 0.000 description 1
- 101710179510 Proteasome assembly chaperone 3 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- HJKXQQVDTIEFDD-FAVUQDIBSA-N Scytonemide A Chemical compound N/1=C/[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H]\1CC1=CC=C(O)C=C1 HJKXQQVDTIEFDD-FAVUQDIBSA-N 0.000 description 1
- 101000959886 Solanum tuberosum Aspartic protease inhibitor 2 Proteins 0.000 description 1
- 101000959868 Solanum tuberosum Aspartic protease inhibitor 8 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- ZIAXNZCTODBCKW-UHFFFAOYSA-N TMC-95 C Natural products C12=CC=CC3=C2NC(=O)C3(O)C(O)C(C(=O)NC=CC)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(=O)C(C)CC)CC2=CC=C(O)C1=C2 ZIAXNZCTODBCKW-UHFFFAOYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102100040411 Tripeptidyl-peptidase 2 Human genes 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- LZDNBBYBDGBADK-KBPBESRZSA-N Val-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- GBJVAVGBSGRRKN-JYEBCORGSA-N Z-DEVD-FMK Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1 GBJVAVGBSGRRKN-JYEBCORGSA-N 0.000 description 1
- 108010066665 acetyl-aspartyl-glutamyl-valyl-aspartal Proteins 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- MXGWDBFUMHUPTG-UHFFFAOYSA-N argyrin A Natural products C1=2C(OC)=CC=CC=2NC=C1CC(C(NCC(=O)NC(C)C(=O)NC(=C)C(=O)N(C)CC(=O)NC(C)C=1SC=C(N=1)C(=O)N1)=O)NC(=O)C1CC1=CNC2=CC=CC=C12 MXGWDBFUMHUPTG-UHFFFAOYSA-N 0.000 description 1
- 108010003647 argyrin A Proteins 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 108010071933 benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 1
- 108010088607 benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone Proteins 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CAILNONEKASNSH-ZEQRLZLVSA-N benzyl n-[(2s)-1-[[(2s)-4-fluoro-3-oxo-1-phenylbutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamate Chemical compound C([C@@H](C(=O)CF)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 CAILNONEKASNSH-ZEQRLZLVSA-N 0.000 description 1
- 108010005726 benzyloxycarbonyl-alanyl-glutamyl-valyl-aspartic acid fluoromethyl ketone Proteins 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- 125000003180 beta-lactone group Chemical group 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- MHVCSDLBQKSFQV-HNNXBMFYSA-N boldine Natural products COc1cc2c(C[C@@H]3N(C)CCc4cc(C)c(OC)c2c34)cc1O MHVCSDLBQKSFQV-HNNXBMFYSA-N 0.000 description 1
- LZJRNLRASBVRRX-UHFFFAOYSA-N boldine trifluoroacetic acid salt Natural products CN1CCC2=CC(O)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 LZJRNLRASBVRRX-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 229940123098 caspase 6 inhibitor Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000007348 cell dedifferentiation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- NVGFSTMGRRADRG-IOJSEOPQSA-N chembl553939 Chemical compound CS(O)(=O)=O.O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1N[C@H]1CC[C@H](OC(=O)CN)CC1 NVGFSTMGRRADRG-IOJSEOPQSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002442 collagenase inhibitor Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- OCXGTPDKNBIOTF-UHFFFAOYSA-N dibromo(triphenyl)-$l^{5}-phosphane Chemical compound C=1C=CC=CC=1P(Br)(C=1C=CC=CC=1)(Br)C1=CC=CC=C1 OCXGTPDKNBIOTF-UHFFFAOYSA-N 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108010054812 diprotin A Proteins 0.000 description 1
- OQKHVXFOYFBMDJ-ODIUWQMJSA-L disodium;(2s)-3-(1h-indol-3-yl)-2-[[(2s)-4-methyl-2-[[oxido-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyphosphoryl]amino]pentanoyl]amino]propanoate Chemical compound [Na+].[Na+].N([C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C([O-])=O)P([O-])(=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O OQKHVXFOYFBMDJ-ODIUWQMJSA-L 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
- 108700002672 epoxomicin Proteins 0.000 description 1
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010065713 glycyl-glycyl-tyrosyl-arginine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940126097 immunoproteasome inhibitor Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 108010027775 interleukin-1beta-converting enzyme inhibitor Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950005069 luminespib Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000002824 mRNA display Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- PJGDFLJMBAYGGC-XLPNERPQSA-N methoxysuccinyl-Ala-Ala-Pro-Val chloromethyl ketone Chemical compound COC(=O)CCC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)CCl PJGDFLJMBAYGGC-XLPNERPQSA-N 0.000 description 1
- YXRKBEPGVHOXSV-QORCZRPOSA-N methyl (4s)-5-[[(2s)-1-[[(3s)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-5-oxopentanoate Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)OC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(=O)OC)C(=O)CF)C(=O)OCC1=CC=CC=C1 YXRKBEPGVHOXSV-QORCZRPOSA-N 0.000 description 1
- CHZRBQFKZDGMTP-UHFFFAOYSA-N methyl 5-[[1-[(5-fluoro-1-methoxy-1,4-dioxopentan-3-yl)amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxo-4-[2-(phenylmethoxycarbonylamino)propanoylamino]pentanoate Chemical compound COC(=O)CC(C(=O)CF)NC(=O)C(C(C)C)NC(=O)C(CCC(=O)OC)NC(=O)C(C)NC(=O)OCC1=CC=CC=C1 CHZRBQFKZDGMTP-UHFFFAOYSA-N 0.000 description 1
- MXOOUCRHWJYCAL-UHFFFAOYSA-N methyl 5-fluoro-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxopentanoate Chemical compound COC(=O)CC(C(=O)CF)NC(=O)OC(C)(C)C MXOOUCRHWJYCAL-UHFFFAOYSA-N 0.000 description 1
- ANTIWMNLIROOQF-UHFFFAOYSA-N methyl 5-fluoro-3-[2-[[2-[[4-methoxy-2-[[3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]propanoylamino]-4-oxopentanoate Chemical compound COC(=O)CC(C(=O)CF)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(CC(=O)OC)NC(=O)C(C(C)C)NC(=O)OCC1=CC=CC=C1 ANTIWMNLIROOQF-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XGWSRLSPWIEMLQ-YTFOTSKYSA-N methyl n-({(2s,3s)-3-[(propylamino)carbonyl]oxiran-2-yl}carbonyl)-l-isoleucyl-l-prolinate Chemical compound CCCNC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@H](C(=O)OC)CCC1 XGWSRLSPWIEMLQ-YTFOTSKYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- 229950005750 oprozomib Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- 108010049249 scytonemide A Proteins 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 108010026668 snake venom protein C activator Proteins 0.000 description 1
- NGDIAZZSCVVCEW-UHFFFAOYSA-M sodium;butyl sulfate Chemical compound [Na+].CCCCOS([O-])(=O)=O NGDIAZZSCVVCEW-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- UVFAEQZFLBGVRM-MSMWPWNWSA-N succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCC(O)=O)CC(C)C)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C1=CC=C(O)C=C1 UVFAEQZFLBGVRM-MSMWPWNWSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- FDMCEXDXULPJPG-MERQFXBCSA-N tert-butyl (2s)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=CC=C1 FDMCEXDXULPJPG-MERQFXBCSA-N 0.000 description 1
- RFUWRXIYTQGFGA-QRPNPIFTSA-N tert-butyl (2s)-2-amino-4-methylpentanoate;hydron;chloride Chemical compound Cl.CC(C)C[C@H](N)C(=O)OC(C)(C)C RFUWRXIYTQGFGA-QRPNPIFTSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 108010039189 tripeptidyl-peptidase 2 Proteins 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- SUPVGFZUWFMATN-UHFFFAOYSA-N zelavespib Chemical compound N1=CN=C2N(CCCNC(C)C)C(SC=3C(=CC=4OCOC=4C=3)I)=NC2=C1N SUPVGFZUWFMATN-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/08—Methods of screening libraries by measuring catalytic activity
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the present disclosure relates to a protein-degradation inducing tag and use thereof.
- Controlling the amount (expression) of a target protein in a cell, a living body, and the like is very useful for analyzing the functions of the target protein and life phenomena in which the target protein is involved.
- a target protein is responsible for a disease, the disease can be prevented or treated by decreasing the amount of the target protein.
- RNAi RNA interference
- siRNA small interfering RNA
- a technique has recently gathered much attention in which a target protein is degraded in a cell to control the amount of the target protein at the protein level.
- This technique is roughly categorized into an ubiquitin dependent technique in which ubiquitination of a target protein is used and an ubiquitin independent technique in which ubiquitination of a target protein is not used.
- ubiquitin dependent technique known is a technique in which a complex is used, the complex having a structure where a molecule capable of binding to a target protein is linked to a molecule capable of binding ubiquitin ligase (E3)
- E3 ubiquitin ligase
- Hines et al. Hines, J. et al., "Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs.”, Proc. Natl. Acad. Sci. U.S.A., 2013, 110(22), 8942-8947 )
- This technique involves allowing a target protein to be connected with ubiquitin ligase through the aforementioned complex to specifically ubiquitinate the target protein. This can lead the target protein to degradation by a proteasome.
- the aforementioned complex may also be referred to as SNIPER (Specific and Nongenetic IAP-dependent Protein ERaser), PROTAC (PROteolysis TArgeting Chimera), and the like.
- a complex As the ubiquitin independent technique, known is a technique in which a complex is used, the complex having a structure where a molecule capable of binding to a target protein is linked to a hydrophobic tag (for example, see WO2012/003281 , a report by Long et al. ( Long, M. J. et al., "Inhibitor mediated protein degradation.”, Chem. Biol., 2012, 19(5), 629-637 ), and a report by Neklesa et al. ( Neklesa, T.K. et al., "Greasy tags for protein removal.”, Nature, 2012, 487, 308-309 )).
- This technique involves allowing the aforementioned complex to bind with a target protein to mimic a partially unfolded state of the target protein. This appears to lead the target protein to degradation by a proteasome.
- the aforementioned ubiquitin dependent technique involving use of a complex having a structure where a molecule capable of binding to a target protein is linked to a molecule capable of binding ubiquitin ligase suffers from low versatility. That is, there are 1000 or more types of ubiquitin ligases in mammal, and ubiquitin ligase plays an important role in recognition of a target protein. Therefore, the complex needs to be individually designed per target protein. Further, the requirement of preparing an individually designed complex per target protein means that the target protein has to be known. Therefore, the technique is difficult to apply, for example, as a tool for identifying a target protein among degraded proteins.
- the aforementioned ubiquitin independent technique involving use of a complex having a structure where a molecule capable of binding to a target protein is linked to a hydrophobic tag suffers from low cell membrane permeability and high cytotoxicity due to the hydrophobic tag.
- an object of the present disclosure is to provide a novel protein-degradation inducing tag configured to induce degradation of a target protein, and use thereof.
- a novel protein-degradation inducing tag configured to induce degradation of a protein, and use thereof can be provided.
- protein refers to any having two or more amino acid residues, and encompasses a so-called “peptide.”
- a range of numerical values specified using "-” as used herein refers to a range including values indicated before and after "-” as the the minimum value and the maximum value, respectively.
- step as used herein encompasses a step independent from the other steps as well as a step which can not be clearly separated from the other steps as long as the purpose of that step can be achieved.
- the protein-degradation inducing tag according to the present disclosure is a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease.
- the protein-degradation inducing tag is used to lead a protein directly bound or indirectly bound through a protein binding molecule to degradation (knockdown) by a protease.
- the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease without ubiquitination of the target protein (i.e., in a ubiquitin independent manner), the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule described below) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein.
- the phrase "the protein-degradation inducing tag is capable of binding to a target protein” means that the protein-degradation inducing tag is capable of binding to the target protein via a covalent bond, a hydrogen bond, a hydrophobic bond, Van der Waals force, and the like. There is no particular limitation for the binding mode thereof.
- the above protein-degradation inducing tag may also be referred to a CiKD (Chemical interaction and KnockDown) tag.
- protease there is no particular limitation for the protease, and any molecule having a protease activity can be used.
- it may be a protease complex such as a proteasome, or may be a protease other than the proteasome.
- it may be a portion of a proteasome as long as the portion has a protease activity.
- Examples of the proteasome include 26S proteasome, an immunoproteasome, and a thymus proteasome.
- 26S proteasome is composed of 20S proteasome and two units of 19S proteasome, the two units of 19S proteasome being attached to the 20S proteasome.
- 20S proteasome has a cylindrical structure in which an ⁇ -ring consisting of 7 subunits of ⁇ 1 to ⁇ 7 and a ⁇ -ring consisting of 7 subunits of ⁇ 1 to ⁇ 7 are stacked in order of ⁇ , and ⁇ 1, ⁇ 2, and ⁇ 5 show catalytic activities of a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity, respectively.
- the catalytic subunits ⁇ 1, ⁇ 2, and ⁇ 5 are replaced with ⁇ 1i, ⁇ 2i, and ⁇ 5i, respectively ( Science, 1994, 265, 1234-1237 ).
- ⁇ 5t which is expressed specifically in cortical thymic epithelial cells (cTEC) is incorporated along with ⁇ 1i and ⁇ 2i ( Science, 2007, 316, 1349-1353 ).
- protease other than the proteasome examples include ⁇ -secretase, ⁇ -secretase, aminopeptidase, angiotensin-converting enzyme, bromelain, calpine I, calpine II, carboxypeptidase A, carboxypeptidase B, carboxypeptidase P, carboxypeptidase Y, caspase 1, caspase 2, caspase 3, caspase 5, caspase 6, caspase 7, caspase 8, caspase 9, caspase 13, cathepsin B, cathepsin C, cathepsin D, cathepsin G, cathepsin L, chymotrypsin, clostripain, collagenase, complement C1r, complement C1s, complement factor B, complement factor D, dipeptidyl peptidase I, dipeptidyl peptidase II, dipeptidyl peptidase IV, dispase, elastase, endoproteinase
- the phrase "having an affinity with a protease” means the capability of binding to a protease, for example, via a covalent bond, a hydrogen bond, a hydrophobic bond, Van der Waals force, and the like.
- the thermal stability of a protease changes in the presence of a protein-degradation inducing tag, the protein-degradation inducing tag can be considered as capable of interacting with that protease.
- the phrase "without inhibiting degradation of a protein by a protease” means that, for example, the protein-degradation inducing tag does not bind to the degradation active site of the protease via a covalent bonding.
- the protein-degradation inducing tag can be considered not to inhibit the degradation of the protein by the protease.
- protein-degradation inducing tag examples include low molecular weight compounds, natural products, peptides, and the like.
- the protein-degradation inducing tag has a molecular weight within the range of, for example, 50 to 5000.
- the protein-degradation inducing tag can be obtained from candidate molecules by the screening method as described below, and can also be manufactured according to the method of manufacture as described below.
- the protein-degradation inducing tag may have a structure represented by following formula (I):
- R 1 and R 2 each independently represent a hydrocarbon group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms, a hydroxy group, a carboxy group, an amino group, or a halogeno group.
- hydrocarbon group examples include an alkyl group, an alkenyl group, an aryl group, combinations thereof, and the like. Specifically, the followings can be mentioned: an alkyl group having 1 to 20 carbon atoms such as a methyl group and an ethyl group; an alkenyl group having 2 to 20 carbon atoms such as a vinyl group and an allyl group; an aryl group having 6 to 20 carbon atoms such as a phenyl group and a naphthyl group; an arylalkyl group having 7 to 20 carbon atoms such as a benzyl group and a phenethyl group; an alkylaryl group having 7 to 20 carbon atoms such as a tolyl group and a xylyl group; and the like.
- the halogeno group include a fluoro group, a chloro group, a bromo group, and the like.
- the protein-degradation inducing tag may have a structure in which the proteasome inhibitory activity of a proteasome inhibitor is inactivated. More specifically, at least one inhibitory activity selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity can be mentioned as the proteasome inhibitory activity.
- the term "structure in which a proteasome inhibitory activity is inactivated" as used herein encompasses a structure in which a proteasome inhibitory activity is attenuated in addition to a structure in which a proteasome inhibitory activity is completely eliminated.
- the protein-degradation inducing tag has a 50% inhibition concentration (IC 50 ) against at least one selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity which is 2 times or more of the 50% inhibition concentration (IC 50 ) of the original proteasome inhibitor.
- proteasome inhibitor any compound having a proteasome inhibitory activity can be used.
- a proteasome inhibitor is a compound which has an affinity with a proteasome (a protease complex), and inhibits degradation of a protein by a proteasome. Therefore, a protein-degradation inducing tag may be obtained by replacing the active site of a proteasome inhibitor with another structural moiety to inactivate the proteasome inhibitory activity.
- proteasome inhibitors have been progressively explored as anticancer agent and the like. Many compounds have been approved as pharmaceutical products, or are under clinical trials. Moreover, many of proteasome inhibitors have relatively small molecular weights and low hydrophobicity, and are less problematic in terms of cell membrane permeability, cytotoxicity, and the like. For these reasons, synthesizing a protein-degradation inducing tag based on a proteasome inhibitor is quite reasonable and efficient.
- proteasome inhibitor examples are shown in the following Tables 1 and 2.
- the proteasome inhibitors shown in Tables 1 and 2 are each a 20S proteasome inhibitor having an affinity with 20S proteasome.
- a proteasome inhibitor which can be used in the present embodiment shall not be limited to these examples. [Table 1] No.
- bortezomib as a boronic acid-based proteasome inhibitor is known to inhibit a proteasome activity when the boronyl group as an active site covalently binds to the degradation active site of 20S proteasome as shown in the following scheme ( Kisselev, A.F. et al., Chemistry & Biology, 2012, 19, 99-115 ).
- MLN9708 and MLN2238 which are boronic acid-based proteasome inhibitors, are known to inhibit a proteasome activity when the boronic acid ester moiety or the boronyl group as an active site covalently binds to the degradation active site of 20S proteasome as shown in the following scheme ( Kisselev, A.F. et al., Chemistry & Biology, 2012, 19, 99-115 ) .
- a protein-degradation inducing tag may be obtained by replacing the boronyl group or the boronic acid ester moiety as the active sites of bortezomib, MLN9708, and MLN2238 with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like) to inactive the proteasome inhibitory activity.
- a protein-degradation inducing tag can be obtained by replacing the active site with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like).
- ALLN which is an aldehyde proteasome inhibitor, is known to inhibit a proteasome activity when the formyl group as an active site covalently binds to the degradation activity site of 20S proteasome as shown in the following scheme ( Kisselev, A.F. et al., Chemistry & Biology, 2012, 19, 99-115 ).
- a protein-degradation inducing tag can be obtained by replacing the formyl group as the active site of ALLN with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like) to inactivate the proteasome inhibitory activity.
- another structural moiety a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like
- a protein-degradation inducing tag can be obtained by replacing the formyl group as an active site with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like).
- Examples of the protein-degradation inducing tag having a structure in which the proteasome inhibitory activity of a proteasome inhibitor is inactivated are shown in the following Tables 3 and 4.
- Examples of the monovalent group represented by R in the tables include a carboxy group, an alkyl group having 1 to 20 carbon atoms, an aryl group having 6 to 20 atoms, an amino group, a hydroxy group, and the like. [Table 3] No.
- Structural formula 8 (In the formula, R represents a monovalent group except for -CHO.) 9 (In the formula, R represents a monovalent group except for -CHO.) 10 (In the formula, R represents a monovalent group except for .) 11 (In the formula, R represents a monovalent group except for .) 12 (In the formula, R represents a monovalent group except for ) 13 (In the formula, R represents a monovalent group.) 14 (In the formula, R represents a monovalent group.)
- proteasome inhibitor examples include but not limited to, a protein-degradation inducing tag. Even for these proteasome inhibitor, a protein-degradation inducing tag can be obtained by inactivating the proteasome inhibitory activity in a similar way as described above.
- Table 5 20S proteasome inhibitor No. Generic name / Product name Structural formula Molecular weight 15 Aspirin 180.15 16 Hydroxyurea inhibitor 354.54 17 PI-1840 394.47 18 PI-083 439.87 19 Cerastol 450.61
- Table 6 20S proteasome inhibitor (Continued) No.
- the protein-degradation inducing tag may have a structure in which the protease inhibitory activity of a protease inhibitor (except for the proteasome inhibitors described above) is inactivated.
- structure in which a protease inhibitory activity is inactivated encompasses a structure in which the protease inhibitory activity is attenuated in addition to a structure in which the protease inhibitory activity is completely eliminated.
- the protein-degradation inducing tag has a 50% inhibition concentration (IC 50 ) against a protease as an inhibition target of a protease inhibitor which is 2 times or more of the 50% inhibition concentration (IC 50 ) of the original protease inhibitor.
- protease inhibitor any compound having a protease inhibitory activity can be used.
- the protease inhibitor is a compound having an affinity with a protease and inhibiting degradation of a protein by the protease. Therefore, a protein-degradation inducing tag can be obtained by replacing the active site of a protease inhibitor with another structural moiety to inactivate the protease inhibitory activity.
- protease inhibitor examples are shown in the following Tables 11 to 78. Protein-degradation inducing tags can be obtained by replacing the active sites of these protease inhibitor with another structural moieties to inactivate the protease inhibitory activities. However, a protease inhibitor which can be used in the present embodiment shall not be limited to these examples. Existing data bases (for example, " MEROPS-the peptidase database" (http://merops.sanger.ac.uk/index.shtml )) can be consulted for information about proteases and protease inhibitors if needed. [Table 11] ⁇ -secretase inhibitor No.
- C Chymostatin A
- X Leu B, H, L
- Chymostatin B X Val ⁇ Proteasome ( ⁇ 5)
- Chymostatin C X Ile 6 Cystamine dihydrochloride 225.2 7 3,4-Dichloroisocoumarin 215.03 ⁇ Thrombin ⁇ Papain ⁇ Plasmin 8 N-p-Tosyl-L-phenilalanine chloromethyl ketone 351.85 ⁇ Papain ⁇ Chymotrypsin ⁇ Ficin ⁇ Bromelain 9 Leupeptin 426.55 ⁇ Plasmin ⁇ Trypsin ⁇ Papain ⁇ Cal
- proteasome inhibitors and protease inhibitors other than the proteasome inhibitors are separately discussed for convenience, but a compound is also known which can inhibit the activities of both a proteasome and a protease other than proteasomes. Therefore, a protein-degradation inducing tag having an affinity with both a proteasome and a protease other than proteasomes can be obtained when such a compound is used.
- Example 10 the protein-degradation inducing tag is used in which the protease (proteasome) inhibitory activity of a calpain inhibitor (ALLN) shown in No. 1 of Table 79 is inactivated.
- ALLN calpain inhibitor
- the compound which can inhibit the activities of both a proteasome and a protease other than proteasomes shall not be limited to these examples. [Table 79] No.
- a proteasome activator can be used as a protein-degradation inducing tag.
- a proteasome activator is a compound having an affinity with a proteasome (a protease complex) without inhibiting degradation of a protein by the proteasome, and can be used as a protein-degradation inducing tag. That is, according to the present disclosure, use of a proteasome activator as a protein-degradation inducing tag is provided.
- proteasome activator examples of the proteasome activator are shown in the following Tables 80 to 82. However, the proteasome activator which can be used in the present embodiment shall not be limited to these examples.
- the method of screening for a protein-degradation inducing tag includes a step of selecting a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease from candidate molecules.
- the protease is a proteasome (a protease complex).
- candidate molecules are prepared.
- a library can be used such as a compound library, a drug library, and a natural-product library.
- the candidate molecules are preferably pre-immobilized on each well of a plate for high throughput screening (HTS), a microarray plate, a metal plate, and the like.
- HTS high throughput screening
- the candidate molecules immobilized on each well are subjected to treatment with a protease labelled with a fluorochrome, nucleic acid (mRNA or DNA), or the like, and then each well is washed.
- a protease labelled with a fluorochrome a fusion protein with GFP (Green Fluorescent Protein), labelling by C-terminus labeling, and the like can be used.
- a display method can be used such as the IVV (in vitro virus) method (may also be referred to as the mRNA display method) and the DNA display method.
- a molecule having an affinity with a protease will be specified based on the label on a protease.
- a protease is labelled with a fluorochrome
- a molecule having an affinity with the protease can be specified by detecting fluorescence.
- a protease is labelled with mRNA
- a molecule having an affinity with the protease can be specified by detecting the sequence of the nucleic acid by reverse transcription PCR.
- a molecule which does not inhibit degradation of a protein by the protease will be specified from molecules having an affinity with the protease.
- a method can be use which is described in Example below.
- the method of manufacturing a protein-degradation inducing tag according to the present disclosure includes a step of modifying a structure of an active site of a protease inhibitor to inactivate the protease inhibitory activity.
- the protease inhibitor is a proteasome inhibitor
- a protein-degradation inducing tag is manufactured by inactivating the proteasome inhibitory activity of the proteasome inhibitor.
- the protease inhibitor is a compound having an affinity with a protease and inhibiting degradation of a protein by the protease. Therefore, a protein-degradation inducing tag can be obtained by modifying structure of the active site of a protease inhibitor to inactivate the protease inhibitory activity.
- the protease inhibitor used for manufacturing a protein-degradation inducing tag may be a known protease inhibitor, or may be obtained by screening candidate molecules. That is, the method of manufacturing a protein-degradation inducing tag may further include a step of selecting, as a protease inhibitor, a molecule having an affinity with a protease and inhibiting degradation of a protein by the protease from candidate molecules.
- a molecule which does not inhibit degradation of a protein by a protease is specified from molecules having an affinity with the protease, and thus a molecule (a protease inhibitor) having an affinity with the protease and inhibiting degradation of a protein by the protease is specified during the screening process. Therefore, a protein-degradation inducing tag may be manufactured using a protease inhibitor obtained by the screening method as described above.
- the library of protein-degradation inducing tags according to the present disclosure includes two or more types of the aforementioned protein-degradation inducing tags.
- the library of protein-degradation inducing tags can be used in the screening method described below.
- the protein-degradation inducing molecule is a conjugate of at least one protein-degradation inducing tag described above and at least one protein binding molecule capable of binding to a protein.
- the above protein-degradation inducing molecule enables the at least one protein binding molecule to bind with a target protein, leading the target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein (see Examples 2, 7, 12, 15, 16, 21 to 23 described above).
- a protease for example, a proteasome
- the binding mode include a covalent bond, a hydrogen bond, a hydrophobic bond, Van der Waals force, and the like.
- the target protein examples include proteins residing inside a cell or on a cell membrane.
- the target protein may be a mutant protein produced by mutation, or may be a fusion protein produced by translocation and the like.
- the target protein may be an endogenous protein, or may be an exogenous protein from viruses, bacteria, and the like.
- the target protein may be a protein which is not promptly degraded, and thus accumulated for some reasons.
- the target protein is a protein involving in cell cycle, signal transduction, cell differentiation, cell dedifferentiation, cell proliferation, production of a biologically active substance such as cytokine, or the like. It is noted that the target protein does not need to be prespecified.
- An unknown target protein can be identified as described below by using a protein-degradation inducing molecule.
- the protein binding molecule examples include medicaments such as low molecular weight compounds, antibodies, and peptides; endogenous biologically active substances such as cytokines, growth factors, hormones; natural products; metabolites; plant ingredients; food ingredients; and the like.
- Binding molecules (eg.inhibitors) in some types of the target protein are known (for example, see WO2008/123266 ), and thus these known molecules can be used as protein binding molecules.
- binding molecules may be screened by high throughput screening (HTS).
- HTS high throughput screening
- an antibody capable of binding to a target protein may be produced, which may be used as a protein binding molecule.
- the protein-degradation inducing molecule may have a structure in which at least one protein-degradation inducing tag and at least one protein binding molecule are linked.
- the protein-degradation inducing molecule may have a structure in which one protein-degradation inducing tag is linked to one protein binding molecule, or may have a structure in which one protein-degradation inducing tag is linked to a plurality of protein binding molecules, or may have a structure in which a plurality of protein-degradation inducing tags are linked to one protein binding molecule, or may have a structure in which a plurality of protein-degradation inducing tags are linked to a plurality of protein binding molecules.
- the protein-degradation inducing molecule has a structure in which one protein-degradation inducing tag is linked to one protein binding molecule.
- the linkage position of a protein-degradation inducing tag with the protein binding molecule is no particular limitation.
- the protein-degradation inducing tag has a structure in which the active site of a protease inhibitor (for example, a proteasome inhibitor) is replaced with another structural moiety as described above, the protein-degradation inducing tag can be bound to the protein binding molecule at the replaced another structural moiety.
- the active site of a protease inhibitor is replaced with a carboxy group
- the protein-degradation inducing tag can be bound to the protein binding molecule through the carboxy group.
- the linkage position of the protein binding molecule with the protein-degradation inducing tag is no particular limitation for the linkage position of the protein binding molecule with the protein-degradation inducing tag as long as binding property with a protein is maintained.
- the protein-degradation inducing tag and the protein binding molecule may be configured to be linked to each other.
- a structure which enables mutual linkage may be introduced into at least one of the protein-degradation inducing tag and the protein binding molecule.
- a molecule known to bind with a target protein can be used as a protein binding molecule, but a direct linkage between this known molecule and a protein-degradation inducing tag may potentially be difficult to form.
- a structure which can be linked to a protein-degradation inducing tag may be introduced into the aforementioned known molecule for use as a protein binding molecule.
- the library of protein-degradation inducing molecules according to the present disclosure includes two or more types of the aforementioned protein-degradation inducing molecules.
- Examples of the form in which two or more types of protein-degradation inducing molecules are included include a form in which two or more types of protein-degradation inducing molecules having the same type of protein-degradation inducing tags but having different types of protein binding molecules are included, a form in which two or more types of protein-degradation inducing molecules having the same type of protein binding molecules but having different types of protein-degradation inducing tags are included, and a form in which two or more types of protein-degradation inducing molecules having different types of protein-degradation inducing tags and having different types of protein binding molecules are included.
- Examples of the method of manufacturing a library of protein-degradation inducing molecules include a method in which protein-degradation inducing tags are conjugated to each protein binding molecule included in the library of protein binding molecules.
- Examples of the library of protein binding molecules include a compound library, a drug library, a natural product library, and the like.
- a library of protein-degradation inducing molecules can be manufactured by linking protein-degradation inducing molecules to each protein binding molecule included in a library of protein binding molecules using a chemical reaction, a crosslinking reaction, and the like.
- Other examples of the method of manufacturing a library of protein-degradation inducing molecules include a method in which protein binding molecules are conjugated to each protein-degradation inducing tag included in the aforementioned library of protein-degradation inducing tags.
- the library of protein-degradation inducing molecules can be used in the screening method described below.
- the pharmaceutical composition according to the present disclosure includes the aforementioned protein-degradation inducing tag or the protein-degradation inducing molecule.
- the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein.
- a protease for example, a proteasome
- a pharmaceutical composition against that disease can be manufactured by using a protein-degradation inducing tag or a protein-degradation inducing molecule which can lead the target protein to degradation. Then, the above pharmaceutical composition is administered to a patient to promote degradation of the target protein in the body of the patient. This can lead to prevention or treatment of that disease (for example, see Example 16 described below which represents a knockdown experiment in mouse individuals).
- the target protein is from eukaryote or prokaryote (animal, plant, fungus, yeast, E. coli, and the like).
- the target protein may be a mutant protein produced by mutation, or may be a fusion protein produced by translocation and the like.
- the target protein may be an endogenous protein, or may be an exogenous protein from viruses, bacteria, and the like.
- the target protein may be a protein which is not promptly degraded, and thus accumulated for some reasons.
- the pharmaceutical composition may include an ingredient other than the protein-degradation inducing tag or protein-degradation inducing molecule.
- the pharmaceutical composition may include an organic or inorganic carrier which is conventionally used as a formulation material.
- the above carrier is formulated as an excipient, a lubricant, a binder, a disintegrating agent, and the like in a solid preparation, and as a solvent, a solubilizing agent, a suspending agent, an isotonizing agent, a buffer agent, and the like in a liquid preparation.
- the pharmaceutical composition may include a formulation additive such as an antiseptic agent, an anti-oxidative agent, a coloring agent, a sweetening agent, and the like.
- the dosage form of the pharmaceutical composition there is no particular limitation for the dosage form of the pharmaceutical composition.
- examples of the dosage form of the pharmaceutical composition include oral preparations such as tablet, capsule, granule, powder, trochiscus, syrup, emulsion, suspension, and film preparations; parenteral preparations such injectable preparations, infusion preparations, external preparations, suppository, pellets, transnasal preparations, pulmonary preparations (inhalation), and eye drops; and the like.
- the dose of the pharmaceutical composition is appropriately determined depending on the subject, route of administration, target disease, conditions, and the like.
- the method of degrading a target protein according to the present disclosure includes a step of inducing degradation of a target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule.
- the protein-degradation inducing tag or protein-degradation inducing molecule may be added to a medium in which cells, a tissue, or an organ is cultured. Any cells, tissue, and organ can be used as long as they are from eukaryote or prokaryote (animal, plant, fungus, yeast, E. coli, and the like) which have a protease (for example, a proteasome).
- the protein-degradation inducing tag or protein-degradation inducing molecule may be administered orally or parenterally to the living body of eukaryote or prokaryote which has a protease (for example, a proteasome).
- a protease for example, a proteasome
- Subjects of administration include primate such as human, mouse, rat, swine, canine, feline, and the like.
- the protein-degradation inducing tag or protein-degradation inducing molecule may be added to an in vitro (cell free) protease degradation system (for example, a proteasome degradation system).
- the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein.
- a protease for example, a proteasome
- the method of performing functional analysis on a target protein includes a step of inducing degradation of the target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule.
- functional analysis on a target protein means analyzing functions of the target protein when the target protein is specified.
- the target protein may have completely unknown functions or partially elucidated functions.
- the protein-degradation inducing tag or protein-degradation inducing molecule may be added to a medium in which cells, a tissue, or an organ is cultured.
- the protein-degradation inducing tag or protein-degradation inducing molecule may be administered orally or parenterally to the living body of eukaryote or prokaryote which has a protease (for example, a proteasome).
- the protein-degradation inducing tag or protein-degradation inducing molecule may be added to an in vitro (cell free) functional analysis system along with a protease degradation system (for example, a proteasome degradation system).
- the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein.
- a protease for example, a proteasome
- functions of a target protein can be analyzed by, for example, inducing degradation of the target protein using the protein-degradation inducing tag or protein-degradation inducing molecule, and then analyzing changes in the phenotype of the cells or living body.
- functions of a target protein can be analyzed by inducing degradation of the target protein using the protein-degradation inducing tag or protein-degradation inducing molecule, and then analyzing differences (changes) in molecular networks in the presence or absence of the target protein.
- a gene knockout mouse is usually created.
- a long period of time for example, 1 year or more
- CRISPR/CAS9 genome editing technique
- creation of a gene knockout mouse takes several months to half a year even when this CRISPR/CAS9 technique is used.
- a target protein can be led to degradation (knockdown) in a short period of time, and an effect comparable to a case where a gene knockout mouse is created can be obtained.
- functions of a target protein can also be analyzed dynamically.
- the method of identifying a target protein includes a step of inducing degradation of the target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule; and a step of identifying a protein subjected to degradation induced by the protein-degradation inducing tag or protein-degradation inducing molecule.
- identifying a target protein means that a target protein capable of binding to a protein-degradation inducing tag or a protein binding molecule is identified.
- the protein-degradation inducing tag or the protein binding molecule may bind to not only a completely unknown target protein but a partially known target protein.
- protein degradation is first induced using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule.
- the method of inducing protein degradation using the protein-degradation inducing tag or protein-degradation inducing molecule is no particular limitation.
- the method of degrading a target protein as described above may be adopted.
- the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein.
- the target protein can be identified by, for example, extracting proteins from cells, and performing proteome analysis to specify a protein present in a reduced amount.
- the method of identifying a pathway molecule through a target protein includes a step of inducing degradation of the target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule; and a step of identifying a protein showing an altered activity or expression, the protein being different from the target protein.
- identifying a pathway molecule through a target protein means that identifying a protein other than the target protein in a protein pathway (a signal transduction pathway and the like) where the target protein is involved.
- the pathway molecule through a target protein may be not only completely unknown but partially known.
- protein degradation is first induced using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule.
- the method of inducing protein degradation using the protein-degradation inducing tag or protein-degradation inducing molecule is no particular limitation.
- the method of degrading a target protein as described above may be adopted.
- the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein.
- the activity or expression of another protein along a protein pathway where the target protein is involved may be altered as the target protein undergoes degradation. Therefore, a pathway molecule can be identified through a target protein by specifying another protein showing an altered activity or expression.
- the method of screening for a protein-degradation inducing tag or protein-degradation inducing molecule includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecules, or library of protein-degradation inducing molecules to a system including a target protein present, and a step of selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has induced degradation of the target protein.
- the system including a target protein may be, for example, a protease degradation system (for example, a proteasomal degradation system) using eukaryotic or prokaryotic cells which have a protease (for example, a proteasome) or an in vitro (cell-free) protease degradation system (for example, a proteasomal degradation system).
- a protease degradation system for example, a proteasomal degradation system
- eukaryotic or prokaryotic cells which have a protease (for example, a proteasome) or an in vitro (cell-free) protease degradation system (for example, a proteasomal degradation system).
- a protein-degradation inducing tag or protein-degradation inducing molecule capable of binding to a target protein is included in the protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules introduced to the system including the target protein, the target protein is led to degradation (knockdown) by a protease (for example, a proteasome). Therefore, what is necessary is just to select a protein-degradation inducing tag or protein-degradation inducing molecule which has induced such degradation of the target protein upon screening.
- a protease for example, a proteasome
- a protein-degradation inducing tag or protein-degradation inducing molecule which leads any selected target protein to degradation can be obtained in principle. Further, when a target protein is responsible for a certain disease (disease causative agent), a protein-degradation inducing tag or protein-degradation inducing molecule which leads the target protein to degradation can be selected as a candidate ingredient for preventing or treating that disease.
- One embodiment of the method of screening for a candidate ingredient for preventing or treating a disease includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules to a disease model system, and selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has improves a condition of the disease.
- another embodiment of the method of screening for a candidate ingredient for preventing or treating a disease includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules to a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which has aggravated a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- disease model system there is no particular limitation for the disease model system, but examples thereof include disease model animals, disease model cells, and the like.
- a protein-degradation inducing tag or protein-degradation inducing molecule capable of binding to a protein related to a disease is included in the protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules introduced into the disease model system, the disease-related protein is led to degradation (knockdown) by a protease (for example, a proteasome).
- a protease for example, a proteasome
- a candidate ingredient for preventing or treating a disease can be obtained by selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has improved a condition of the disease.
- a condition of the disease is aggravated as a result of degradation of the disease-related protein, a decrease in the disease-related protein may potentially be related to development or progress of the disease. Therefore, a candidate ingredient for preventing or treating a disease can be obtained by extracting a protein-degradation inducing tag or protein-degradation inducing molecule which aggravates a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- the method of specifying a disease-related protein includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules into a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which has altered a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- disease-related protein can be specified by extracting a protein-degradation inducing tag or protein-degradation inducing molecule which has altered a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- Information about a disease-related protein specified can be used, for example, to develop an ingredient for preventing or treating a disease.
- Example 1 Synthesis of protein-degradation inducing molecule (TMP-CiKD_Bortezomib) having CiKD_Bortezomib as protein-degradation inducing tag and TMP derivative as protein binding molecule>
- TMP-CiKD_Bortezomib as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme.
- Bortezomib-COOH (CiKD_Bortezomib) in which the boronyl group as the active site of bortezomib was replaced with a carboxy group was used as a protein-degradation inducing tag.
- TMP derivative TMP-NH 2
- TMP-NH 2 TMP derivative
- Bortezomib-COOH was linked to TMP-NH 2 to synthesize TMP-CiKD_Bortezomib as a protein-degradation inducing molecule.
- the compound 1 (398.4 mg, 1.22 mmol) was charged into an eggplant flask, and 5 mL of dichloromethane was then added. This was stirred at room temperature for 5 minutes, and then 7 mL of TFA was added, and stirred at room temperature for 2 hours. After evaporating the solvent under reduced pressure, vacuum drying was performed to obtain a compound 2 (318.8 mg, 96%) .
- the compound 2 (271.3 mg, 1.00 mmol, 1 eq) and H-Leu-OtBu ⁇ HCl (223.8 mg, 1.00 mmol, 1 eq, Code No. 14G110356, Watanabe Chemical Industries, Ltd.) were charged into an eggplant flask, and 10 mL of dehydrate DMF was then added. After stirred at room temperature for 5 minutes, 2 mL of DIEA was added to neutralize the solution. After stirred for 5 minutes at room temperature, DMT-MM (553.4 mg, 2.00 mmol, 2 eq, Code No. 329-53751, Wako Pure Chemical Industries, Ltd.) was directly added to the reaction solution, and stirred at room temperature for 3 hours.
- Example 2 Evaluation (FACS analysis) of degradation (knockdown) of forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_Bortezomib) was added>
- Example 2 degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib was added was evaluated by FACS analysis.
- E. coli DHFR forcedly expressed target protein
- a preculture medium prepared was a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No. AYG161516, HyClone) and 1 mass% PenStrep (100 U/mL sodium penicillin G and 100 ⁇ g/mL streptomycin sulfate) (Code No. 168-23191, Wako Pure Chemical Industries, Ltd.) were added to D-MEM (low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.). Then, HeLa cells (Lot No. 60143948, ATCC) were cultured in the preculture medium under conditions of 37°C and 5 vol% CO 2 .
- FBS Code No. SH30910.03, Lot. No. AYG161516, HyClone
- PenStrep 100 U/mL sodium penicillin G and 100 ⁇ g/mL streptomycin sulfate
- D-MEM low D-glucos
- a culture dish for passage culture used was a cell culture-dish, treated having a diameter of 100 mm (sterile, non pyrogenic) (Code No. TR4002, TrueLine). Passage culture was performed at the time of 70% to 80% confluence. Cells were detached by trypsin treatment (0.25 w/v% trypsin-1 mmol/L EDTA ⁇ 4 Na solution with phenol red) (Code No. 201-16945, Wako Pure Chemical Industries, Ltd.), and then one quarter of the cells were cultured in 10 mL of the preculture medium.
- a plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_Bortezomib on the target protein were evaluated.
- the plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) ( Long, M. J. et al., "Inhibitor mediated protein degradation.” Chem. Biol., 2012, 19 (5), 629-637 ).
- the plasmid map of pMIR DsRed-IRES-ecDHFR-HA-GFP is shown in Fig. 1 .
- the plasmid was amplified in E. coli, and then purified with a Miniprep kit (Code No. 27106, QIAGEN).
- ScreenFectTM A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells.
- a dilution buffer of ScreenFectTM A was added to two 1.5 mL tubes at 600 ⁇ L per tube.
- 30 ⁇ L of a transfection reagent of ScreenFectTM A was added to one tube (a solution A), and 12 ⁇ g of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes.
- the solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C).
- the solution C was mixed with a cell solution at 1.2 x 10 5 cells/24 mL collected from trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 10 4 cells/ 800 ⁇ L/well, and then cultured under conditions of 37°C and 5 vol% CO 2 for 40 hours.
- TMP-CiKD_Bortezomib Additional protein-degradation inducing molecule
- TMP-CiKD_Bortezomib was added to HeLa cells as follows. Culture was performed for 40 hours after introduction of the plasmid, and then the preculture medium was removed, and a serum-free medium (37°C) in which a 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-Glucose, phenol red, and sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.) was added to each well at 300 ⁇ L/well. It is noted that the L-glutamine solution was added immediately before use.
- a DMSO solution containing a predetermined concentration of TMP-CiKD_Bortezomib was added to each well at 3 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 . It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_Bortezomib.
- the medium was removed 24 hours after addition of TMP-CiKD_Bortezomib (80 ⁇ M) or TMP (80 ⁇ M), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 2 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA ⁇ 4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 200 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot No.
- PenStrep 100 U/mL sodium penicillin G and 100 ⁇ g/mL streptomycin sulfate
- D-MEM low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.)) was added to each well at 300 ⁇ L/well, and suspended, and then a cell solution was collected in a 15 mL tube.
- the cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C).
- the cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 500 ⁇ L of an FACS buffer (1 mass% FBS/PBS) at 4°C was added, and allowed to stand on ice.
- a BD FACSCantoTM II (BD Biosciences) was used for flow cytometry, and the expression levels of GFR and DsRed in cells were quantified.
- the cell solution was passed through a mesh with a pore size of 32 ⁇ m, and transferred to an FACS tube immediately before FACS analysis.
- the GFR/DsRed ratio per cell was computed using an analysis software FLOWJOTM (TOMY Digital Biology Co., Ltd.), and the efficiency of target degradation (knockdown) by TMP-CiKD_Bortezomib was determined from a shift by target degradation in a graph.
- Fig. 2A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib was added.
- Fig. 2B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added.
- TMP-CiKD_Bortezomib 80 ⁇ M
- the graph was found to be significantly shifted to the left as compared with that of the control (DMSO), indicating that the target protein (E. coli DHFR) was degraded.
- the degradation efficiency estimated from the amount of a shift was about 50% to 60%.
- TMP 80 ⁇ M
- the graph was found to be overlapped with that of the control (DMSO), indicating that the target protein was not degraded.
- Example 3 Evaluation (thermal shift assay) of affinity of protein-degradation inducing molecule (TMP-CiKD_Bortezomib) with forcedly expressed target protein (ecDHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_Bortezomib) was added>
- Example 3 the affinity of TMP-CiKD_Bortezomib with a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib was added was evaluated by thermal shift assay.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_Bortezomib Additional protein-degradation inducing molecule
- TMP-CiKD_Bortezomib was added to HeLa cells as in Example 2.
- a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_Bortezomib.
- the medium was removed 3 hours after addition of TMP-CiKD_Bortezomib (40 ⁇ M) or TMP (40 ⁇ M), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 2 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA ⁇ 4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 200 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot No.
- PenStrep 100 U/mL sodium penicillin G and 100 ⁇ g/mL streptomycin sulfate
- D-MEM low D-glucose, L-glutamine, phenol red
- D-MEM low D-glucose, L-glutamine, phenol red
- the cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C).
- the cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 180 ⁇ L of a CETSA buffer (cOmpleteTM Mini, EDTA-free (Roche) as a protease inhibitor was added to TBS immediately before use) was added, and then suspended.
- the cell solution after suspension was dispensed to nine 1.5 mL tubes at 20 ⁇ L per tube, and allowed to stand at room temperature for 30 minutes.
- the 9 tubes were heat-treated for 3 minutes, one each at 38°C, 42°C, 46 °C, 50°C, 54°C, 58°C, 62°C, 66°C, or 70°C, and allowed to stand at room temperature for 3 minutes.
- the cell solution was flash frozen in liquid nitrogen, and thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- the cell extract collected was subjected to Western blot analysis.
- a SDS-PAGE gel (14 wells) was prepared using TGXTM FastCastTM Acrylamide Kit, 12% (Bio-Rad). Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 17 ⁇ L/well. Precision Plus ProteinTM Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 150 V for 40 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- proteins were transferred to a PVDF membrane (ImmobionTM-P, Millipore) under conditions of 100 V and 40 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol).
- the membrane after transfer was shaken and blocked in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T.
- anti-HA-peroxidase, high-affinity (3F10) rat monoclonal antibody 25 U/mL (Roche) diluted 1500 times was used.
- the membrane was shaken at room temperature for 90 minutes, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes.
- the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- Fig. 3 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib or TMP was added.
- E. coli DHFR was able to be detected only up to about 50°C for the control (DMSO).
- DMSO control
- E. coli DHFR was able to be detected up to about 54°C by virtue of interaction between E. coli DHFR and TMP when TMP (40 ⁇ M) was added.
- E. coli DHFR was able to be detected up to about 54°C by virtue of interaction between E.
- TMP-CiKD_Bortezomib in which TMP-NH 2 is linked to CiKD_Bortezomib, has an affinity with E. coli DHFR to a similar extent as TMP.
- Example 4 Evaluation of proteasome inhibitory activity of protein-degradation inducing molecule (TMP-CiKD_Bortezomib) and affinity thereof with proteasome>
- Example 4 the proteasome inhibitory activity of TMP-CiKD_Bortezomib, and the affinity of TMP-CiKD_Bortezomib with a proteasome were evaluated.
- AMC released when the C-terminus of an AMC-conjugated proteasome fluorescent substrate specific to a ⁇ subunit of ⁇ 5 (chymotrypsin-like activity), ⁇ 2 (trypsin-like activity), and ⁇ 1 (caspase-like activity) of 20S proteasome was cut using 20S Proteasome StressXpressTM Assay Kit Gold (Bioscience) was measured with a multi-detection microplate reader (Synergy HT, BIO-TEK). The measurement wavelengths were 360 nm for excitation light (Ex.), and 460 nm for fluorescence (Em.).
- Figs. 4A to 4C show the proteasome activities against ⁇ 1 (caspase-like activity), ⁇ 2 (trypsin-like activity), and ⁇ 5 (chymotrypsin-like activity), respectively.
- the inhibitory activity of TMP-CiKD_Bortezomib against ⁇ 1 and ⁇ 5 was found to be substantially weakened as compared with bortezomib alone, indicating that the inhibitory activity of bortezomib was inactivated.
- the present results were consistent with a previous report stating that ⁇ 2 was not significantly inhibited by bortezomib ( Kisselev, A. F.
- Example 5 Measurement of 50% inhibition concentration (IC 50 ) of protein-degradation inducing molecule (TMP-CiKD_Bortezomib)>
- Example 5 50% inhibition concentrations (IC 50 ) of TMP-CiKD_Bortezomib and bortezomib (Code No. sc-217785, Santa Cruz Biotechnology) were measured for each of the proteasome activities of ⁇ 1, ⁇ 2, and ⁇ 5 of 20S proteasome.
- Test compounds (TMP-CiKD_Bortezomib and bortezomib) were each adjusted to 6 concentrations as shown in the following Table 83.
- Table 83 TMP-CiKD_Bortezomib ⁇ 1 : 1, 4, 10, 40, 80, 160 ⁇ M ⁇ 2: 1, 4, 10, 40, 80, 160 ⁇ M ⁇ 5: 1, 4, 10, 40, 80, 160 ⁇ M Bortezomib ⁇ 1: 0.01, 0.04, 0.1, 0.4, 1, 10 ⁇ M ⁇ 2: 0.4, 1, 4, 10, 40, 100 ⁇ M ⁇ 5: 0.001, 0.004, 0.01, 0.04, 0.1, 0.4 ⁇ M
- a test compound and 20S proteasome were incubated at room temperature for 30 minutes.
- Suc-LLVY-AMC degradable by ⁇ 5
- Bz-VGR-AMC degradable by ⁇ 2
- Z-LLE-AMC degradable by ⁇ 1
- TMP-CiKD_Bortezomib and bortezomib are shown in the following Table 84.
- TMP-CiKD_Bortezomib was found to have significantly increased 50% inhibition concentrations (IC 50 ) against all of ⁇ 1, ⁇ 2, and ⁇ 5 as compared with bortezomib, indicating that the inhibitory activity of bortezomib was inactivated.
- Example 6 Synthesis of protein-degradation inducing molecule (TMP-CiKD_ALLN) using CiKD_ALLN as protein-degradation inducing tag and TMP derivative as protein binding molecule>
- TMP-CiKD_ALLN as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme.
- ALLN-COOH CiKD_ALLN
- TMP-NH 2 was used as in Example 1. Then, ALLN-COOH was linked to TMP-NH 2 to synthesize TMP-CiKD_ALLN as a protein-degradation inducing molecule.
- Example 7 Evaluation (FACS analysis) of degradation (knockdown) of forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_ALLN) was added>
- Example 7 degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN was added was evaluated by FACS analysis.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_ALLN Protein-degradation inducing molecule
- TMP-CiKD_ALLN was added to HeLa cells as in Example 2 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
- a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_ALLN.
- TMP-CiKD_ALLN The efficiency of target degradation (knockdown) by TMP-CiKD_ALLN was determined as in Example 2 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
- Fig. 5A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN was added.
- Fig. 5B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added.
- TMP-CiKD_ALLN 80 ⁇ M
- the graph was found to be significantly shifted to the left as compared with that of the control (DMSO), indicating that the target protein (E. coli DHFR) was degraded.
- the degradation efficiency estimated from the amount of a shift was about 60% to 70%.
- Fig.5B when TMP (80 ⁇ M) was added, the graph was found to be overlapped with that of the control (DMSO), indicating that the target protein was not degraded.
- Example 8 Evaluation (thermal shift assay) of affinity of protein-degradation inducing molecule (TMP-CiKD_ALLN) with forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_ALLN) was added>
- Example 8 the affinity of TMP-CiKD_ALLN with a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN was added was evaluated by thermal shift assay.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_ALLN Protein-degradation inducing molecule
- TMP-CiKD_ALLN was added to HeLa cells as in Example 2 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
- a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_ALLN.
- TMP-CiKD_ALLN The affinity of TMP-CiKD_ALLN with a target was evaluated by thermal shift assay as in Example 3 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
- Fig. 6 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN or TMP was added.
- E. coli DHFR was able to be detected only up to about 50°C for the control (DMSO).
- DMSO control
- E. coli DHFR was able to be detected up to about 54°C by virtue of interaction between E. coli DHFR and TMP when TMP (40 ⁇ M) was added.
- E. coli DHFR was able to be detected up to about 58°C by virtue of interaction between E.
- TMP-CiKD_ALLN in which TMP-NH 2 is linked to CiKD_ALLN, has a higher affinity with E. coli DHFR than TMP.
- Example 9 Evaluation of proteasome inhibitory activity of protein-degradation inducing molecule (TMP-CiKD_ALLN) and affinity thereof with proteasome>
- Example 9 the proteasome inhibitory activity of TMP-CiKD_ALLN, and the affinity of TMP-CiKD_ALLN with a proteasome were evaluated as in Example 4 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
- Figs. 7A to 7C show the proteasome activities against ⁇ 1 (caspase-like activity), ⁇ 2 (trypsin-like activity), and ⁇ 5 (chymotrypsin-like activity), respectively.
- the inhibitory activity of TMP-CiKD_ALLN against ⁇ 2 and ⁇ 5 was found to be weakened as compared with ALLN alone, indicating that the activity of ALLN was inactivated.
- the present results were consistent with a previous report stating that ⁇ 1 was not significantly inhibited by ALLN ( Kaiser, M. et al., Chem. Bio. Chem., 2004, 5, 1256-1266 ).
- TMP-CiKD_ALLN had an affinity with a proteasome.
- Example 10 Measurement of 50% inhibition concentration (IC 50 ) of protein-degradation inducing molecule (TMP-CiKD_ALLN)>
- Example 10 the 50% inhibition concentrations (IC 50 ) of TMP-CiKD_ALLN and ALLN (Code No. 07036-82, Nacalai Tesque, Inc.) were measured for each of the proteasome activities of ⁇ 1, ⁇ 2, and ⁇ 5 of 20S proteasome as in Example 5 except that TMP-CiKD_ALLN and ALLN were used in place of TMP-CiKD_Bortezomib and bortezomib. It is noted that test compounds (TMP-CiKD_ALLN and ALLN) were each adjusted to 6 concentrations as shown in the following Table 85.
- TMP-CiKD_ALLN ⁇ 1 5, 10, 20, 40, 80, 160 ⁇ M ⁇ 2: 5, 10, 20, 40, 80, 160 ⁇ M ⁇ 5: 5, 10, 20, 40, 80, 160 ⁇ M ALLN ⁇ 1 : 0.4, 1, 4, 10, 20, 40 ⁇ M ⁇ 2: 0.4, 1, 4, 10, 20, 40 ⁇ M ⁇ 5: 0.04, 0.1, 0.4, 1, 4, 10 ⁇ M
- TMP-CiKD_ALLN 50% inhibition concentrations (IC 50 ) of TMP-CiKD_ALLN and ALLN are shown in the following Table 86. [Table 86] IC 50 ( ⁇ M) ⁇ 1 ⁇ 2 ⁇ 5 TMP-CiKD. ALLN 38.8 > 160 42.3 ALLN 12.4 5.25 1.15
- TMP-CiKD_ALLN was found to have significantly increased 50% inhibition concentrations (IC 50 ) for all of ⁇ 1, ⁇ 2, and ⁇ 5 as compared with ALLN, indicating that the inhibitory activity of ALLN was inactivated.
- Example 11 Synthesis of protein-degradation inducing molecule (TMP-CiKD_MLN) using CiKD_MLN as protein-degradation inducing tag and TMP derivative as protein binding molecule>
- TMP-CiKD_MLN as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme.
- MLN-COOH CiKD_MLN
- TMP-NH 2 was used as in Example 1.
- MLN-COOH was linked to TMP-NH 2 to synthesize TMP-CiKD_MLN as a protein-degradation inducing molecule.
- H-Gly-OtBu ⁇ HCl (286.8 mg, 1.69 mmol, 1 eq, Code No. AK-46074, Ark Pharm) was charged into a side-arm eggplant flask, and purged with nitrogen. Under nitrogen gas stream, 10 mL of dehydrate DMF and 5 mL of DIEA were added, and stirred at room temperature. In 1 mL of dehydrate DMF and 1 mL of DIEA, dissolved was 2,5-dichlorobenzoic acid (309.3 mg, 1.62 mmol, 1 eq, Code No. AK-47665, Ark Pharm), which was then added to the reaction solution, and stirred at room temperature for 20 minutes.
- the compound 8 (212.4 mg, 0.70 mmol) was charged into an eggplant flask, and 5 mL of dichloromethane was then added. This was stirred at room temperature for 5 minutes, and then 5 mL of TFA was added, and stirred at room temperature for 1 hour. After evaporating the solvent under reduced pressure, vacuum drying was performed to obtain a compound 9 (190.7 mg, quant.).
- the compound 10 (240.8 mg, 0.58 mmol) was charged into an eggplant flask, and 5 mL of dichloromethane was added. This was stirred at room temperature for 5 minutes, and then 5 mL of TFA was added, and stirred at room temperature for 1 hour. After evaporating the solvent under reduced pressure, vacuum drying was performed to obtain a compound 11 (MLN-COOH) (214.7 mg, 0.59 mmol, 100%).
- the compound 11 (MLN-COOH) (210.3 mg, 0.58 mmol, 1 eq) was charged into a side-arm eggplant flask, and purged with nitrogen.
- TMP-NH 2 synthesized separately ( Long, M. J. et al., Chem. Biol., 2012, 19 (5), 629-637 ) (207.6 mg, 0.48 mmol, 0.8 eq) was dissolved in 5 mL of dehydrate DMF, and added to the reaction solution. To this, 5 ml of DIEA was added, and stirred at room temperature for 20 minutes.
- PyBOP (765.2 mg, 1.47 mmol, 2.5 eq, Code No.
- Example 12 Evaluation (FACS analysis) of degradation (knockdown) of forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_MLN) was added>
- Example 12 degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN was added was evaluated by FACS analysis.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_MLN Protein-degradation inducing molecule
- TMP-CiKD_MLN was added to HeLa cells as in Example 2 except that TMP-CiKD_MLN was used in place of TMP-CiKD_Bortezomib. Further, an experiment group where a DMSO solution containing TMP-CiKD_MLN and bortezomib was added was also prepared in addition to an experiment group where a DMSO solution containing TMP-CiKD_MLN was added. A DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_MLN.
- TMP-CiKD_MLN The efficiency of target degradation (knockdown) by TMP-CiKD_MLN was determined as in Example 2 except that TMP-CiKD_MLN or TMP-CiKD_MLN and bortezomib were used in place of TMP-CiKD_Bortezomib.
- Fig. 8A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN was added.
- Fig. 8B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added.
- Fig. 8C shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN and bortezomib were added.
- Fig. 8A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN and bortezomib were added.
- Example 13 Synthesis of protein-degradation inducing molecule (MTX-CiKD_MLN) using CiKD_MLN as protein-degradation inducing tag and MTX derivative as protein binding molecule>
- MTX-CiKD_MLN as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme.
- MLN-COOH CiKD_MLN
- MTX-NH 2 MTX derivative
- MTX-NH 2 MTX-NH 2
- the compound 13 was allowed to react with triphenylphosphine dibromide in DMA to obtain a compound 14.
- the compound 14 was dissolved in DMA under nitrogen gas stream, and then the compound 15 and DIEA were added and reacted to obtain a compound 16 (yield: 69%).
- the compound 16 and the compound 17 were dissolved in DMSO under nitrogen gas stream, and condensation reaction was performed with a BOP reagent to obtain a compound 18 (yield: 46%).
- the compound 18 and the compound 19 were dissolved in DMA under nitrogen gas stream, and condensation reaction was performed with HATU to obtain a compound 20 (yield: 69%).
- the compound 20 was dissolved in dichloromethane, and deprotection was performed with TFA to obtain a compound 21 (MTX-NH 2 ).
- the compound 21 (MTX-NH 2 ) and the compound 11 used for synthesis of the compound 12 (TMP-CiKD_MLN) were dissolved in DMF under nitrogen gas stream, and a condensation reaction was performed with PyBOP (at room temperature for 3 hours).
- Example 14 Evaluation (thermal shift assay) of the affinity of a protein-degradation inducing molecule (MTX-CiKD_MLN) with endogenously expressed target protein (human DHFR) in HeLa cells to which a protein-degradation inducing molecule (MTX-CiKD_MLN) was added>
- Example 14 the affinity of MTX-CiKD_MLN with an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN was added was evaluated by thermal shift assay.
- HeLa cells were prepared as in Example 2.
- the cell solution collected after trypsin treatment was seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 10 4 cells/800 ⁇ L/well, and then cultured under conditions of 37°C and 5 vol% CO 2 for 16 hours.
- MTX-CiKD_MLN was added to HeLa cells as follows 16 hours after cell seeding.
- a medium used was a serum free medium (37°C) in which a 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.). It is noted that the L-glutamine solution was added immediately before use.
- a DMSO solution containing MTX-CiKD_MLN was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well where the pre-culture medium had been removed at 500 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 . It is noted that a DMSO solution containing MTX or DMSO was used as a control in place of the DMSO solution containing MTX-CiKD_MLN.
- the medium was removed 3 hours after addition of MTX-CiKD_MLN (40 ⁇ M) or MTX (40 ⁇ M), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 1 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA ⁇ 4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 200 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No.
- PenStrep 100 U/mL sodium penicillin G and 100 ⁇ g/mL streptomycin sulfate
- D-MEM low D-glucose, L-glutamine, phenol red
- D-MEM low D-glucose, L-glutamine, phenol red
- the cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C).
- the cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 170 ⁇ L of a CETSA buffer (cOmpleteTM Mini, EDTA-free (Roche) as a protease inhibitor was added to TBS just before use) was added, and then suspended.
- the cell solution after suspension was dispensed to nine 1.5 mL tubes at 20 ⁇ L per tube, and allowed to stand at room temperature for 30 minutes.
- the 9 tubes were heat-treated for 3 minutes, one each at 38°C, 42°C, 46°C, 50°C, 54°C, 58°C, 62°C, 66°C, or 70°C, and allowed to stand at room temperature for 3 minutes.
- the cell solution was flash frozen in liquid nitrogen, and thawed on ice. After repeating this freeze-thaw cycle for 3 times, the cell solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 17 ⁇ L/well. Precision Plus ProteinTM Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 60 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- proteins were transferred to a PVDF membrane (ImmobionTM-P, Millipore) under conditions of 100 V and 2 hours using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol).
- the membrane after transfer was shaken and blocked in 5% skim milk/TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T.
- anti-DHFR antibody sc-377091, SantaCruz
- a secondary antibody reaction was performed in 2% skim milk/TBS-T.
- anti-mouse IgG (H+L) antibody A90-116P-33, BETHYL
- the membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times.
- the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- Fig. 9 shows results from the thermal shift assay of an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN or MTX was added.
- human DHFR was able to be detected only up to about 42°C for the control (DMSO) while human DHFR was able to be detected up to about 50°C by virtue of interaction between human DHFR and MTX-CiKD_MLN when MTX-CiKD_MLN (40 ⁇ M) was added.
- Example 15 Evaluation (Western blot analysis) of degradation (knockdown) of endogenously expressed target protein (human DHFR) in HeLa cells to which protein-degradation inducing molecule (MTX-CiKD_MLN) was added>
- Example 15 degradation (knockdown) of an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN was added was evaluated by Western blot analysis.
- HeLa cells were prepared, and seeded on a 24-well plate as in Example 14.
- MTX-CiKD_MLN was added to HeLa cells as in Example 14.
- a DMSO solution containing MTX or DMSO was used as a control in place of the DMSO solution containing MTX-CiKD_MLN.
- the medium was removed 16 hours after addition of MTX-CiKD_MLN (50 ⁇ M, 100 ⁇ M, or 200 ⁇ M) or MTX (50 ⁇ M, 100 ⁇ M, or 200 ⁇ M), and then PBS (Wako Pure Chemical Industries, Ltd.) at 4°C was added to each well at 1 mL/well to wash the cells. After removing PBS, a mixed solution of a cell lysis buffer (CelLyticTM M, Sigma) and a protease inhibitor (cOmpleteTM Mini, EDTA-free (REF 11 836 170 001), Roche) was added to each well at 27 ⁇ L/well.
- a cell lysis buffer (CelLyticTM M, Sigma)
- a protease inhibitor cOmpleteTM Mini, EDTA-free (REF 11 836 170 001), Roche
- cells were detached with a pipette tip (P1000) on ice.
- a cell solution was collected in a 1.5 mL tube, and flash frozen in liquid nitrogen, and then thawed on ice. After thawed, the cell solution was centrifuged (at 12000 rpm x 15 minutes, 4°C), and the supernatant (cell extract) was collected.
- Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 20 ⁇ L/well. Precision Plus ProteinTM Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 65 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- proteins were transferred to a PVDF membrane (ImmobionTM-P, Millipore) under conditions of 100 V and 2 hours using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol).
- the Membrane was split into two at the position of a 25 kDa marker.
- the membrane after transfer was shaken and blocked in 5% skim milk/TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T.
- anti-DHFR antibody sc-14780, SantaCruz, diluted 500 times
- anti-GAPDH antibody sc-32233, SantaCruz, diluted 20000 times
- the membranes were washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times.
- a secondary antibody reaction was performed in 2% skim milk/TBS-T. The membranes were shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times.
- the membranes were washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membranes were treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation). Detected bands were quantified with an image processing software ImageJ (NIH).
- Fig. 10A shows results from quantification of bands detected in the Western blot analysis of the endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN or MTX was added.
- Fig. 10B shows the detected bands.
- the amount of the target protein (human DHFR) was decreased in a concentration dependent manner when MTX-CiKD_MLN was added.
- MTX was added, a decrease in the amount of the target protein (human DHFR) was not observed even at a concentration of 200 ⁇ M.
- Example 16 Evaluation of degradation (knockdown) of endogenously expressed target protein (mouse DHFR) in mouse individuals to which protein-degradation inducing molecule (MTX-CiKD_MLN) is administered>
- Example 16 degradation (knockdown) of an endogenously expressed target protein (mouse DHFR) in mouse individuals to which MTX-CiKD_MLN was administered was evaluated by Western blot analysis.
- mice administering protein-degradation inducing molecule (MTX-CiKD_MLN) to mice.
- MTX-CiKD_MLN and MTX were dissolved in DMSO, and then dissolved in corn oil (Code No. 25606-55, Nacalai Tesque, Inc.) so that the concentration of DMSO was 10 vol%, and then administered intraperitoneally.
- the mice were kept under an environment of ad libitum access to food and water.
- mice were dissected under deep Somnopentyl anesthesia (serial number: 3214101, Kyoritsuseiyaku Corporation) 24 hours after administration.
- the liver, kidney, spleen, heart, and lung were excised, and flash freeze in liquid nitrogen.
- the frozen liver (40 mg) was triturated, and then 980 ⁇ L of 1x TKM tissue lysis buffer (50 mM triethanolamine (pH 7.8), 50 mM KCl, 5 mM MgCl 2 , 0.25 M sucrose, 1 mM PMSF, Protein Inhibitors Cocktail-EDTA free (Code No. 03969-21, Nacalai Tesque, Inc.), 1 mM DTT, recombinant RNase inhibitor 5 ⁇ L/mL (40 U/ ⁇ L, Cat No. 2313A, Lot No. K8402DA, TAKARA) were added, and rotated for 15 minutes (1 rpm, 25°C). After centrifugation (at 3000 rpm x 15 minutes, 4°C), the supernatant (liver tissue extract) was collected. The concentration of extracted proteins was quantified with a spectrophotometer.
- 1x TKM tissue lysis buffer 50 mM triethanolamine (pH 7.8), 50 mM KCl, 5 m
- the liver tissue extract collected was subjected to Western blot analysis.
- An SDS-PAGE gel (14 wells) was prepared using TGXTM FastCastTM Acrylamide Kit, 12% (Bio-Rad) .
- Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 5 minutes.
- the electrophoresis samples prepared were applied at 100 ⁇ g/20 ⁇ L/well (for detection of DHFR) or 50 ⁇ g/10 ⁇ L/well (for detection of GAPDH). Precision Plus ProteinTM Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 60 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- proteins were transferred to a PVDF membrane (ImmobionTM-P, Millipore) under conditions of 100 V and 90 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol).
- the membrane after transfer was shaken and blocked in 5% skim milk/TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T.
- anti-DHFR antibody sc-14780, SantaCruz, diluted 500 times
- anti-GAPDH antibody sc-32233, SantaCruz, diluted 20000 times
- the membrane was shaken at room temperature for 60 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times.
- a secondary antibody reaction was performed in 1% skim milk/TBS-T. The membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times.
- the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 10 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- Fig. 11 shows results from the Western blot analysis of an endogenous expressed target protein (mouse DHFR) in a liver tissue extract from a mouse individual to which MTX-CiKD_MLN or MTX was administered.
- the amount of the target protein (mouse DHFR) in the liver tissue was decreased in a concentration dependent manner.
- Example 17 Synthesis of protein-degradation inducing molecule (TMP-CiKD_DMT) using CiKD_DMT as protein-degradation inducing tag and TMP derivative as protein binding molecule>
- TMP-CiKD_DMT as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme.
- a protein-degradation inducing tag used was a compound (DMT) in which R 1 and R 2 in the aforementioned formula (I) were each a methoxy group.
- DMT is a compound which is not derived from a proteasome inhibitor, but has an affinity with a proteasome.
- TMP-NH 2 was used as in Example 1. Then, DMT was linked to TMP-NH 2 to synthesize TMP-CiKD_DMT as a protein-degradation inducing molecule.
- TMP-NH 2 Long, M. J. et al., Chem. Biol., 2012, 19 (5), 629-637 ) (31.7 mg, 0.073 mmol) was charged into an eggplant flask, and 0.3 mL of dehydrate DMF was added. After stirred at room temperature for 10 minutes, 0.1 mL of DIEA was added, and stirred at room temperature for 10 minutes. DMT-MM (33.6 mg, 0.12 mmol, 1.6 eq, Code No. 329-53751, Wako Pure Chemical Industries, Ltd.) was directly added to the reaction solution, and stirred at room temperature for 18 hours. The reaction solution was diluted with water and aqueous sodium hydrogen carbonate, and extracted with chloroform for 5 times.
- Example 18 Evaluation of proteasome inhibitory activity of protein-degradation inducing molecule (TMP-CiKD_DMT) and affinity thereof with proteasome>
- Example 18 the proteasome inhibitory activity of TMP-CiKD_DMT and the affinity of TMP-CiKD_DMT with a proteasome were evaluated as in Example 4 except that 10 ⁇ M or 100 ⁇ M of TMP-CiKD_DMT was used in place of TMP-CiKD_Bortezomib. As a positive control, used was MG-132 as a proteasome inhibitor.
- Figs. 12A to 12C show the proteasome activities against ⁇ 1 (caspase-like activity), ⁇ 2 (trypsin-like activity), and ⁇ 5 (chymotrypsin-like activity), respectively.
- TMP-CiKD_DMT was found to have a significantly lower proteasome inhibitory activity as compared with MG-132.
- the inhibitory activity of TMP-CiKD_DMT was increased in a concentration dependent manner against any of ⁇ 1, ⁇ 2, and ⁇ 5, suggesting that TMP-CiKD_DMT has a moderate affinity with a proteasome. That is, DMT was evaluated to have an affinity with a proteasome, but does not inhibit degradation.
- Example 19 Measurement of 50% inhibition concentration (IC 50 ) of protein-degradation inducing molecule (TMP-CiKD_DMT)>
- Example 19 the 50% inhibition concentration (IC 50 ) of TMP-CiKD_DMT against each of the proteasome activities of ⁇ 1, ⁇ 2, and ⁇ 5 of 20S proteasome was measured as in Example 5 except that TMP-CiKD_DMT was used in place of TMP-CiKD_Bortezomib.
- IC 50 50% inhibition concentration
- TMP-CiKD_DMT was found to have a significantly lower proteasome inhibitory activity as compared with MLN2238.
- Example 20 Evaluation (thermal shift assay) of affinity of protein-degradation inducing molecule (TMP-CiKD_ALLN) with forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_DMT) was added>
- Example 20 the affinity of TMP-CiKD_DMT with a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added was evaluated by thermal shift assay.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid was introduced into HeLa cells to transiently overexpress ecDHFR as a target protein (specifically, a fusion protein of ecDHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- a target protein specifically, a fusion protein of ecDHFR and GFP through a HA tag
- DsRed for comparison in the cells
- the plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) ( Long, M. J. et al., "Inhibitor mediated protein degradation.” Chem. Biol., 2012, 19 (5), 629-637 ). The plasmid was amplified in E. coli, and then purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFectATM (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells.
- a dilution buffer of ScreenFectTM A was added to two 1.5 mL tubes at 250 ⁇ L per tube. Then, 12 ⁇ L of a transfection reagent of ScreenFectTM A was added to one tube (a solution A), and 6 ⁇ g of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes.
- the solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C).
- the solution C was mixed in a cell solution of 6 x 10 5 cells/12 mL collected by trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, and Nippon Genetics Co., Ltd.) at a cell density of 4 x 10 4 cells/800 ⁇ L/well, and then cultured under conditions of 37°C and 5 vol% CO 2 for 40 hours.
- TMP-CiKD_DMT Protein-degradation inducing molecule
- TMP-CiKD_DMT was added to HeLa cells as follows.
- a medium used was a serum free medium (37°C) in which 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.). It is noted that the L-glutamine solution was added immediately before use.
- a DMSO solution containing MTX-CiKD_DMT was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well at 300 ⁇ L/well where the pre-culture medium had been removed, and cultured under conditions of 37°C and 5 vol% CO 2 . It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_DMT.
- the medium was removed 3 hours after addition of TMP-CiKD_DMT (28 ⁇ M) or TMP (40 ⁇ M), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 1 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA ⁇ 4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 300 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 for 1 minutes. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No.
- PenStrep 100 U/mL sodium penicillin G and 100 ⁇ g/mL streptomycin sulfate
- D-MEM low D-glucose, L-glutamine, phenol red
- D-MEM low D-glucose, L-glutamine, phenol red
- the cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C).
- the cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 180 ⁇ L of a CETSA buffer (completeTM Mini, EDTA-free (Roche) as a protease inhibitor was added to TBS immediately before use) was added and suspended.
- the cell solution after suspension was dispensed to nine 1.5 mL tubes at 20 ⁇ L per tube, and allowed to stand at room temperature for 30 minutes.
- the 9 tubes were heat-treated for 3 minutes, one each at 38°C, 42°C, 46°C, 50°C, 54°C, 58°C, 62°C, 66°C, or 70°C, and allowed to stand at room temperature for 3 minutes.
- the cell solution was flash frozen in liquid nitrogen, and thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 17 ⁇ L/well. Precision Plus ProteinTM Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 150 V for 40 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- proteins were transferred to a PVDF membrane (ImmobionTM-P, Millipore) under conditions of 100 V and 40 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol).
- the membrane after transfer was shaken and blocked at room temperature for 30 minutes in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6). After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T.
- anti-HA-peroxidase high-affinity (3F10) rat monoclonal antibody (25 U/mL) (Roche) diluted 1000 times was used.
- the membrane was shaken at room temperature for 90 minutes, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes.
- the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- Fig. 13 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT or TMP was added.
- E. coli DHFR was able to be detected only up to about 50°C for the control (DMSO) while E. coli DHFR was able to be detected up to about 54°C for TMP (40 ⁇ M) and up to about 62°C for TMP-CiKD_DMT (28 ⁇ M).
- Example 21 Evaluation (FACS analysis) of degradation (knockdown) of forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_DMT) was added>
- Example 21 degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added was evaluated by FACS analysis.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- the plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) ( Long, M. J. et al., "Inhibitor mediated protein degradation.” Chem. Biol., 2012, 19 (5), 629-637 ). The plasmid was amplified in E. coli, and purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFectTM A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells.
- a dilution buffer of ScreenFectTM A was added to two 1.5 mL tubes at 960 ⁇ L per tube.
- 40 ⁇ L of a transfection reagent of ScreenFectTM A was added to one tube (a solution A), and 16 ⁇ g of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes.
- the solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C).
- the solution C was mixed with a cell solution of 2.7 x 10 5 cells/18 mL collected from trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 6 x 10 4 cells/400 ⁇ L/well, and then cultured under conditions of 37 °C and 5 vol% CO 2 for 40 hours.
- TMP-CiKD_DMT Protein-degradation inducing molecule
- TMP-CiKD_DMT was added to HeLa cells as follows. Culture was performed for 40 hours after introduction of the plasmid, and then the preculture medium was removed. Then, a serum-free medium (37°C) in which 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, and sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.) was added to each well at 297 ⁇ L/well. It is noted that the L-glutamine solution was added immediately before use.
- L-glutamine solution Code No. G7513, Sigma-Aldrich
- a DMSO solution containing a predetermined concentration of TMP-CiKD_DMT was added to each well at 3 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 . It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_DMT.
- the medium was removed 24 hours after addition of TMP-CiKD_DMT (56 ⁇ M or 112 ⁇ M) or TMP (80 ⁇ M), PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 1 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA ⁇ 4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 300 ⁇ L/well, and cultured under conditions of 37°C and 5 vol% CO 2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No.
- PenStrep 100 U/mL sodium penicillin G and 100 ⁇ g/mL streptomycin sulfate
- D-MEM low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.)) was added to each well at 500 ⁇ L/well, and suspended, and then a cell solution was collected in a 15 mL tube.
- the cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C).
- the cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 500 ⁇ L of an FACS buffer (1 mass% FBS/PBS) at 4°C was added, and allowed to stand on ice.
- a BD FACSCantoTM II (BD Biosciences) was used for flow cytometry, and the expression levels of GFR and DsRed in the cells were quantified.
- the cell solution was passed through a mesh with a pore size of 32 ⁇ m, and transferred to an FACS tube immediately before FACS analysis.
- the GFR/DsRed ratio per cell was computed using an analysis software FLOWJOTM (TOMY Digital Biology Co., Ltd.), and the efficiency of target degradation (knockdown) by TMP-CiKD_DMT was determined from a shift in a graph of target degradation.
- Fig. 14A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT (56 ⁇ M) was added.
- Fig. 14B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT (112 ⁇ M) was added.
- Fig. 14C shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added.
- Figs. 14A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added.
- Example 22 Evaluation (Western blot analysis) of degradation (knockdown) of forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_DMT) was added>
- Example 22 degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added was evaluated by Western blot analysis.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- the plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) ( Long, M. J. et al., "Inhibitor mediated protein degradation.” Chem. Biol., 2012, 19 (5), 629-637 ). The plasmid was amplified in E. coli, and purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFectTM A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells.
- a dilution buffer of ScreenFectTM A was added to two 1.5 mL tubes at 250 ⁇ L per tube. Then, 12 ⁇ L of a transfection reagent of ScreenFectTM A was added to one tube (a solution A), and 4.8 ⁇ g of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes.
- the solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C).
- the solution C was mixed with a cell solution of 7.7 x 10 4 cells/7.7 mL collected from trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 10 4 cells/400 ⁇ L/well, and then cultured under conditions of 37°C and 5 vol% CO 2 for 40 hours.
- TMP-CiKD_DMT Protein-degradation inducing molecule
- TMP-CiKD_DMT was added to HeLa cells as follows.
- a medium used was a serum free medium (37°C) in which 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.)). It is noted that the L-glutamine solution was added immediately before use.
- a DMSO solution containing TMP-CiKD_DMT was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well at 300 ⁇ L/well where the pre-culture medium had been removed, and cultured under conditions of 37°C and 5 vol% CO 2 . Further, an experiment group where a DMSO solution containing TMP-CiKD_DMT and bortezomib was added was also prepared in addition to an experiment group where a DMSO solution containing TMP-CiKD_DMT was added.
- Cycloheximide as a protein synthesis inhibitor was added to the medium so as to give a concentration of 50 ⁇ g/mL 12 hours after addition of TMP-CiKD_DMT or TMP-CiKD_DMT and bortezomib. It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_DMT.
- the medium was removed 24 hours after addition of TMP-CiKD_DMT or TMP-CiKD_DMT and bortezomib, and 1 mL of PBS (Wako Pure Chemical Industries, Ltd.) at 4°C was added to each well to wash the cells.
- PBS Pur Chemical Industries, Ltd.
- a mixed solution of a cell lysis buffer (CelLyticTM M, Sigma) and a protease inhibitor (completeTM Mini, EDTA-free (REF 11 836 170 001), Roche) was added to each well at 55 ⁇ L/well. After allowed to stand at 4°C for 15 minutes, cells were detached with a pipette tip (P1000) on ice.
- a cell solution was collected in a 1.5 mL tube, and flash frozen in liquid nitrogen, and then thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13000 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 40 ⁇ L/well. Precision Plus ProteinTM Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 150 V for 50 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- proteins were transferred to a PVDF membrane (ImmobionTM-P, Millipore) under conditions of 100 V and 40 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol).
- the membrane after transfer was shaken and blocked at room temperature for 30 minutes in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6). After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T.
- anti-HA-peroxidase high-affinity (3F10) rat monoclonal antibody (25 U/mL) (Roche) diluted 1000 times was used.
- the membrane was shaken at room temperature for 1 hour, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes.
- the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- a reaction for detecting GAPDH as a control was performed using the same membrane.
- the membrane was washed with TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6), and blocked by shaking at room temperature for 30 minutes in 5% skim milk/TBS-T. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T.
- anti-GAPDH antibody sc-32233, SantaCruz, diluted 20000 times
- the membrane was shaken at room temperature for 60 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times.
- a secondary antibody reaction was performed in 2% skim milk/TBS-T.
- anti-mouse IgG (H+L) antibody (A90-116P-33, BETHYL) diluted 20000 times was used.
- the membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes.
- the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation). Detected bands were quantified with an image processing software ImageJ (NIH).
- Fig. 15A shows results from quantification of bands detected in the Western blot analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT or TMP-CiKD_DMT and bortezomib were added.
- Fig. 10B shows the detected bands.
- the degradation efficiency was about 60% relative to the control (DMSO) when TMP-CiKD_DMT (112 ⁇ M) was added.
- DMSO control
- TMP-CiKD_DMT 112 ⁇ M
- bortezomib (1 ⁇ M
- Example 23 Evaluation (Western blot analysis) of degradation (knockdown) of forcedly expressed target protein (E. coli DHFR) in HeLa cells to which protein-degradation inducing molecule (TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib) was added>
- Example 23 degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib were added was evaluated by Western blot analysis.
- E. coli DHFR forcedly expressed target protein
- HeLa cells were prepared as in Example 2.
- a plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- the plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) ( Long, M. J. et al., "Inhibitor mediated protein degradation.” Chem. Biol., 2012, 19 (5), 629-637 ). The plasmid was amplified in E. coli, and purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFectTM A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells.
- a dilution buffer of ScreenFectTM A was added to two 1.5 mL tubes at 400 ⁇ L per tube.
- 20 ⁇ L of a transfection reagent of ScreenFectTM A was added to one tube (a solution A), and 10.3 ⁇ g of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes.
- the solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C).
- the solution C was mixed in a cell solution of 8 x 10 5 cells/16 mL collected by trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 10 4 cells/800 ⁇ L/well, and then cultured under conditions of 37°C and 5 vol% CO 2 for 40 hours.
- TMP-CiKD_DMT Additional protein-degradation inducing molecule (TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib) to HeLa cells)
- TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib was added to HeLa cells as follows.
- a medium used was a serum free medium (37°C) in which a 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.)). It is noted that the L-glutamine solution was added immediately before use.
- a DMSO solution containing TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well at 300 ⁇ L/well where the pre-culture medium had been removed, and cultured under conditions of 37°C and 5 vol% CO 2 . It is noted that a DMSO solution containing TMP or DMSO was used as a control.
- the medium was removed 24 hours after addition of TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib, and PBS (Wako Pure Chemical Industries, Ltd.) at 4°C was added to each well at 1 mL/well to wash the cells.
- PBS Waako Pure Chemical Industries, Ltd.
- a mixed solution of a cell lysis buffer (CelLyticTM M, Sigma) and a protease inhibitor (completeTM Mini, EDTA-free (REF 11 836 170 001), Roche) was added to each well at 30 ⁇ L/well.
- cells were detached with a pipette tip (P1000) on ice.
- a cell solution was collected in a 1.5 mL tube, and flash frozen in liquid nitrogen, and then thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 20 ⁇ L/well. Precision Plus ProteinTM Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 45 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- proteins were transferred to a PVDF membrane (ImmobionTM-P, Millipore) under conditions of 100 V and 35 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol).
- the membrane after transfer was shaken and blocked at room temperature for 30 minutes in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6). After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T.
- anti-HA-peroxidase, high-affinity (3F10) rat monoclonal antibody 25 U/mL (Roche) diluted 500 times was used.
- the membrane was shaken at room temperature for 2 hours, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes.
- the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- a reaction for detecting GAPDH as a control was performed using the same membrane.
- the membrane was washed with TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6), and blocked by shaking in 5% skim milk/TBS-T at room temperature for 30 minutes.
- a primary antibody reaction was performed in 5% skim milk/TBS-T.
- anti-GAPDH antibody sc-32233, SantaCruz, diluted 10000 times
- the membrane was shaken at room temperature for 60 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times.
- a secondary antibody reaction was performed in 2% skim milk/TBS-T.
- anti-mouse IgG (H+L) antibody (A90-116P-33, BETHYL) diluted 20000 times was used.
- the membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes.
- the membrane was treated with a chemiluminescence reagent ImmobilonTM Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation). Detected bands were quantified with an image processing software ImageJ (NIH).
- Fig. 16 shows results from the Western blot analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib was added.
- TMP-CiKD_DMT was added in an amount of 80 ⁇ M or 160 ⁇ M
- the degradation efficiency relative to the control (DMSO) was 72% or 91%, respectively.
- TMP-CiKD_MLN, TMP-CiKD_ALLN, and TMP-CiKD_Bortezomib at 160 ⁇ M was 82%, 45%, and 28%, respectively.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present disclosure relates to a protein-degradation inducing tag and use thereof.
- Controlling the amount (expression) of a target protein in a cell, a living body, and the like is very useful for analyzing the functions of the target protein and life phenomena in which the target protein is involved. When a target protein is responsible for a disease, the disease can be prevented or treated by decreasing the amount of the target protein.
- As a conventional technique for controlling the amount of a target protein at the DNA level, known is the gene knockout technique in which a gene coding the target protein is made defective. As another technique for controlling the amount of a target protein at the RNA level, known is the RNAi (RNA interference) technique in which mRNA of the target protein is degraded with siRNA (small interfering RNA). However, the gene knockout technique is time consuming and expensive, and in addition, may involve bioethical issues. Further, the gene knockout technique cannot be applied to medicine because the gene of a target protein itself is made defective in the technique. Meanwhile, the RNAi technique suffers from off-target effects, and thus the amount of a target protein is difficult to be controlled in a specific manner. Further, the RNAi technique has been challenged in terms of the delivery of siRNA, and many problems need to be solved for applying to medicine.
- In view of the above circumstances, a technique has recently gathered much attention in which a target protein is degraded in a cell to control the amount of the target protein at the protein level. This technique is roughly categorized into an ubiquitin dependent technique in which ubiquitination of a target protein is used and an ubiquitin independent technique in which ubiquitination of a target protein is not used.
- As the ubiquitin dependent technique, known is a technique in which a complex is used, the complex having a structure where a molecule capable of binding to a target protein is linked to a molecule capable of binding ubiquitin ligase (E3) (For example, see Japanese Unexamined Patent Application Publication No.
2013-056837 U.S. Patent No. 7208157 , a report by Itoh, Y. et al., (Itoh, Y. et al., "Development of target protein-selective degradation inducer for protein knockdown.", Bioorg. Med. Chem., 2011, 19, 3229-3241), a report by Demizu et al., (Demizu, Y. et al., "Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy.", Bioorg. Med. Chem. Lett., 2012, 15, 1793-1796), and a report by Hines et al. (Hines, J. et al., "Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs.", Proc. Natl. Acad. Sci. U.S.A., 2013, 110(22), 8942-8947)) This technique involves allowing a target protein to be connected with ubiquitin ligase through the aforementioned complex to specifically ubiquitinate the target protein. This can lead the target protein to degradation by a proteasome. It is noted that the aforementioned complex may also be referred to as SNIPER (Specific and Nongenetic IAP-dependent Protein ERaser), PROTAC (PROteolysis TArgeting Chimera), and the like. - As the ubiquitin independent technique, known is a technique in which a complex is used, the complex having a structure where a molecule capable of binding to a target protein is linked to a hydrophobic tag (for example, see
WO2012/003281 , a report by Long et al. (Long, M. J. et al., "Inhibitor mediated protein degradation.", Chem. Biol., 2012, 19(5), 629-637), and a report by Neklesa et al. (Neklesa, T.K. et al., "Greasy tags for protein removal.", Nature, 2012, 487, 308-309)). This technique involves allowing the aforementioned complex to bind with a target protein to mimic a partially unfolded state of the target protein. This appears to lead the target protein to degradation by a proteasome. - However, the aforementioned ubiquitin dependent technique involving use of a complex having a structure where a molecule capable of binding to a target protein is linked to a molecule capable of binding ubiquitin ligase suffers from low versatility. That is, there are 1000 or more types of ubiquitin ligases in mammal, and ubiquitin ligase plays an important role in recognition of a target protein. Therefore, the complex needs to be individually designed per target protein. Further, the requirement of preparing an individually designed complex per target protein means that the target protein has to be known. Therefore, the technique is difficult to apply, for example, as a tool for identifying a target protein among degraded proteins.
- On the other hand, the aforementioned ubiquitin independent technique involving use of a complex having a structure where a molecule capable of binding to a target protein is linked to a hydrophobic tag suffers from low cell membrane permeability and high cytotoxicity due to the hydrophobic tag.
- In view of the above circumstances, an object of the present disclosure is to provide a novel protein-degradation inducing tag configured to induce degradation of a target protein, and use thereof.
- Specific means for achieving the above object include the following embodiments.
- (1) A protein-degradation inducing tag, which is a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease.
- (2) The protein-degradation inducing tag according to (1), in which the protein-degradation inducing tag has a structure where a proteasome inhibitory activity of a protease inhibitor is inactivated.
- (3) The protein-degradation inducing tag according to (1), in which the protease is a proteasome.
- (4) The protein-degradation inducing tag according to (3), in which the protein-degradation inducing tag has a structure where a proteasome inhibitory activity of a proteasome inhibitor is inactivated.
- (5) The protein-degradation inducing tag according to (4), in which the proteasome inhibiting activity is an inhibitory activity against at least one selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity.
- (6) A method of screening for a protein-degradation inducing tag, the method including a step of selecting a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease from candidate molecules.
- (7) The method of screening for a protein-degradation inducing tag according to (6), in which the protease is a proteasome.
- (8) A method of manufacturing a protein-degradation inducing tag, the method including a step of a modifying a structure of an active site of a protease inhibitor to inactivate a protease inhibitory activity.
- (9) The method of manufacturing a protein-degradation inducing tag according to (8), the method further including a step of selecting, as the protease inhibitor, a molecule having an affinity with a protease and inhibiting degradation of a protein by the protease from candidate molecules.
- (10) A library of protein-degradation inducing tags, including two or more types of protein-degradation inducing tags, each of the two or more types of protein-degradation inducing tags being the protein-degradation inducing tag according to any one of (1) to (5).
- (11) A protein-degradation inducing molecule, which is a conjugate of at least one protein-degradation inducing tag and at least one protein binding molecule capable of binding to a protein, the at least one protein-degradation inducing tag being the protein-degradation inducing tag according to any one of (1) to (5).
- (12) A library of protein-degradation inducing molecules, including two or more types of protein-degradation inducing molecules, each of the two or more types of protein-degradation inducing molecules being the protein-degradation inducing molecule according to (11).
- (13) A pharmaceutical composition including the protein-degradation inducing tag according to any one of (1) to (5) or the protein-degradation inducing molecule according to (11).
- (14) A method of degrading a target protein, the method including a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of (1) to (5) or the protein-degradation inducing molecule according to (11).
- (15) A method of performing functional analysis on a target protein, the method including a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of (1) to (5) or the protein-degradation inducing molecule according to (11).
- (16) A method of identifying a target protein, the method including a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of (1) to (5) or the protein-degradation inducing molecule according to (11), and a step of identifying a protein subjected to degradation induced by the protein-degradation inducing tag or the protein-degradation inducing molecule.
- (17) A method of identifying a pathway molecule through a target protein, the method including a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of (1) to (5) or the protein-degradation inducing molecule according to (11), and a step of identifying a protein showing an altered activity or expression, the protein being different from the target protein.
- (18) A method of screening for a protein-degradation inducing tag or a protein-degradation inducing molecule, the method including a step of introducing the protein-degradation inducing tag according to any one of (1) to (5), the library of protein-degradation inducing tags according to (10), the protein-degradation inducing molecule according to (11), or the library of protein-degradation inducing molecules according to (12) into a system including a target protein, and selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has induced degradation of the target protein.
- (19) The method of screening for a protein-degradation inducing tag or a protein-degradation inducing molecule according to (18), wherein the target protein is a disease causative agent, and the protein-degradation inducing tag or the protein-degradation inducing molecule which has induced degradation of the target protein is selected as a candidate ingredient for preventing or treating a disease.
- (20) A method of screening for a candidate ingredient for preventing or treating a disease, the method including a step of supllying the protein-degradation inducing tag according to any one of (1) to (5), the library of protein-degradation inducing tags according to (10), the protein-degradation inducing molecule according to (11), or the library of protein-degradation inducing molecules according to (12) into a disease model system, and selecting a protein-degradation inducing tag or a protein-degradation inducing molecule which has improved a condition of the disease.
- (21) A method of screening for a candidate ingredient for preventing or treating a disease, the method including a step of introducing the protein-degradation inducing tag according to any one of (1) to (5), the library of protein-degradation inducing tags according to (10), the protein-degradation inducing molecule according to (11), or the library of protein-degradation inducing molecules according to (12) into a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which has aggravated a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- (22) A method of specifying a disease-related protein, the method including a step of introducing the protein-degradation inducing tag according to any one of (1) to (5), the library of protein-degradation inducing tags according to (10), the protein-degradation inducing molecule according to (11), or the library of protein-degradation inducing molecules according to (12) into a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which has altered a condition of a disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- According to the present disclosure, a novel protein-degradation inducing tag configured to induce degradation of a protein, and use thereof can be provided.
-
-
Fig. 1 shows the plasmid map of a plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) used in Example. -
Fig. 2A shows results from FACS (Fluorescence Activated Cell Sorting) analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib was added. -
Fig. 2B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. -
Fig. 3 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib or TMP was added. -
Fig. 4A shows the inhibitory activity of TMP-CiKD_Bortezomib and Bortezomib against the catalytic subunit β1 of a proteasome. -
Fig. 4B shows the inhibitory activity of TMP-CiKD_Bortezomib and Bortezomib against the catalytic subunit β2 of the proteasome. -
Fig. 4C shows the inhibitory activity of TMP-CiKD_Bortezomib and Bortezomib against the catalytic subunit β5 of the proteasome. -
Fig. 5A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN was added. -
Fig. 5B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. -
Fig. 6 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN or TMP was added. -
Fig. 7A shows the inhibitory activity of TMP-CiKD_ALLN and ALLN against the catalytic subunit β1 of the proteasome. -
Fig. 7B shows the inhibitory activity of TMP-CiKD_ALLN and ALLN against the catalytic subunit β2 of the proteasome. -
Fig. 7C shows the inhibitory activity of TMP-CiKD_ALLN and ALLN against the catalytic subunit β5 of the proteasome. -
Fig. 8A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN was added. -
Fig. 8B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. -
Fig. 8C shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN and Bortezomib were added. -
Fig. 9 shows results from the thermal shift assay of an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN or MTX was added. -
Fig. 10A shows results from quantification of bands detected in the Western blot analysis of an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN or MTX was added. -
Fig. 10B shows bands detected in the Western blot analysis of an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN or MTX was added. -
Fig. 11 shows results from the Western blot analysis of an endogenously expressed target protein (human DHFR) in a liver tissue extract from a mouse individual to which MTX-CiKD_MLN or MTX was administered. -
Fig. 12A shows the inhibitory activity of TMP-CiKD_DMT and MG-132 against the catalytic subunit β1 of the proteasome. -
Fig. 12B shows the inhibitory activity of TMP-CiKD_DMT and MG-132 against the catalytic subunit β2 of the proteasome. -
Fig. 12C shows the inhibitory activity of TMP-CiKD_DMT and MG-132 against the catalytic subunit β5 of the proteasome. -
Fig. 13 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT or TMP was added. -
Fig. 14A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added. -
Fig. 14B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added. -
Fig. 14C shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. -
Fig. 15A shows results from quantification of bands detected in the Western blot analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT, TMP, or TMP-CiKD_DMT and bortezomib were added. -
Fig. 15B shows bands detected in the Western blot analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT, TMP, or TMP-CiKD_DMT and bortezomib were added. -
Fig. 16 shows results from the Western blot analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, TMP-CiKD_Bortezomib, or TMP was added. - Below, the embodiments of the present invention will be described in detail. However, the present invention shall not be limited to the following embodiments.
- The term "protein" as used herein refers to any having two or more amino acid residues, and encompasses a so-called "peptide." A range of numerical values specified using "-" as used herein refers to a range including values indicated before and after "-" as the the minimum value and the maximum value, respectively. The term "step" as used herein encompasses a step independent from the other steps as well as a step which can not be clearly separated from the other steps as long as the purpose of that step can be achieved.
- The protein-degradation inducing tag according to the present disclosure is a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease. The protein-degradation inducing tag is used to lead a protein directly bound or indirectly bound through a protein binding molecule to degradation (knockdown) by a protease. The protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease without ubiquitination of the target protein (i.e., in a ubiquitin independent manner), the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule described below) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein. It is noted that the phrase "the protein-degradation inducing tag is capable of binding to a target protein" means that the protein-degradation inducing tag is capable of binding to the target protein via a covalent bond, a hydrogen bond, a hydrophobic bond, Van der Waals force, and the like. There is no particular limitation for the binding mode thereof.
- Below, the above protein-degradation inducing tag may also be referred to a CiKD (Chemical interaction and KnockDown) tag.
- There is no particular limitation for the protease, and any molecule having a protease activity can be used. For example, it may be a protease complex such as a proteasome, or may be a protease other than the proteasome. Alternatively, it may be a portion of a proteasome as long as the portion has a protease activity.
- Examples of the proteasome include 26S proteasome, an immunoproteasome, and a thymus proteasome. 26S proteasome is composed of 20S proteasome and two units of 19S proteasome, the two units of 19S proteasome being attached to the 20S proteasome. 20S proteasome has a cylindrical structure in which an α-ring consisting of 7 subunits of α1 to α7 and a β-ring consisting of 7 subunits of β1 to β7 are stacked in order of αββα, and β1, β2, and β5 show catalytic activities of a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity, respectively. In the immunoproteasome, the catalytic subunits β1, β2, and β5 are replaced with β1i, β2i, and β5i, respectively (Science, 1994, 265, 1234-1237). In the thymus proteasome, β5t which is expressed specifically in cortical thymic epithelial cells (cTEC) is incorporated along with β1i and β2i (Science, 2007, 316, 1349-1353).
- Examples of a protease other than the proteasome include β-secretase, γ-secretase, aminopeptidase, angiotensin-converting enzyme, bromelain, calpine I, calpine II, carboxypeptidase A, carboxypeptidase B, carboxypeptidase P, carboxypeptidase Y,
caspase 1,caspase 2,caspase 3,caspase 5,caspase 6,caspase 7, caspase 8,caspase 9, caspase 13, cathepsin B, cathepsin C, cathepsin D, cathepsin G, cathepsin L, chymotrypsin, clostripain, collagenase, complement C1r, complement C1s, complement factor B, complement factor D, dipeptidyl peptidase I, dipeptidyl peptidase II, dipeptidyl peptidase IV, dispase, elastase, endoproteinase Arg-C, endoproteinase Glu-C, endoproteinase Lys-C, ficin, granzyme B, kallikrein, leucine aminopeptidase, matrix metalloprotease, metalloprotease, papain, pepsin, plasmin,procaspase 3, pronase E, proteinase K, renin, thermolysin, thrombin, trypsin, cytosol alanyl aminopeptidase, enkephalinase, neprilysin, and the like. - As used herein, the phrase "having an affinity with a protease" means the capability of binding to a protease, for example, via a covalent bond, a hydrogen bond, a hydrophobic bond, Van der Waals force, and the like. When the thermal stability of a protease changes in the presence of a protein-degradation inducing tag, the protein-degradation inducing tag can be considered as capable of interacting with that protease.
- As used herein, the phrase "without inhibiting degradation of a protein by a protease" means that, for example, the protein-degradation inducing tag does not bind to the degradation active site of the protease via a covalent bonding. When a protein is degraded by a protease in the presence of a protein-degradation inducing tag, and the degradation of the protein is inhibited in the presence of a protease inhibitor, the protein-degradation inducing tag can be considered not to inhibit the degradation of the protein by the protease.
- Examples of the protein-degradation inducing tag include low molecular weight compounds, natural products, peptides, and the like. The protein-degradation inducing tag has a molecular weight within the range of, for example, 50 to 5000.
- There is no particular limitation for the structure of the protein-degradation inducing tag as long as the protein-degradation inducing tag has an affinity with a protease without inhibiting degradation of a protein by the protease. The protein-degradation inducing tag can be obtained from candidate molecules by the screening method as described below, and can also be manufactured according to the method of manufacture as described below.
-
- In the formula (I), R1 and R2 each independently represent a hydrocarbon group having 1 to 20 carbon atoms, an alkoxy group having 1 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms, a hydroxy group, a carboxy group, an amino group, or a halogeno group.
- Examples of the hydrocarbon group include an alkyl group, an alkenyl group, an aryl group, combinations thereof, and the like. Specifically, the followings can be mentioned: an alkyl group having 1 to 20 carbon atoms such as a methyl group and an ethyl group; an alkenyl group having 2 to 20 carbon atoms such as a vinyl group and an allyl group; an aryl group having 6 to 20 carbon atoms such as a phenyl group and a naphthyl group; an arylalkyl group having 7 to 20 carbon atoms such as a benzyl group and a phenethyl group; an alkylaryl group having 7 to 20 carbon atoms such as a tolyl group and a xylyl group; and the like. Examples of the halogeno group include a fluoro group, a chloro group, a bromo group, and the like.
- In another embodiment, the protein-degradation inducing tag may have a structure in which the proteasome inhibitory activity of a proteasome inhibitor is inactivated. More specifically, at least one inhibitory activity selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity can be mentioned as the proteasome inhibitory activity.
- The term "structure in which a proteasome inhibitory activity is inactivated" as used herein encompasses a structure in which a proteasome inhibitory activity is attenuated in addition to a structure in which a proteasome inhibitory activity is completely eliminated. In a certain embodiment, the protein-degradation inducing tag has a 50% inhibition concentration (IC50) against at least one selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity which is 2 times or more of the 50% inhibition concentration (IC50) of the original proteasome inhibitor.
- As the proteasome inhibitor, any compound having a proteasome inhibitory activity can be used. A proteasome inhibitor is a compound which has an affinity with a proteasome (a protease complex), and inhibits degradation of a protein by a proteasome. Therefore, a protein-degradation inducing tag may be obtained by replacing the active site of a proteasome inhibitor with another structural moiety to inactivate the proteasome inhibitory activity. Proteasome inhibitors have been progressively explored as anticancer agent and the like. Many compounds have been approved as pharmaceutical products, or are under clinical trials. Moreover, many of proteasome inhibitors have relatively small molecular weights and low hydrophobicity, and are less problematic in terms of cell membrane permeability, cytotoxicity, and the like. For these reasons, synthesizing a protein-degradation inducing tag based on a proteasome inhibitor is quite reasonable and efficient.
- Examples of the proteasome inhibitor are shown in the following Tables 1 and 2. The proteasome inhibitors shown in Tables 1 and 2 are each a 20S proteasome inhibitor having an affinity with 20S proteasome. However, a proteasome inhibitor which can be used in the present embodiment shall not be limited to these examples.
[Table 1] No. Generic name / Product name Structural formula (Circles indicate active sites) Molecular weight 1 Bortezomib 384.24 2 ALLN (MG-101, Calpain inhibitor I 383.53 3 MLN9708 (Ixazomib) 517.12 4 MLN2238 361.03 5 CEP-18770 413.28 6 ONO-7058 (Oprozomib) 532.61 7 MG-132 475.63 [Table 2] No. Generic name / Product name Structural formula (Circles indicate active sites) Molecular weight 8 Carfilzomib 719.92 9 BSc-2118 533.66 10 PSI 604.75 11 Epoxomicin 554.73 12 ONX-0914 580.68 13 125I-NIP-L3VS 720.64 14 NPI-0052 (Marizomib) 313.78 - For example, bortezomib as a boronic acid-based proteasome inhibitor is known to inhibit a proteasome activity when the boronyl group as an active site covalently binds to the degradation active site of 20S proteasome as shown in the following scheme (Kisselev, A.F. et al., Chemistry & Biology, 2012, 19, 99-115).
- Further, MLN9708 and MLN2238, which are boronic acid-based proteasome inhibitors, are known to inhibit a proteasome activity when the boronic acid ester moiety or the boronyl group as an active site covalently binds to the degradation active site of 20S proteasome as shown in the following scheme (Kisselev, A.F. et al., Chemistry & Biology, 2012, 19, 99-115) .
- Therefore, a protein-degradation inducing tag may be obtained by replacing the boronyl group or the boronic acid ester moiety as the active sites of bortezomib, MLN9708, and MLN2238 with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like) to inactive the proteasome inhibitory activity.
- It is noted that even for other boronic acid-based proteasome inhibitors such as CEP-18770, a protein-degradation inducing tag can be obtained by replacing the active site with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like).
- Further, ALLN, which is an aldehyde proteasome inhibitor, is known to inhibit a proteasome activity when the formyl group as an active site covalently binds to the degradation activity site of 20S proteasome as shown in the following scheme (Kisselev, A.F. et al., Chemistry & Biology, 2012, 19, 99-115).
- Therefore, a protein-degradation inducing tag can be obtained by replacing the formyl group as the active site of ALLN with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like) to inactivate the proteasome inhibitory activity.
- It is noted that even for other aldehyde proteasome inhibitors such as MG-132, BSc-2118, and PSI, a protein-degradation inducing tag can be obtained by replacing the formyl group as an active site with another structural moiety (a carboxy group, an alkyl group, an aryl group, an amino group, a hydroxy group, and the like).
- Examples of the protein-degradation inducing tag having a structure in which the proteasome inhibitory activity of a proteasome inhibitor is inactivated are shown in the following Tables 3 and 4. Examples of the monovalent group represented by R in the tables include a carboxy group, an alkyl group having 1 to 20 carbon atoms, an aryl group having 6 to 20 atoms, an amino group, a hydroxy group, and the like.
[Table 3] No. Structural formula 1 (In the formula, R represents a monovalent group except for 2 (In the formula, R represents a monovalent group except for -CHO.) 3 (In the formula, R represents a monovalent group except for 4 (In the formula, R represents a monovalent group except for 5 (In the formula, R represents a monovalent group except for 6 (In the formula, R represents a monovalent group except for -CHO.) 7 (In the formula, R represents a monovalent group except for [Table 4] No. Structural formula 8 (In the formula, R represents a monovalent group except for -CHO.) 9 (In the formula, R represents a monovalent group except for -CHO.) 10 (In the formula, R represents a monovalent group except for 11 (In the formula, R represents a monovalent group except for 12 (In the formula, R represents a monovalent group except for 13 (In the formula, R represents a monovalent group.) 14 (In the formula, R represents a monovalent group.) - Other examples of the proteasome inhibitor are shown in the following Tables 5 to 10. Even for these proteasome inhibitor, a protein-degradation inducing tag can be obtained by inactivating the proteasome inhibitory activity in a similar way as described above.
[Table 5] 20S proteasome inhibitor No. Generic name / Product name Structural formula Molecular weight 15 Aspirin 180.15 16 Hydroxyurea inhibitor 354.54 17 PI-1840 394.47 18 PI-083 439.87 19 Cerastol 450.61 [Table 6] 20S proteasome inhibitor (Continued) No. Generic name / Product name Structural formula Molecular weight 20 CVT-659 571.66 21 Capped dipeptide 2645.15 22 TMC95A 677.71 23 Capped dipeptide 1699.80 [Table 7] 20S proteasome inhibitor (Continued) No. Generic name / Product name Structural formula Molecular weight 24 Ritonavir 720.94 25 Scytonemide A 744.89 26 Argyrin A 824.91 27 Benzylstatine peptide 1826.00 [Table 8] 19S proteasome inhibitor No. Generic name / Product name Structural formula Molecular weight 1 RIP-1 (Rpt4 inhibitor) 1348.76 [Table 9] Inhibitor for a constituent factor other than 20S/19S No. Generic name / Product name Structural formula Molecular weight Others 1 JBIR-22 419.52 PAC-3 (molecule assembly factor) inhibition) [Table 10] 20S immunoproteasome inhibitor No. Generic name / Product name Structural formula Molecular weight Others 1 PR-957 580.68 β5i is inhibited 2 IPSI-001 362.47 β2i is inhibited 3 LMP2-sp-ek 484.75 β2i is inhibited - In another embodiment, the protein-degradation inducing tag may have a structure in which the protease inhibitory activity of a protease inhibitor (except for the proteasome inhibitors described above) is inactivated.
- The term "structure in which a protease inhibitory activity is inactivated" as used herein encompasses a structure in which the protease inhibitory activity is attenuated in addition to a structure in which the protease inhibitory activity is completely eliminated. In a certain embodiment, the protein-degradation inducing tag has a 50% inhibition concentration (IC50) against a protease as an inhibition target of a protease inhibitor which is 2 times or more of the 50% inhibition concentration (IC50) of the original protease inhibitor.
- As a protease inhibitor, any compound having a protease inhibitory activity can be used. The protease inhibitor is a compound having an affinity with a protease and inhibiting degradation of a protein by the protease. Therefore, a protein-degradation inducing tag can be obtained by replacing the active site of a protease inhibitor with another structural moiety to inactivate the protease inhibitory activity.
- Examples of the protease inhibitor are shown in the following Tables 11 to 78. Protein-degradation inducing tags can be obtained by replacing the active sites of these protease inhibitor with another structural moieties to inactivate the protease inhibitory activities. However, a protease inhibitor which can be used in the present embodiment shall not be limited to these examples. Existing data bases (for example, "MEROPS-the peptidase database" (http://merops.sanger.ac.uk/index.shtml)) can be consulted for information about proteases and protease inhibitors if needed.
[Table 11] β-secretase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 OM99-2 892.99 [Table 12] γ-secretase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 γ-Secretase inhibitor 705.83 2 L-685,458 672.85 [Table 13] Aminopeptidase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Cysteamine 113.61 2 Bestatin 344.83 ▪Aminopeptidase B ▪Leucine aminopeptidase [Table 14] Angiotensin converting enzyme inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Captopril 217.29 ▪Formation of angiotensin II is inhibited 2 Fenoldopam monohydrobromide 386.67 3 Angiotensin Converting Enzyme Inhibitor 1101.26 [Table 15] Bromelain inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 E-64 357.41 ▪Cathepsin B ▪Ficin ▪Papain ▪Bromelain 2 N-Ethylmalei mide 125.13 ▪Calpine ▪ Ficin 3 N-p-Tosyl-L-phenilalan ine chlorometh yl ketone 351.85 ▪Papain ▪Chymotrypsin ▪Ficin ▪Bromelain 4 Sodium iodoacetat e 207.93 ▪Carboxypeptidase P ▪Bromelain ▪Ficin ▪Cathepsin [Table 16] Calpain inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 E-64c 314.38 2 E-64d 342.43 3 Z-Leu-Leu-Leu-fluorometh yl ketone 507.64 4 N-Ethylmalei mide 125.13 ▪Ficin ▪ Calpine 5 Antipain dihydrochl oride from microbial source 677.62 ▪Calpine ▪Papain ▪Trypsin ▪Cathepsin A ▪Cathepsin B ▪Cathepsin D ▪Plasmin ▪Chymotrypsin ▪Pepsin ▪Granzyme B ▪ Thrombin 6 4-Chloromerc uribenzoic acid 357.16 ▪Calpine ▪Carboxypeptidase ▪ Clostripain 7 Leupeptin 426.55 ▪Plasmin ▪Trypsin ▪Papain ▪Calpine ▪Cathepsin B ▪Thrombin ▪Kallikrein ▪Endoproteinase ▪Chymotrypsin ▪Proteasome (β2) [Table 17] Calpain I inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Calpain Inhibitor I (ALLN, Ac-LLnL-CHO, MG-101) 383.53 ▪Cathepsin B ▪Cathepsin L ▪Calpine ▪ Proteasome 2 Calpain Inhibitor II 401.56 ▪Cathepsin B ▪Calpine ▪Proteasome [Table 18] Calpain II inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 E-64c 314.38 2 Calpain Inhibitor I (ALLN, Ac-LLnL-CHO, MG-101) 383.53 ▪Cathepsin B ▪Cathepsin L ▪Calpine ▪ Proteasome 3 Calpain Inhibitor II 401.56 ▪Cathepsin B ▪Calpine ▪Proteasome 4 N-Ethylmalei mide 125.13 ▪Ficin ▪ Calpine 5 Antipain dihydrochl oride from microbial source 677.62 ▪Calpine ▪Papain ▪Trypsin ▪Cathepsin A ▪Cathepsin B ▪Cathepsin D ▪Plasmin ▪Chymotrypsin ▪Pepsin ▪Granzyme B ▪ Thrombin 6 4-Chloromerc uribenzoic acid 357.16 ▪Calpine ▪Carboxypeptidase ▪ Clostripain 7 Leupeptin 426.55 ▪Plasmin ▪Trypsin ▪Papain ▪Calpine ▪Cathepsin B ▪Thrombin ▪Kallikrein ▪Endoproteinase ▪Chymotrypsin ▪Proteasome (β2) [Table 19] Carboxypeptidase A/B inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraaceti c acid 380.35 ▪Carboxypeptidase A ▪ Carboxypeptidase B 2 EDTA disodium salt 372.24 ▪Carboxypeptidase A ▪Carboxypeptidase B ▪Dispase ▪Collagenase 3 Pentetic acid (DETAPAC, DTPA) 393.35 ▪Carboxypeptidase A ▪Carboxypeptidase B 4 1,10-Phenanthro line monohydrat e 198.22 ▪Carboxypeptidase A ▪Carboxypeptidase B ▪Dispase ▪Leucine aminopeptidase ▪Thermolysin [Table 20] Carboxypeptidase P inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropy lfluoropho sphate 184.15 ▪Carboxypeptidase ▪Chymotrypsin ▪Complement ▪Elastase ▪Endoproteinase ▪Kallikrein ▪Plasmin ▪Thrombin ▪Pronase ▪ Proteinase 2 4-Chloromerc uribenzoic acid 357.16 ▪Calpine ▪Carboxypeptidase ▪ Clostripain 3 Diethyl pyrocarbon ate (DEP) 162.14 4 Sodium iodoacetat e 207.93 ▪Carboxypeptidase P ▪Bromelain ▪Ficin ▪Cathepsin [Table 21] Carboxypeptidase Y inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropy lfluoropho sphate 184.15 ▪Carboxypeptidase ▪Chymotrypsin ▪Complement ▪Elastase ▪Endoproteinase ▪Kallikrein ▪Plasmin ▪Thrombin ▪Pronase ▪ Proteinase 2 Phenylmeth anesulfony 1 fluoride174.19 ▪Thrombin ▪Elastase ▪Plasmin ▪Proteinase [Table 22] Cathepsin B inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 CA-074 383.44 2 CA-074 methyl ester 397.47 3 E-64 357.41 ▪Cathepsin B ▪Ficin ▪Papain ▪Bromelain 4 Z-Phe-Phe-fluorometh yl ketone (Z-FF-FMK) 462.51 5 Antipain dihydrochl oride from microbial source 677.62 ▪Calpine ▪Papain ▪Trypsin ▪Cathepsin A ▪Cathepsin B ▪Cathepsin D ▪Plasmin ▪Chymotrypsin ▪Pepsin [Table 23] Cathepsin B inhibitor (Continued) No. Name Structural formula Molecular weight Protease to be inhibited 6 Calpain Inhibitor I (ALLN, Ac-LLnL-CHO, MG-101) 383.53 ▪Cathepsin B ▪Cathepsin L ▪Calpine ▪ Proteasome 7 Calpain Inhibitor II 401.56 ▪Cathepsin B ▪Calpine ▪Proteasome 8 Chymostati n A: MW = 607.7 B: MW = 593.7 C: MW = 607.7 ▪Chymotrypsin ▪Papain ▪Chymotrypsin-like serine proteinase ▪Cathepsin A, B, C, B, H, L 9 Leupeptin 426.55 ▪Plasmin ▪Trypsin ▪Papain ▪Calpine ▪Cathepsin B ▪Thrombin ▪Kallikrein ▪Endoproteinase ▪Chymotrypsin ▪Proteasome (β2) [Table 24] Cathepsin C inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Sodium iodoacetat e 207.93 ▪Carboxypeptidase P ▪Bromelain ▪Ficin ▪Cathepsin [Table 25] Cathepsin D inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Antipain dihydrochl oride from microbial source 677.62 ▪Calpine ▪Papain ▪Trypsin ▪Cathepsin A ▪Cathepsin B ▪Cathepsin D ▪Plasmin ▪Chymotrypsin ▪Pepsin ▪Granzyme B ▪ Thrombin 2 Chymostatin A: MW = 607.7 B: MW = 593.7 C: MW = 607.7 ▪Chymotrypsin ▪Papain ▪Chymotrypsin-like serine proteinase Chymostatin A X = Leu ▪Cathepsin A, B, C, B, H, L Chymostatin B X = Val ▪Proteasome (β5) Chymostatin C X = Ile 3 Pepstatin A 685.89 ▪Pepsin ▪Cathepsin [Table 26] Cathepsin L inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Z-Phe-Phe-fluoromethyl ketone (Z-FF-FMK) 462.51 2 Calpain Inhibitor I (ALLN, Ac-LLnL-CHO, MG-101) 383.53 ▪Cathepsin B ▪Cathepsin L ▪Calpine ▪Proteasome [Table 27] Chymotrypsin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropyl fluorophosphate 184.15 ▪Carboxypeptidase ▪Chymotrypsin ▪Complement ▪Elastase ▪Endoproteinase ▪Kallikrein ▪Plasmin ▪Thrombin ▪Pronase ▪ Proteinase 2 4-(2-Aminoethyl )benzenesu lfonyl fluoride hydrochlor ide (AEBSF) 239.69 ▪Plasmin ▪Trypsin ▪ Chymotrypsin 3 6-Aminocapro ic acid 131.17 4 Chymostatin A: MW = 607.7 B: MW = 593.7 C: MW = 607.7 ▪Chymotrypsin ▪Papain ▪Chymotrypsin-like serine proteinase Chymostatin A X = Leu ▪Cathepsin A, B, C, B, H, L Chymostatin B X = Val ▪Proteasome (β5) Chymostatin C X = Ile [Table 28] Chymotrypsin inhibitor (Continued) No. Name Structural formula Molecular weight Protease to be inhibited 1 N-p-Tosyl-L-phenyl alanine chloromethyl ketone 351.85 ▪Papain ▪Chymotrypsin ▪Ficin ▪Bromelain 2 Bromoenol lactone 317.18 3 Gabexate mesylate 417.48 4 Leupeptin 426.55 ▪Plasmin ▪Trypsin ▪Papain ▪Calpine ▪Cathepsin B ▪Thrombin ▪Kallikrein ▪Endoproteinase ▪Chymotrypsin ▪Proteasome (β2) [Table 29] Clostripain inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 4-Chloromerc uribenzoic acid 357.16 ▪Calpine ▪Carboxypeptidase ▪ Clostripain 2 Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride 369.31 [Table 30] Collagenase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 EDTA disodium salt 372.24 ▪Carboxypeptidase A ▪Carboxypeptidase B ▪Dispase ▪Collagenase 2 Dichlorome thylenediphosphonic acid disodium salt (DMDP) 288.86 [Table 31] Complement C1r/C1s inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluoropho sphate 184.15 ▪Carboxypeptidase ▪Chymotrypsin ▪Complement ▪Elastase ▪Endoproteinase ▪Kallikrein ▪Plasmin ▪Thrombin ▪Pronase ▪Proteinase [Table 32] Complement factor D/B inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪Carboxypeptidase ▪Chymotrypsin ▪Complement ▪Elastase ▪Endoproteinase ▪Kallikrein ▪Plasmin ▪Thrombin ▪Pronase ▪Proteinase [Table 33] Dipeptidyl peptidase II inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Puromycin 471.51 ▪Dipeptidyl peptidase II ▪Cytosol alanyl aminopeptidase [Table 34] Dipeptidyl peptidase III inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Opiorphin 692.77 ▪Enkephalinase ▪Neprilysin ▪Dipeptidyl peptidase III ▪Cytosol alanyl aminopeptidase [Table 35] Dipeptidyl peptidase IV inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Ile-Pro-Ile 341.45 ▪Dipeptidyl peptidase IV [Table 36] Dispase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 EDTA disodium salt 372.24 ▪Carboxypeptidase A ▪Carboxypeptidase B ▪Dispase ▪Collagenase 2 1,10-Phenanthro line monohydrat e 198.22 ▪Carboxypeptidase A ▪Carboxypeptidase B ▪Dispase ▪Leucine aminopeptidase ▪Thermolysin [Table 37] Elastase (granulocyte) inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 N-(Methoxysu ccinyl)-Ala-Ala-Pro-Val-chloromethyl ketone 502.99 [Table 38] Elastase (leukocyte) inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪Carboxypeptidase ▪Chymotrypsin ▪Complement ▪Elastase ▪Endoproteinase ▪Kallikrein ▪Plasmin ▪Thrombin ▪Pronase ▪ Proteinase 2 3,4-Dichloroisocoumarin 215.03 ▪Thrombin ▪Papain ▪ Plasmin 3 Phenylmeth anesulfonyl fluoride 174.19 ▪Thrombin ▪Elastase ▪Plasmin ▪Proteinase [Table 39] Elastase (pancreas) inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪Carboxypeptidase ▪Chymotrypsin ▪Complement ▪Elastase ▪Endoproteinase ▪Kallikrein ▪Plasmin ▪Thrombin ▪Pronase ▪ Proteinase 2 3,4-Dichlorois ocoumarin 215.03 ▪Thrombin ▪Papain ▪Plasmin [Table 40] Endoproteinase Arg-C inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase 2 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin [Table 41] Endoproteinase Glu-C inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase [Table 42] Endoproteinase Lys-C inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase 2 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin 3 Leupeptin 426.55 ▪ Plasmin ▪ Trypsin ▪ Papain ▪ Calpine ▪ Cathepsin B ▪ Thrombin ▪ Kallikrein ▪ Endoproteinase ▪ Chymotrypsin ▪ Proteasome (β2) [Table 43] Ficin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 E-64 357.41 ▪ Cathepsin B ▪ Ficin ▪ Papain ▪ Bromelain 2 N-Ethylmaleimide 125.13 ▪ Calpine ▪ Ficin 3 N-p-Tosyl-L-phenilalanine chloromethyl ketone 351.85 ▪ Papain ▪ Chymotrypsin ▪ Ficin ▪ Bromelain 4 Sodium iodoacetat e 207.93 ▪ Carboxypeptidase P ▪ Bromelain ▪ Ficin ▪ Cathepsin 5 Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride 369.31 [Table 44] Granzyme B inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Antipain dihydrochloride from microbial source 677.62 ▪ Calpine ▪ Papain ▪ Trypsin ▪ Cathepsin A ▪ Cathepsin B ▪ Cathepsin D ▪ Plasmin ▪ Chymotrypsin ▪ Pepsin ▪ Granzyme B ▪ Thrombin 2 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin [Table 45] Kallikrein (tissue) inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase 2 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin 3 Leupeptin 426.55 ▪ Plasmin ▪ Trypsin ▪ Papain ▪ Calpine ▪ Cathepsin B ▪ Thrombin ▪ Kallikrein ▪ Endoproteinase ▪ Chymotrypsin ▪ Proteasome (β2) [Table 46] Kallikrein (plasma) inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Gabexate mesylate 417.48 [Table 47] Leucine aminopeptidase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Actinonin 385.5 2 Bestatin hydrochloride 344.83 ▪ Aminopeptidase B [Table 48] Leucine aminopeptidase (cytosol) inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Actinonin 385.5 2 Amastatin hydrochloride hydrate 511.01 (anhydrous basis) 3 Ethylene glycol-bis (2-aminoethylether)-N,N,N',N'-tetraaceti c acid 380.35 4 Ethylenediaminetetra acetic acid disodium salt dihydrate 372.24 [Table 49] Leucine aminopeptidase (cytosol) inhibitor (Continued) No. Name Structural formula Molecular weight Protease to be inhibited 5 Diethylene triaminepe ntaacetic acid 393.35 6 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin 7 1,10-Phenanthro line monohydrat e 198.22 ▪ Carboxypeptidase A ▪ Carboxypeptidase B ▪ Dispase ▪ Leucine aminopeptidase ▪ Thermolysin 8 Bestatin hydrochloride 344.83 ▪ AminopeptidaseB [Table 50] Leucine aminopeptidase (microsome) inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Actinonin 385.5 2 Amastatin hydrochloride hydrate 511.01 (anhydrous basis) 3 Bestatin hydrochloride 344.83 ▪ Aminopeptidase B [Table 51] Matrix aminopeptidase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 GM6001 388.46 [Table 52] Metalloprotease inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Epiamastatin hydrochloride 474.55 [Table 53] Papain inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 E-64 357.41 2 Gly-Gly-Tyr-Arg 451.48 3 Antipain dihydrochloride from microbial source 677.62 ▪ Calpine ▪ Papain ▪ Trypsin ▪ Cathepsin A ▪ Cathepsin B ▪ Cathepsin D ▪ Plasmin ▪ Chymotrypsin ▪ Pepsin ▪ Granzyme B ▪ Thrombin 4 Ebselen 274.18 [Table 54] Papain inhibitor (Continued) No. Name Structural formula Molecular weight Protease to be inhibited 5 Chymostatin A: MW = 607.7 B: MW = 593.7 C: MW = 607.7 ▪ Chymotrypsin ▪ Papain ▪ Chymotrypsin-like serine proteinase ▪ Cathepsin A, B, C, Chymostatin A X = Leu B, H, L Chymostatin B X = Val ▪ Proteasome (β5) Chymostatin C X = Ile 6 Cystamine dihydrochloride 225.2 7 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin 8 N-p-Tosyl-L-phenilalanine chloromethyl ketone 351.85 ▪ Papain ▪ Chymotrypsin ▪ Ficin ▪ Bromelain 9 Leupeptin 426.55 ▪ Plasmin ▪ Trypsin ▪ Papain ▪ Calpine ▪ Cathepsin B ▪ Thrombin ▪ Kallikrein ▪ Endoproteinase ▪ Chymotrypsin ▪ Proteasome (β2) [Table 55] Pepsin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Pepstatin A 685.89 ▪ Cathepsin D [Table 56] Plasmin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase 2 Elastatina 1512.56 3 4-(2-Aminoethyl )benzenesu lfonyl fluoride hydrochloride (AEBSF) 239.69 ▪ Plasmin ▪ Trypsin ▪ Chymotrypsin 4 6-Aminocapro ic acid 131.17 5 Antipain dihydrochloride from microbial source 677.62 ▪ Calpine ▪ Papain ▪ Trypsin ▪ Cathepsin A ▪ Cathepsin B ▪ Cathepsin D ▪ Plasmin ▪ Chymotrypsin ▪ Pepsin ▪ Granzyme B ▪ Thrombin [Table 57] Plasmin inhibitor (Continued) No. Name Structural formula Molecular weight Protease to be inhibited 6 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin 7 Phenylmeth anesulfonylfuoride 174.19 ▪ Thrombin ▪ Elastase ▪ Plasmin ▪ Proteinase 8 Gabexate mesylate 417.48 9 Leupeptin 426.55 ▪ Plasmin ▪ Trypsin ▪ Papain ▪ Calpine ▪ Cathepsin B ▪ Thrombin ▪ Kallikrein ▪ Endoproteinase ▪ Chymotrypsin ▪ Proteasome (β2) [Table 58] Thrombin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase 2 Nα-Tosyl-L-lysine chloromethyl ketone hydrochloride 369.31 3 4-(2-Aminoethyl)benzenesu lfonyl fluoride hydrochloride (AEBSF) 239.69 4 Antipain dihydrochloride from microbial source 677.62 ▪ Calpine ▪ Papain ▪ Trypsin ▪ Cathepsin A ▪ Cathepsin B ▪ Cathepsin D ▪ Plasmin ▪ Chymotrypsin ▪ Pepsin [Table 59] Thrombin inhibitor (Continued) No. Name Structural formula Molecular weight Protease to be inhibited 5 3,4-Dichloroisocoumarin 215.03 ▪ Thrombin ▪ Papain ▪ Plasmin 6 Phenylmeth anesulfonylfluoride 174.19 ▪ Thrombin ▪ Elastase ▪ Plasmin ▪ Proteinase 7 Gabexate mesylate 417.48 8 Leupeptin 426.55 ▪ Plasmin ▪ Trypsin ▪ Papain ▪ Calpine ▪ Cathepsin B ▪ Thrombin ▪ Kallikrein ▪ Endoproteinase ▪ Chymotrypsin ▪ Proteasome (β2) [Table 60] Thermolysin inhibitor No. Name Structural formula Molecular weight Protease to be inhibi ted 1 Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'- tetraacetic acid 380.35 2 Ethylenedi aminetetra acetic acid disodium salt dihydrate 372.24 ▪ Carboxypeptidase A ▪ Carboxypeptidase B ▪ Dispase ▪ Collagenase 3 Diethylene triaminepe ntaacetic acid 393.35 4 1,10-Phenanthroline monohydrate 198.22 ▪ Carboxypeptidase A ▪ Carboxypeptidase B ▪ Dispase ▪ Leucine aminopeptidase ▪ Thermolysin 5 Phosphoramidon disodium salt 587.47 [Table 61] Trypsin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride 239.69 ▪ Plasmin ▪ Trypsin ▪ Chymotrypsin 2 Antipain dihydrochloride from microbial source 677.62 ▪ Calpine ▪ Papain ▪ Trypsin ▪ Cathepsin A ▪ Cathepsin B ▪ Cathepsin D ▪ Plasmin ▪ Chymotrypsin ▪ Pepsin ▪ Granzyme B ▪ Thrombin 3 Boldine 327.37 [Table 62] Pronase E inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 EDTA disodium salt 372.24 ▪ Carboxypeptidase A ▪ Carboxypeptidase B ▪ Dispase ▪ Collagenase 2 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase [Table 63] Procaspase 3 inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 N-Acetyl-Glu-Ser-Met-Asp-al (Ac-ESMD-CHO) 506.53 2 N-Acetyl-Ile-Glu-Thr-Asp-al (Ac-IETD-CHO) 502.52 [Table 64] Proteinase K inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Phenylmeth anesulfonylfuoride 174.19 ▪ Thrombin ▪ Elastase ▪ Plasmin ▪ Proteinase 2 Diisopropylfluorophosphate 184.15 ▪ Carboxypeptidase ▪ Chymotrypsin ▪ Complement ▪ Elastase ▪ Endoproteinase ▪ Kallikrein ▪ Plasmin ▪ Thrombin ▪ Pronase ▪ Proteinase [Table 65] Renin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Pepstatin A 685.89 ▪ Cathepsin D [Table 66] Caspase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Asp(OMe)-fluoromethyl ketone (Boc-D-FMK) 263.26 2 Z-Ala-Glu(OMe)-Val-Asp(OMe)-fluoromethyl ketone (Z-AEVD-FMK) 610.63 [Table 67] Caspase 1 inhibitorNo. Name Structural formula Molecular weight Protease to be inhibited 1 N-Acetyl-Trp-Glu-His-Asp-al (Ac-WEHD-CHO) 611.6 [Table 68] Caspase 2 inhibitorNo. Name Structural formula Molecular weight Protease to be inhibited 1 N-Acetyl-Val-Asp-Val-Ala-Asp-CHO (Ac-VDVAD-CHO) 543.52 2 Z-Val-Asp(O-Me)-Val-Ala-Asp(O-Me)fluoromethyl ketone (Z-VDVAD-FMK) 695.73 [Table 69] Caspase 3 inhibitorNo. Name Structural formula Molecular weight Protease to be inhibited 1 N-Acetyl-Glu-Ser-Met-Asp-al (Ac-ESMD-CHO) 506.53 2 Z-Asp(OMe)-Gln-Met-Asp (OMe) fl uoromethylketone 685.72 3 N-Acetyl-Asp-Glu-Val-Asp-al (Ac-DEVD-CHO) 502.47 4 N-Acetyl-Ile-Glu-Thr-Asp-al (Ac-IETD-CHO) 502.52 [Table 70] Caspase 5 inhibitorNo. Name Structural formula Molecular weight Protease to be inhibited 1 N-Acetyl-Trp-Glu-His-Asp-al (Ac-WEHD-CHO) 611.6 [Table 71] Caspase 6 inhibitorNo. Name Structural formula Molecular weight Protease to be inhibited 1 N-Acetyl-Val-Glu-Ile-Asp-al 500.54 2 Z-Asp(OMe)-Gln-Met-Asp (OMe) floromethyl ketone 685.72 3 Z-Val-Glu(O-Me)-Ile-Asp(O-Me)fluorom ethyl ketone 652.71 [Table 72] Caspase 7 inhibitorNo. Name Structural formula Molecular weight Protease to be inhibited 1 Z-Asp(O-Me)-Glu(O-Me)-Val-Asp(O-Me)fluoeom ethyl ketone (Z-DEVD-FMK) 668.66 [Table 73] Caspase 8 inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Z-Ile-Glu(O-Me)-Thr-Asp(O-Me)fluoromethyl ketone (Z-IETD-FMK) 654.68 2 Z-Leu-Glu(OMe)-Thr-Asp(OMe)-fluoromethyl ketone (Z-LETD-FMK) 655.69 3 N-Acetyl-Ile-Glu-Thr-Asp-al (Ac-IETD-CHO) 502.52 [Table 74] Caspase 9 inhibitorNo. Name Structural formula Molecular weight Protease to be inhibited 1 Z-Leu-Glu(O-Me)-His-Asp (O-Me)fluoromethyl ketone (Z-LE(OMe)HD( OMe)-FMK, Z-LEHD-FMK) 690.72 [Table 75] Caspase 13 inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Z-Leu-Glu(OMe)-Glu(OMe)-Asp(OMe)-fluoromethyl ketone (Z-LEED-FMK) 696.72 [Table 76] Cytosol alanyl aminopeptidase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Puromycin 471.51 ▪ Dipeptidyl peptidase II ▪ Cytosol alanyl aminopeptidase 2 Opiorphin 692.77 ▪ Enkephalinase ▪ Neprilysin ▪ Dipeptidyl peptidase III ▪ Cytosol alanyl aminopeptidase [Table 77] Enkephalinase inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Opiorphin 692.77 ▪ Enkephalinase ▪ Neprilysin ▪ Dipeptidyl peptidase III ▪ Cytosol alanyl aminopeptidase [Table 78] Neprilysin inhibitor No. Name Structural formula Molecular weight Protease to be inhibited 1 Opiorphin 692.77 ▪ Enkephalinase ▪ Neprilysin ▪ Dipeptidyl peptidase III ▪ Cytosol alanyl aminopeptidase - It is noted that in the above descriptions, proteasome inhibitors and protease inhibitors other than the proteasome inhibitors are separately discussed for convenience, but a compound is also known which can inhibit the activities of both a proteasome and a protease other than proteasomes. Therefore, a protein-degradation inducing tag having an affinity with both a proteasome and a protease other than proteasomes can be obtained when such a compound is used.
- Examples of the compound which can inhibit the activities of both a proteasome and a protease other than proteasomes are shown in the following table 79. In Example 10 described below, the protein-degradation inducing tag is used in which the protease (proteasome) inhibitory activity of a calpain inhibitor (ALLN) shown in No. 1 of Table 79 is inactivated. However, the compound which can inhibit the activities of both a proteasome and a protease other than proteasomes shall not be limited to these examples.
[Table 79] No. Name Structural formula Molecular weight Protease to be inhibited 1 Calpain Inhibitor I (ALLN, Ac-LLnL-CHO, MG-101) 383.53 ▪ Proteasome ▪ Cathepsin B ▪ Cathepsin L ▪ Calpine 2 Calpain Inhibitor II 401.56 ▪ Proteasome ▪ Cathepsin B ▪ Calpine 3 Leupeptin 426.55 ▪ Plasmin ▪ Trypsin ▪ Papain ▪ Calpine ▪ Cathepsin B ▪ Thrombin ▪ Kallikrein ▪ Endoproteinase ▪ Chymotrypsin ▪ Proteasome (β2) 4 Chymostatin A: MW = 607.7 B: MW = 593.7 C: MW = 607.7 ▪ Proteasome (β5) ▪ Chymotrypsin ▪ Papain ▪ Chymotrypsin-like serine proteinase Chymostatin A X = Leu ▪ Cathepsin A, B, C, B, H, L Chymostatin B X = Val Chymostatin C X - Ile 5 clasto-Lactacysti n β-lactone 213.23 ▪ tripeptidyl peptidase II ▪ chlamydial protease-like activity factor - In another embodiment, a proteasome activator can be used as a protein-degradation inducing tag. A proteasome activator is a compound having an affinity with a proteasome (a protease complex) without inhibiting degradation of a protein by the proteasome, and can be used as a protein-degradation inducing tag. That is, according to the present disclosure, use of a proteasome activator as a protein-degradation inducing tag is provided.
- Examples of the proteasome activator are shown in the following Tables 80 to 82. However, the proteasome activator which can be used in the present embodiment shall not be limited to these examples.
[Table 80] 20S proteasome activator No. Generic name / Product name Structural formula Molecular weight 1 Oleuropein 540.51 2 Betulinic acid 456.70 [Table 81] 19S/11S (PA28) proteasome activator No. Generic name / Product name Structural formula Molecular weight 1 IU1 (Usp 14 inhibitor) 300.38 2 b-AP-15 (Usp 14 and Uch-L5 inhibitor) 419.39 3 17-AAG 585.7 4 PU3 371.44 5 PU-H71 512.37 6 NVP-AUY922 493.60 [Table 82] 19S/11S (PA28) proteasome activator (Continued) No. Generic name / Product name Structural formula Molecular weight 7 SNX-5422 521.54 8 HBX 19,818 407.94 9 LS1 518.53 10 LDN91946 314.32 11 P005091 348.21 12 P0040429 484.38 - The method of screening for a protein-degradation inducing tag according to the present disclosure includes a step of selecting a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease from candidate molecules. In a certain embodiment, the protease is a proteasome (a protease complex).
- There is no particular limitation for a method of selecting, from candidate molecules, a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease, but, for example, the following method may be used.
- First, candidate molecules are prepared. As the candidate molecules, a library can be used such as a compound library, a drug library, and a natural-product library. The candidate molecules are preferably pre-immobilized on each well of a plate for high throughput screening (HTS), a microarray plate, a metal plate, and the like.
- Next, the candidate molecules immobilized on each well are subjected to treatment with a protease labelled with a fluorochrome, nucleic acid (mRNA or DNA), or the like, and then each well is washed. In order to label a protease with a fluorochrome, a fusion protein with GFP (Green Fluorescent Protein), labelling by C-terminus labeling, and the like can be used. In order to label a protease with nucleic acid, a display method can be used such as the IVV (in vitro virus) method (may also be referred to as the mRNA display method) and the DNA display method. Then, a molecule having an affinity with a protease will be specified based on the label on a protease. When a protease is labelled with a fluorochrome, a molecule having an affinity with the protease can be specified by detecting fluorescence. When a protease is labelled with mRNA, a molecule having an affinity with the protease can be specified by detecting the sequence of the nucleic acid by reverse transcription PCR.
- Next, a molecule which does not inhibit degradation of a protein by the protease will be specified from molecules having an affinity with the protease. To evaluate whether degradation of a protein by a protease is inhibited or not, a method can be use which is described in Example below.
- The method of manufacturing a protein-degradation inducing tag according to the present disclosure includes a step of modifying a structure of an active site of a protease inhibitor to inactivate the protease inhibitory activity. In a certain embodiment, the protease inhibitor is a proteasome inhibitor, and a protein-degradation inducing tag is manufactured by inactivating the proteasome inhibitory activity of the proteasome inhibitor.
- As described above, the protease inhibitor is a compound having an affinity with a protease and inhibiting degradation of a protein by the protease. Therefore, a protein-degradation inducing tag can be obtained by modifying structure of the active site of a protease inhibitor to inactivate the protease inhibitory activity.
- The protease inhibitor used for manufacturing a protein-degradation inducing tag may be a known protease inhibitor, or may be obtained by screening candidate molecules. That is, the method of manufacturing a protein-degradation inducing tag may further include a step of selecting, as a protease inhibitor, a molecule having an affinity with a protease and inhibiting degradation of a protein by the protease from candidate molecules. For example, in the aforementioned method of screening for a protein-degradation inducing tag, a molecule which does not inhibit degradation of a protein by a protease is specified from molecules having an affinity with the protease, and thus a molecule (a protease inhibitor) having an affinity with the protease and inhibiting degradation of a protein by the protease is specified during the screening process. Therefore, a protein-degradation inducing tag may be manufactured using a protease inhibitor obtained by the screening method as described above.
- The library of protein-degradation inducing tags according to the present disclosure includes two or more types of the aforementioned protein-degradation inducing tags. The library of protein-degradation inducing tags can be used in the screening method described below.
- The protein-degradation inducing molecule according the present disclosure is a conjugate of at least one protein-degradation inducing tag described above and at least one protein binding molecule capable of binding to a protein. The above protein-degradation inducing molecule enables the at least one protein binding molecule to bind with a target protein, leading the target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein (see Examples 2, 7, 12, 15, 16, 21 to 23 described above). It is noted that there is no particular limitation for the binding mode between the protein binding molecule and the target protein, but examples of the binding mode include a covalent bond, a hydrogen bond, a hydrophobic bond, Van der Waals force, and the like.
- Examples of the target protein include proteins residing inside a cell or on a cell membrane. The target protein may be a mutant protein produced by mutation, or may be a fusion protein produced by translocation and the like. Further, the target protein may be an endogenous protein, or may be an exogenous protein from viruses, bacteria, and the like. Moreover, the target protein may be a protein which is not promptly degraded, and thus accumulated for some reasons. In a certain embodiment, the target protein is a protein involving in cell cycle, signal transduction, cell differentiation, cell dedifferentiation, cell proliferation, production of a biologically active substance such as cytokine, or the like. It is noted that the target protein does not need to be prespecified. An unknown target protein can be identified as described below by using a protein-degradation inducing molecule.
- Examples of the protein binding molecule include medicaments such as low molecular weight compounds, antibodies, and peptides; endogenous biologically active substances such as cytokines, growth factors, hormones; natural products; metabolites; plant ingredients; food ingredients; and the like. Binding molecules (eg.inhibitors) in some types of the target protein are known (for example, see
WO2008/123266 ), and thus these known molecules can be used as protein binding molecules. When a molecule capable of binding to a target protein is unknown, binding molecules may be screened by high throughput screening (HTS). Alternatively, an antibody capable of binding to a target protein may be produced, which may be used as a protein binding molecule. - There is no particular limitation for the form of a conjugate of a protein-degradation inducing tag and a protein binding molecule as long as the affinity of the protein-degradation inducing tag with a protease and the binding of the protein binding molecule with a protein are maintained.
- For example, the protein-degradation inducing molecule may have a structure in which at least one protein-degradation inducing tag and at least one protein binding molecule are linked. The protein-degradation inducing molecule may have a structure in which one protein-degradation inducing tag is linked to one protein binding molecule, or may have a structure in which one protein-degradation inducing tag is linked to a plurality of protein binding molecules, or may have a structure in which a plurality of protein-degradation inducing tags are linked to one protein binding molecule, or may have a structure in which a plurality of protein-degradation inducing tags are linked to a plurality of protein binding molecules. In a certain embodiment, the protein-degradation inducing molecule has a structure in which one protein-degradation inducing tag is linked to one protein binding molecule.
- There is no particular limitation for the linkage position of a protein-degradation inducing tag with the protein binding molecule as long as an affinity with a protease is maintained. For example, when the protein-degradation inducing tag has a structure in which the active site of a protease inhibitor (for example, a proteasome inhibitor) is replaced with another structural moiety as described above, the protein-degradation inducing tag can be bound to the protein binding molecule at the replaced another structural moiety. Specifically, when the active site of a protease inhibitor is replaced with a carboxy group, the protein-degradation inducing tag can be bound to the protein binding molecule through the carboxy group. On the other hand, there is no particular limitation for the linkage position of the protein binding molecule with the protein-degradation inducing tag as long as binding property with a protein is maintained.
- It is noted that the protein-degradation inducing tag and the protein binding molecule may be configured to be linked to each other. When a protein-degradation inducing tag is difficult to be directly linked to a protein binding molecule, a structure which enables mutual linkage may be introduced into at least one of the protein-degradation inducing tag and the protein binding molecule. For example, a molecule known to bind with a target protein can be used as a protein binding molecule, but a direct linkage between this known molecule and a protein-degradation inducing tag may potentially be difficult to form. In such a case, a structure which can be linked to a protein-degradation inducing tag may be introduced into the aforementioned known molecule for use as a protein binding molecule.
- The library of protein-degradation inducing molecules according to the present disclosure includes two or more types of the aforementioned protein-degradation inducing molecules. Examples of the form in which two or more types of protein-degradation inducing molecules are included include a form in which two or more types of protein-degradation inducing molecules having the same type of protein-degradation inducing tags but having different types of protein binding molecules are included, a form in which two or more types of protein-degradation inducing molecules having the same type of protein binding molecules but having different types of protein-degradation inducing tags are included, and a form in which two or more types of protein-degradation inducing molecules having different types of protein-degradation inducing tags and having different types of protein binding molecules are included.
- There is no particular limitation for the method of manufacturing a library of protein-degradation inducing molecules. Examples of the method of manufacturing a library of protein-degradation inducing molecules include a method in which protein-degradation inducing tags are conjugated to each protein binding molecule included in the library of protein binding molecules. Examples of the library of protein binding molecules include a compound library, a drug library, a natural product library, and the like. For example, a library of protein-degradation inducing molecules can be manufactured by linking protein-degradation inducing molecules to each protein binding molecule included in a library of protein binding molecules using a chemical reaction, a crosslinking reaction, and the like. Other examples of the method of manufacturing a library of protein-degradation inducing molecules include a method in which protein binding molecules are conjugated to each protein-degradation inducing tag included in the aforementioned library of protein-degradation inducing tags.
- The library of protein-degradation inducing molecules can be used in the screening method described below.
- The pharmaceutical composition according to the present disclosure includes the aforementioned protein-degradation inducing tag or the protein-degradation inducing molecule. As described above, the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein. Therefore, when a target protein is responsible for a certain disease (disease causative agent), a pharmaceutical composition against that disease can be manufactured by using a protein-degradation inducing tag or a protein-degradation inducing molecule which can lead the target protein to degradation. Then, the above pharmaceutical composition is administered to a patient to promote degradation of the target protein in the body of the patient. This can lead to prevention or treatment of that disease (for example, see Example 16 described below which represents a knockdown experiment in mouse individuals).
- In the conventional drug discovery methodology where drug discovery is performed based on the form of a target protein, about 75% of the proteome are thought to be undruggable targets. In contrast, according to the aforementioned protein-degradation inducing tag, or protein-degradation inducing molecule, any protein can be be targeted in principle. Here, the target protein is from eukaryote or prokaryote (animal, plant, fungus, yeast, E. coli, and the like). The target protein may be a mutant protein produced by mutation, or may be a fusion protein produced by translocation and the like. Further, the target protein may be an endogenous protein, or may be an exogenous protein from viruses, bacteria, and the like. Moreover, the target protein may be a protein which is not promptly degraded, and thus accumulated for some reasons.
- The pharmaceutical composition may include an ingredient other than the protein-degradation inducing tag or protein-degradation inducing molecule. For example, the pharmaceutical composition may include an organic or inorganic carrier which is conventionally used as a formulation material. The above carrier is formulated as an excipient, a lubricant, a binder, a disintegrating agent, and the like in a solid preparation, and as a solvent, a solubilizing agent, a suspending agent, an isotonizing agent, a buffer agent, and the like in a liquid preparation. Further, the pharmaceutical composition may include a formulation additive such as an antiseptic agent, an anti-oxidative agent, a coloring agent, a sweetening agent, and the like.
- There is no particular limitation for the dosage form of the pharmaceutical composition. Examples of the dosage form of the pharmaceutical composition include oral preparations such as tablet, capsule, granule, powder, trochiscus, syrup, emulsion, suspension, and film preparations; parenteral preparations such injectable preparations, infusion preparations, external preparations, suppository, pellets, transnasal preparations, pulmonary preparations (inhalation), and eye drops; and the like.
- The dose of the pharmaceutical composition is appropriately determined depending on the subject, route of administration, target disease, conditions, and the like.
- The method of degrading a target protein according to the present disclosure includes a step of inducing degradation of a target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule.
- There is no particular limitation for the method of inducing degradation of a target protein using the protein-degradation inducing tag or protein-degradation inducing molecule. For example, the protein-degradation inducing tag or protein-degradation inducing molecule may be added to a medium in which cells, a tissue, or an organ is cultured. Any cells, tissue, and organ can be used as long as they are from eukaryote or prokaryote (animal, plant, fungus, yeast, E. coli, and the like) which have a protease (for example, a proteasome). Alternatively, the protein-degradation inducing tag or protein-degradation inducing molecule may be administered orally or parenterally to the living body of eukaryote or prokaryote which has a protease (for example, a proteasome). Subjects of administration include primate such as human, mouse, rat, swine, canine, feline, and the like. Alternatively, the protein-degradation inducing tag or protein-degradation inducing molecule may be added to an in vitro (cell free) protease degradation system (for example, a proteasome degradation system).
- As described above, the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein.
- The method of performing functional analysis on a target protein according to the present disclosure includes a step of inducing degradation of the target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule. As used herein, the term "functional analysis on a target protein" means analyzing functions of the target protein when the target protein is specified. The target protein may have completely unknown functions or partially elucidated functions.
- There is no particular limitation for the method of inducing degradation of a target protein using the protein-degradation inducing tag or protein-degradation inducing molecule. For example, the protein-degradation inducing tag or protein-degradation inducing molecule may be added to a medium in which cells, a tissue, or an organ is cultured. Alternatively, the protein-degradation inducing tag or protein-degradation inducing molecule may be administered orally or parenterally to the living body of eukaryote or prokaryote which has a protease (for example, a proteasome). Alternatively, the protein-degradation inducing tag or protein-degradation inducing molecule may be added to an in vitro (cell free) functional analysis system along with a protease degradation system (for example, a proteasome degradation system).
- As described above, the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein. Accordingly, when eukaryote or prokaryote, or cells thereof are used, functions of a target protein can be analyzed by, for example, inducing degradation of the target protein using the protein-degradation inducing tag or protein-degradation inducing molecule, and then analyzing changes in the phenotype of the cells or living body. Alternatively, when an in vitro (cell free) functional analysis system is used, functions of a target protein can be analyzed by inducing degradation of the target protein using the protein-degradation inducing tag or protein-degradation inducing molecule, and then analyzing differences (changes) in molecular networks in the presence or absence of the target protein.
- Traditionally, when functions of a target protein are analyzed in the living body of an animal, a gene knockout mouse is usually created. However, disadvantageously, a long period of time (for example, 1 year or more) is required to create a gene knockout mouse. In recent years, the genome editing technique (CRISPR/CAS9) has been developed. Nonetheless, creation of a gene knockout mouse takes several months to half a year even when this CRISPR/CAS9 technique is used. In contrast, according to the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule, a target protein can be led to degradation (knockdown) in a short period of time, and an effect comparable to a case where a gene knockout mouse is created can be obtained. Further, according to the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule, functions of a target protein can also be analyzed dynamically.
- The method of identifying a target protein according to the present disclosure includes a step of inducing degradation of the target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule; and a step of identifying a protein subjected to degradation induced by the protein-degradation inducing tag or protein-degradation inducing molecule. As used herein, the term "identifying a target protein" means that a target protein capable of binding to a protein-degradation inducing tag or a protein binding molecule is identified. The protein-degradation inducing tag or the protein binding molecule may bind to not only a completely unknown target protein but a partially known target protein.
- According to the method of identifying a target protein, protein degradation is first induced using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule. There is no particular limitation for the method of inducing protein degradation using the protein-degradation inducing tag or protein-degradation inducing molecule. For example, the method of degrading a target protein as described above may be adopted.
- Next, a protein is identified, of when degradation having been induced by the protein-degradation inducing tag or the protein-degradation inducing molecule. As described above, the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein. Subsequently, the target protein can be identified by, for example, extracting proteins from cells, and performing proteome analysis to specify a protein present in a reduced amount.
- The method of identifying a pathway molecule through a target protein according to the present disclosure includes a step of inducing degradation of the target protein using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule; and a step of identifying a protein showing an altered activity or expression, the protein being different from the target protein. As used herein, the term "identifying a pathway molecule through a target protein" means that identifying a protein other than the target protein in a protein pathway (a signal transduction pathway and the like) where the target protein is involved. The pathway molecule through a target protein may be not only completely unknown but partially known.
- According to the method of identifying a pathway molecule through a target protein, protein degradation is first induced using the aforementioned protein-degradation inducing tag or protein-degradation inducing molecule. There is no particular limitation for the method of inducing protein degradation using the protein-degradation inducing tag or protein-degradation inducing molecule. For example, the method of degrading a target protein as described above may be adopted.
- Next, a protein showing an altered activity or expression which is different from the target protein is identified. As described above, the protein-degradation inducing tag can lead a target protein to degradation (knockdown) by a protease (for example, a proteasome) without ubiquitination of the target protein, the protein-degradation inducing tag being used alone when the protein-degradation inducing tag is capable of binding to the target protein, or conjugated (the protein-degradation inducing molecule) to a protein binding molecule capable of binding to the target protein when the protein-degradation inducing tag is incapable of binding to the target protein. At this time, the activity or expression of another protein along a protein pathway where the target protein is involved may be altered as the target protein undergoes degradation. Therefore, a pathway molecule can be identified through a target protein by specifying another protein showing an altered activity or expression.
- It is noted that when an increase or decrease in the target protein is responsible for a decrease, identification of a pathway molecule through the target protein can contribute to elucidation of the mechanism of that disease.
- The method of screening for a protein-degradation inducing tag or protein-degradation inducing molecule according to the present disclosure includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecules, or library of protein-degradation inducing molecules to a system including a target protein present, and a step of selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has induced degradation of the target protein.
- There is no particular limitation for the system including a target protein, but it may be, for example, a protease degradation system (for example, a proteasomal degradation system) using eukaryotic or prokaryotic cells which have a protease (for example, a proteasome) or an in vitro (cell-free) protease degradation system (for example, a proteasomal degradation system).
- When a protein-degradation inducing tag or protein-degradation inducing molecule capable of binding to a target protein is included in the protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules introduced to the system including the target protein, the target protein is led to degradation (knockdown) by a protease (for example, a proteasome). Therefore, what is necessary is just to select a protein-degradation inducing tag or protein-degradation inducing molecule which has induced such degradation of the target protein upon screening.
- According to the above screening method, a protein-degradation inducing tag or protein-degradation inducing molecule which leads any selected target protein to degradation can be obtained in principle. Further, when a target protein is responsible for a certain disease (disease causative agent), a protein-degradation inducing tag or protein-degradation inducing molecule which leads the target protein to degradation can be selected as a candidate ingredient for preventing or treating that disease.
- One embodiment of the method of screening for a candidate ingredient for preventing or treating a disease according to the present disclosure includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules to a disease model system, and selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has improves a condition of the disease. Moreover, another embodiment of the method of screening for a candidate ingredient for preventing or treating a disease according to the present disclosure includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules to a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which has aggravated a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- There is no particular limitation for the disease model system, but examples thereof include disease model animals, disease model cells, and the like.
- When a protein-degradation inducing tag or protein-degradation inducing molecule capable of binding to a protein related to a disease (disease-related protein) is included in the protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules introduced into the disease model system, the disease-related protein is led to degradation (knockdown) by a protease (for example, a proteasome). When a condition of the disease is improves as a result of degradation of the disease-related protein, an increase in the disease-related protein may potentially be related to development or progress of the disease. Therefore, a candidate ingredient for preventing or treating a disease can be obtained by selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has improved a condition of the disease. On the other hand, when a condition of the disease is aggravated as a result of degradation of the disease-related protein, a decrease in the disease-related protein may potentially be related to development or progress of the disease. Therefore, a candidate ingredient for preventing or treating a disease can be obtained by extracting a protein-degradation inducing tag or protein-degradation inducing molecule which aggravates a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- The method of specifying a disease-related protein according to the present disclosure includes a step of introducing the aforementioned protein-degradation inducing tag, library of protein-degradation inducing tags, protein-degradation inducing molecule, or library of protein-degradation inducing molecules into a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which has altered a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- When a protein-degradation inducing tag, a library of protein-degradation inducing tags, a protein-degradation inducing molecule, or a library of protein-degradation inducing molecules is introduced into a disease model system, a condition of a disease may be altered as protein degradation (knockdown) progresses in the disease model system. Therefore, disease-related protein can be specified by extracting a protein-degradation inducing tag or protein-degradation inducing molecule which has altered a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- Information about a disease-related protein specified can be used, for example, to develop an ingredient for preventing or treating a disease.
- Below, the present invention will be described specifically with reference to Examples, but the present invention shall not be limited to Examples.
- Abbreviations of compounds used in the following Examples are as follows.
- ec: Escherichia coli
- DHFR: Dihydrofolate reductase
- TMP: Trimethoprim
- H-Phe-OtBu·HCl: L-Phenylalanine t-butyl ester hydrochloride
- DMF: N,N-Dimethylformamide
- DMT-MM: 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride n-hydrate
- TFA: Trifluoroacetic acid
- H-Leu-OtBu·HCl: L-Leucine t-butyl ester hydrochloride
- DIEA: N,N-Diisopropylethylamine
- D-MEM: Dulbecco's modified eagle's medium
- FBS: Fetal bovine serum
- EDTA: Ethylenediamine tetraacetic acid
- HA: Hemagglutinin
- GFP: Green fluorescent protein
- DsRed: Discosoma sp. red fluorescent protein
- DMSO: Dimethyl sulfoxide
- PBS: Phosphate buffered saline
- TBS: Tris buffered saline
- SDS: Sodium dodecyl sulfate
- PAGE: Polyacrylamide gel ectrophoresis
- BPB: Bromophenol blue
- PVDF: Polyvinylidene difluoride
- AMC: 7-Amino-4-methylcoumarin
- H-Gly-OtBu·HCl: L-Glycine t-butyl ester hydrochloride PyBOP: 1H-Benzotriazol-1-yloxy-tri(pyrrolidino)phosphonium hexafluorophosphate
- MTX: Methotrexate
- DMA: N,N-Dimethylacetamide
- BOP: 1H-Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate
- TEA: Triethylamine
- HATU: O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
- GAPDH: Glyceraldehyde 3-phosphate dehydrogenase
- In Example 1, TMP-CiKD_Bortezomib as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme. Bortezomib-COOH (CiKD_Bortezomib) in which the boronyl group as the active site of bortezomib was replaced with a carboxy group was used as a protein-degradation inducing tag. Further, a TMP derivative (TMP-NH2) in which a functional group including an amino group was introduced into TMP as a dihydrofolate reductase inhibitor capable of binding to E. coli DHFR was used as a protein binding molecule. Then, Bortezomib-COOH was linked to TMP-NH2 to synthesize TMP-CiKD_Bortezomib as a protein-degradation inducing molecule.
- The method of synthesizing TMP-CiKD_Bortezomib is described in detail as follows.
- Pyrazinecarboxylic acid (152.8 mg, 1.23 mmol, 1 eq, Code No. 357-00042, Wako Pure Chem Industries, Ltd.) and H-Phe-OtBu·HCl (253.8 mg, 0.98 mmol, 0.8 eq, Code No. 10Y830617, Watanabe Chemical Industries, Ltd.) were charged into an eggplant flask, and 10 mL of dehydrate DMF was then added. After stirred for 5 minutes at room temperature, DMT-MM (1.02 g, 3.69 mmol, 3 eq, Code No. 329-53751, Wako Pure Chem Industries, Ltd.) was directly added to the reaction solution, and stirred at room temperature for 18 hours. The reaction solution was diluted with water, and extracted with ethyl acetate for 3 times. This was washed with brine, and then dried over anhydrous sodium sulfate. After evaporating the solvent under reduced pressure, separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (hexane/chloroform = 1/1 to 0/1, gradient) to obtain a compound 1 (482.3 mg, 1.47 mmol, quant.).
- The compound 1 (398.4 mg, 1.22 mmol) was charged into an eggplant flask, and 5 mL of dichloromethane was then added. This was stirred at room temperature for 5 minutes, and then 7 mL of TFA was added, and stirred at room temperature for 2 hours. After evaporating the solvent under reduced pressure, vacuum drying was performed to obtain a compound 2 (318.8 mg, 96%) .
- The compound 2 (271.3 mg, 1.00 mmol, 1 eq) and H-Leu-OtBu·HCl (223.8 mg, 1.00 mmol, 1 eq, Code No. 14G110356, Watanabe Chemical Industries, Ltd.) were charged into an eggplant flask, and 10 mL of dehydrate DMF was then added. After stirred at room temperature for 5 minutes, 2 mL of DIEA was added to neutralize the solution. After stirred for 5 minutes at room temperature, DMT-MM (553.4 mg, 2.00 mmol, 2 eq, Code No. 329-53751, Wako Pure Chemical Industries, Ltd.) was directly added to the reaction solution, and stirred at room temperature for 3 hours. Under cooling conditions, 20 mL of 10 mass% brine/0.1 N aqueous hydrochloric acid was added, and extracted with ethyl acetate for 3 times. This was washed with 0.5 N aqueous hydrochloric acid and then brine, and then dried over anhydrous sodium sulfate. After evaporating the solvent under reduced pressure, separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (hexane/chloroform = 1/1 to 0/1, gradient) to obtain a compound 3 (168.1 mg, 0.38 mmol, 38%)
- The compound 3 (157.3 mg, 0.36 mmol) was charged into an eggplant flask, and 5 mL of dichloromethane was then added. This was stirred at room temperature for 5 minutes, and then 6 mL of TFA was added, and stirred at room temperature for 2 hours. After evaluating the solvent under reduced pressure, vacuum drying was performed to obtain a compound 4 (Bortezomib-COOH) (179.6 mg, 0.48 mmol, quant.).
- The compound 4 (Bortezomib-COOH) (55.7 mg, 0.15 mmol, 1 eq) and TMP-NH2 synthesized separately (Long, M. J. et al., Chem. Biol., 2012, 19 (5), 629-637) (62.7 mg, 0.15 mmol, 1 eq) were charged into an eggplant flask, and 7 mL of dehydrate DMF was added. After stirred at room temperature for 5 minutes, 2 mL of DIEA was added to neutralize the solution. After stirred at room temperature for 5 minutes, DMT-MM (207.5 mg, 0.75 mmol, 5 eq, Code No. 329-53751, Wako Pure Chemical Industries, Ltd.) was directly added to the reaction solution, and stirred at room temperature for 3 hours. Under cooling conditions, 20 mL of 10 mass% brine/0.1 N aqueous hydrochloric acid was added, and extracted with ethyl acetate for 3 times. This was washed with 0.5 N aqueous hydrochloric acid and then brine, and then dried over anhydrous sodium sulfate. After evaporating the solvent under reduced pressure, separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (chloroform/methanol = 10/1). Subsequently, separation and purification treatment was performed with a TLC silica gel 60 (Code No. HX264817, Merck) (chloroform/methanol = 10/1) to obtain a compound 5 (TMP-CiKD_Bortezomib) (2.3 mg, 0.0029 mmol, 2%, isolated yield).
- In Example 2, degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib was added was evaluated by FACS analysis.
- As a preculture medium, prepared was a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No. AYG161516, HyClone) and 1 mass% PenStrep (100 U/mL sodium penicillin G and 100 µg/mL streptomycin sulfate) (Code No. 168-23191, Wako Pure Chemical Industries, Ltd.) were added to D-MEM (low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.). Then, HeLa cells (Lot No. 60143948, ATCC) were cultured in the preculture medium under conditions of 37°C and 5 vol% CO2. As a culture dish for passage culture, used was a cell culture-dish, treated having a diameter of 100 mm (sterile, non pyrogenic) (Code No. TR4002, TrueLine). Passage culture was performed at the time of 70% to 80% confluence. Cells were detached by trypsin treatment (0.25 w/v% trypsin-1 mmol/L EDTA·4 Na solution with phenol red) (Code No. 201-16945, Wako Pure Chemical Industries, Ltd.), and then one quarter of the cells were cultured in 10 mL of the preculture medium.
- A plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_Bortezomib on the target protein were evaluated.
- The plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) (Long, M. J. et al., "Inhibitor mediated protein degradation." Chem. Biol., 2012, 19 (5), 629-637). The plasmid map of pMIR DsRed-IRES-ecDHFR-HA-GFP is shown in
Fig. 1 . The plasmid was amplified in E. coli, and then purified with a Miniprep kit (Code No. 27106, QIAGEN). - ScreenFect™ A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells. A dilution buffer of ScreenFect™ A was added to two 1.5 mL tubes at 600 µL per tube. Then, 30 µL of a transfection reagent of ScreenFect™ A was added to one tube (a solution A), and 12 µg of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes. The solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C). The solution C was mixed with a cell solution at 1.2 x 105 cells/24 mL collected from trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 104 cells/ 800 µL/well, and then cultured under conditions of 37°C and 5 vol% CO2 for 40 hours.
- TMP-CiKD_Bortezomib was added to HeLa cells as follows. Culture was performed for 40 hours after introduction of the plasmid, and then the preculture medium was removed, and a serum-free medium (37°C) in which a 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-Glucose, phenol red, and sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.) was added to each well at 300 µL/well. It is noted that the L-glutamine solution was added immediately before use. A DMSO solution containing a predetermined concentration of TMP-CiKD_Bortezomib was added to each well at 3 µL/well, and cultured under conditions of 37°C and 5 vol% CO2. It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_Bortezomib.
- The medium was removed 24 hours after addition of TMP-CiKD_Bortezomib (80 µM) or TMP (80 µM), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 2 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA·4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 200 µL/well, and cultured under conditions of 37°C and 5 vol% CO2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot No. AYG161516, HyClone) and 1 mass% PenStrep (100 U/mL sodium penicillin G and 100 µg/mL streptomycin sulfate) (Code No. 168-23191, Wako Pure Chemical Industries, Ltd.) were added to D-MEM (low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.)) was added to each well at 300 µL/well, and suspended, and then a cell solution was collected in a 15 mL tube.
- The cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C). The cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 500 µL of an FACS buffer (1 mass% FBS/PBS) at 4°C was added, and allowed to stand on ice.
- A BD FACSCanto™ II (BD Biosciences) was used for flow cytometry, and the expression levels of GFR and DsRed in cells were quantified. The cell solution was passed through a mesh with a pore size of 32 µm, and transferred to an FACS tube immediately before FACS analysis. The GFR/DsRed ratio per cell was computed using an analysis software FLOWJO™ (TOMY Digital Biology Co., Ltd.), and the efficiency of target degradation (knockdown) by TMP-CiKD_Bortezomib was determined from a shift by target degradation in a graph.
-
Fig. 2A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib was added. Further,Fig. 2B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. As can be seen inFig. 2A , when TMP-CiKD_Bortezomib (80 µM) was added, the graph was found to be significantly shifted to the left as compared with that of the control (DMSO), indicating that the target protein (E. coli DHFR) was degraded. The degradation efficiency estimated from the amount of a shift was about 50% to 60%. In contrast, as can be seen inFig. 2B , when TMP (80 µM) was added, the graph was found to be overlapped with that of the control (DMSO), indicating that the target protein was not degraded. - In Example 3, the affinity of TMP-CiKD_Bortezomib with a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib was added was evaluated by thermal shift assay.
- HeLa cells were prepared as in Example 2. A plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_Bortezomib was added to HeLa cells as in Example 2. A DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_Bortezomib.
- The medium was removed 3 hours after addition of TMP-CiKD_Bortezomib (40 µM) or TMP (40 µM), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 2 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA·4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 200 µL/well, and cultured under conditions of 37°C and 5 vol% CO2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot No. AYG161516, HyClone) and 1 mass% PenStrep (100 U/mL sodium penicillin G and 100 µg/mL streptomycin sulfate) (Code No. 168-23191, Wako Pure Chemical Industries, Ltd.) were added to D-MEM (low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.) was added to each well at 300 µL/well, and suspended, and then a cell solution was collected in a 15 mL tube.
- The cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C). The cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 180 µL of a CETSA buffer (cOmplete™ Mini, EDTA-free (Roche) as a protease inhibitor was added to TBS immediately before use) was added, and then suspended. The cell solution after suspension was dispensed to nine 1.5 mL tubes at 20 µL per tube, and allowed to stand at room temperature for 30 minutes. After allowed to stand, the 9 tubes were heat-treated for 3 minutes, one each at 38°C, 42°C, 46 °C, 50°C, 54°C, 58°C, 62°C, 66°C, or 70°C, and allowed to stand at room temperature for 3 minutes. After allowed to stand, the cell solution was flash frozen in liquid nitrogen, and thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- The cell extract collected was subjected to Western blot analysis. A SDS-PAGE gel (14 wells) was prepared using TGX™ FastCast™ Acrylamide Kit, 12% (Bio-Rad). Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 17 µL/well. Precision Plus Protein™ Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 150 V for 40 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- After electrophoresis, proteins were transferred to a PVDF membrane (Immobion™-P, Millipore) under conditions of 100 V and 40 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol). The membrane after transfer was shaken and blocked in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T. With regard to antibody, anti-HA-peroxidase, high-affinity (3F10) rat monoclonal antibody (25 U/mL) (Roche) diluted 1500 times was used. The membrane was shaken at room temperature for 90 minutes, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
-
Fig. 3 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_Bortezomib or TMP was added. As shown inFig. 3 , E. coli DHFR was able to be detected only up to about 50°C for the control (DMSO). In contrast, E. coli DHFR was able to be detected up to about 54°C by virtue of interaction between E. coli DHFR and TMP when TMP (40 µM) was added. Similarly, E. coli DHFR was able to be detected up to about 54°C by virtue of interaction between E. coli DHFR and TMP-CiKD_Bortezomib when TMP-CiKD_Bortezomib (40 µM) was added. It is noted that bortezomib alone as a proteasome inhibitor did not interact with E. coli DHFR. These results show that TMP-CiKD_Bortezomib, in which TMP-NH2 is linked to CiKD_Bortezomib, has an affinity with E. coli DHFR to a similar extent as TMP. - In Example 4, the proteasome inhibitory activity of TMP-CiKD_Bortezomib, and the affinity of TMP-CiKD_Bortezomib with a proteasome were evaluated.
- For evaluation, AMC released when the C-terminus of an AMC-conjugated proteasome fluorescent substrate specific to a β subunit of β5 (chymotrypsin-like activity), β2 (trypsin-like activity), and β1 (caspase-like activity) of 20S proteasome was cut using 20S Proteasome StressXpress™ Assay Kit Gold (Bioscience) was measured with a multi-detection microplate reader (Synergy HT, BIO-TEK). The measurement wavelengths were 360 nm for excitation light (Ex.), and 460 nm for fluorescence (Em.).
-
Figs. 4A to 4C show the proteasome activities against β1 (caspase-like activity), β2 (trypsin-like activity), and β5 (chymotrypsin-like activity), respectively. As can be seen inFigs. 4A to 4C , the inhibitory activity of TMP-CiKD_Bortezomib against β1 and β5 was found to be substantially weakened as compared with bortezomib alone, indicating that the inhibitory activity of bortezomib was inactivated. For β2, the present results were consistent with a previous report stating that β2 was not significantly inhibited by bortezomib (Kisselev, A. F. et al., Chemistry & Biology, 2012, 19, 99-115). Further, the inhibitory activity of TMP-CiKD_Bortezomib against β2 and β5 was found to be increased in a concentration dependent manner, indicating that TMP-CiKD_Bortezomib had an affinity with a proteasome. - In Example 5, 50% inhibition concentrations (IC50) of TMP-CiKD_Bortezomib and bortezomib (Code No. sc-217785, Santa Cruz Biotechnology) were measured for each of the proteasome activities of β1, β2, and β5 of 20S proteasome.
- For the 50% inhibition concentration (IC50), AMC released when the C-terminus of an AMC-conjugated proteasome fluorescent substrate specific to a β subunit of β5 (chymotrypsin-like activity), β2 (trypsin-like activity), and β1 (caspase-like activity) of 20S proteasome was cut using 20S Proteasome StressXpress™ Assay Kit Gold (Bioscience) was measured with a multi-detection microplate reader (Synergy HT, BIO-TEK). The measurement wavelengths were 360 nm for excitation light (Ex.), and 460 nm for fluorescence (Em.).
- Test compounds (TMP-CiKD_Bortezomib and bortezomib) were each adjusted to 6 concentrations as shown in the following Table 83.
[Table 83] TMP-CiKD_Bortezomib β1 : 1, 4, 10, 40, 80, 160 µM β2: 1, 4, 10, 40, 80, 160 µM β5: 1, 4, 10, 40, 80, 160 µM Bortezomib β1: 0.01, 0.04, 0.1, 0.4, 1, 10 µM β2: 0.4, 1, 4, 10, 40, 100 µM β5: 0.001, 0.004, 0.01, 0.04, 0.1, 0.4 µM - A test compound and 20S proteasome (0.1 µg) were incubated at room temperature for 30 minutes. To these, Suc-LLVY-AMC (degradable by β5), Bz-VGR-AMC (degradable by β2), and Z-LLE-AMC (degradable by β1) as a luminescent substrates were added so that the concentrations thereof were each 100 µM, and incubated at room temperature. After one hour, AMC produced by the proteasome activity was measured. Values of proteasome degradation inhibition of the test compounds at each concentration were calculated as relative values to the control (DMSO). Using the inhibition values at the 6 concentrations, a regression curve was created with an analysis software ImageJ (NIH) to obtain 4 parameters (a: Malthusian parameter, b: crowdedness constant, c: slope, d: intercept). Then, the obtained 4 parameters and y = 0.5 (50% inhibition) were introduced into the following regression expression of 4-parameter logistic curve, and a value of x (IC50) was computed.
- The 50% inhibition concentrations (IC50) of TMP-CiKD_Bortezomib and bortezomib are shown in the following Table 84.
[Table 84] IC50 (µM) β1 β2 β5 TMP-CiKD. Bortezomib > 160 > 160 > 160 Bortezomib 0.129 2.61 0.00314 - As can be seen in Table 84, TMP-CiKD_Bortezomib was found to have significantly increased 50% inhibition concentrations (IC50) against all of β1, β2, and β5 as compared with bortezomib, indicating that the inhibitory activity of bortezomib was inactivated.
- In Example 6, TMP-CiKD_ALLN as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme. As a protein-degradation inducing tag, used was ALLN-COOH (CiKD_ALLN) in which the formyl group as the active site of ALLN was replaced with a carboxy group. As a protein binding molecule, TMP-NH2 was used as in Example 1. Then, ALLN-COOH was linked to TMP-NH2 to synthesize TMP-CiKD_ALLN as a protein-degradation inducing molecule.
- The method of synthesizing TMP-CiKD_ALLN is described in detail as follows.
- ALLN (87.2 mg, 0.23 mmol, 1 eq, Code No. 07036-24, Nacalai Tesque, Inc.) was charged into an eggplant flask, and 2 mL of dehydrate DMF was added. After stirred at room temperature for 5 minutes, Oxone (212.1 mg, 0.69 mmol, 3 eq, Code No. 228036, Sigma-Aldrich) was added directly to the reaction solution, and stirred at room temperature for 5 hours. The reaction solution was diluted with water, and extracted with chloroform for 3 times. After dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. Separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (chloroform/methanol = 20/1 to 10/1, gradient) to obtain a compound 6 (ALLN-COOH) (27.0 mg, 0.068 mmol, 30%).
- The compound 6 (ALLN-COOH) (26.8 mg, 0.067 mmol, 1 eq) and TMP-NH2 synthesized separately (Long, M. J. et al., Chem. Biol., 2012, 19 (5) 629-637) (26.0 mg, 0.060 mmol, 0.9 eq) was charged into an eggplant flask, and 2 mL of dehydrate DMF was added. After stirred at room temperature for 5 minutes, 0.1 mL of DIEA was added to neutralize the solution. After stirred at room temperature for 5 minutes, DMT-MM (30.0 mg, 0.11 mmol, 1.6 eq, Code No. 329-53751, Wako Pure Chemical Industries, Ltd.) was added directly to the reaction solution, and stirred at room temperature for 2 hours. Under cooling conditions, 10 mL of 10 mass% brine/0.1 N aqueous hydrochloric acid was added, and extracted with ethyl acetate for 3 times. This was washed with 0.5 N aqueous hydrochloric acid and then brine, and then dried over anhydrous sodium sulfate. After evaporating the solvent under reduced pressure, separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (chloroform/methanol = 10/1) to obtain a compound 7 (TMP-CiKD_ALLN) (8.2 mg, 0.010 mmol, 15%, isolated yield).
- In Example 7, degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN was added was evaluated by FACS analysis.
- HeLa cells were prepared as in Example 2. A plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_ALLN was added to HeLa cells as in Example 2 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib. A DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_ALLN.
- The efficiency of target degradation (knockdown) by TMP-CiKD_ALLN was determined as in Example 2 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
-
Fig. 5A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN was added. Further,Fig. 5B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. As can be seen inFig. 5A , when TMP-CiKD_ALLN (80 µM) was added, the graph was found to be significantly shifted to the left as compared with that of the control (DMSO), indicating that the target protein (E. coli DHFR) was degraded. The degradation efficiency estimated from the amount of a shift was about 60% to 70%. In contrast, as can be seen inFig.5B , when TMP (80 µM) was added, the graph was found to be overlapped with that of the control (DMSO), indicating that the target protein was not degraded. - In Example 8, the affinity of TMP-CiKD_ALLN with a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN was added was evaluated by thermal shift assay.
- HeLa cells were prepared as in Example 2. A plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_ALLN was added to HeLa cells as in Example 2 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib. A DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_ALLN.
- The affinity of TMP-CiKD_ALLN with a target was evaluated by thermal shift assay as in Example 3 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
-
Fig. 6 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_ALLN or TMP was added. As shown inFig. 6 , E. coli DHFR was able to be detected only up to about 50°C for the control (DMSO). In contrast, E. coli DHFR was able to be detected up to about 54°C by virtue of interaction between E. coli DHFR and TMP when TMP (40 µM) was added. Similarly, E. coli DHFR was able to be detected up to about 58°C by virtue of interaction between E. coli DHFR and TMP-CiKD_ALLN when TMP-CiKD_ALLN (40 µM) was added. These results show that TMP-CiKD_ALLN, in which TMP-NH2 is linked to CiKD_ALLN, has a higher affinity with E. coli DHFR than TMP. - In Example 9, the proteasome inhibitory activity of TMP-CiKD_ALLN, and the affinity of TMP-CiKD_ALLN with a proteasome were evaluated as in Example 4 except that TMP-CiKD_ALLN was used in place of TMP-CiKD_Bortezomib.
-
Figs. 7A to 7C show the proteasome activities against β1 (caspase-like activity), β2 (trypsin-like activity), and β5 (chymotrypsin-like activity), respectively. As can be seen inFigs. 7A to 7C , the inhibitory activity of TMP-CiKD_ALLN against β2 and β5 was found to be weakened as compared with ALLN alone, indicating that the activity of ALLN was inactivated. For β1, the present results were consistent with a previous report stating that β1 was not significantly inhibited by ALLN (Kaiser, M. et al., Chem. Bio. Chem., 2004, 5, 1256-1266). Further, the inhibitory activity of TMP-CiKD_ALLN was found to be increased against any of β1, β2, and β5 in a concentration dependent manner, indicating that TMP-CiKD_ALLN had an affinity with a proteasome. - In Example 10, the 50% inhibition concentrations (IC50) of TMP-CiKD_ALLN and ALLN (Code No. 07036-82, Nacalai Tesque, Inc.) were measured for each of the proteasome activities of β1, β2, and β5 of 20S proteasome as in Example 5 except that TMP-CiKD_ALLN and ALLN were used in place of TMP-CiKD_Bortezomib and bortezomib. It is noted that test compounds (TMP-CiKD_ALLN and ALLN) were each adjusted to 6 concentrations as shown in the following Table 85.
[Table 85] TMP-CiKD_ALLN β1 : 5, 10, 20, 40, 80, 160 µM β2: 5, 10, 20, 40, 80, 160 µM β5: 5, 10, 20, 40, 80, 160 µM ALLN β1 : 0.4, 1, 4, 10, 20, 40 µM β2: 0.4, 1, 4, 10, 20, 40 µM β5: 0.04, 0.1, 0.4, 1, 4, 10 µM - The 50% inhibition concentrations (IC50) of TMP-CiKD_ALLN and ALLN are shown in the following Table 86.
[Table 86] IC50 (µM) β1 β2 β5 TMP-CiKD. ALLN 38.8 > 160 42.3 ALLN 12.4 5.25 1.15 - As can be seen in Table 86, TMP-CiKD_ALLN was found to have significantly increased 50% inhibition concentrations (IC50) for all of β1, β2, and β5 as compared with ALLN, indicating that the inhibitory activity of ALLN was inactivated.
- In Example 11, TMP-CiKD_MLN as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme. As a protein-degradation inducing tag, used was MLN-COOH (CiKD_MLN) in which the boronic acid ester moiety or boronyl group as the active site of MLN9708 and MLN2238 was replaced with a carboxy group. As a protein binding molecule, TMP-NH2 was used as in Example 1. Then, MLN-COOH was linked to TMP-NH2 to synthesize TMP-CiKD_MLN as a protein-degradation inducing molecule.
- The method of synthesizing TMP-CiKD_MLN is described in detail as follows.
- H-Gly-OtBu·HCl (286.8 mg, 1.69 mmol, 1 eq, Code No. AK-46074, Ark Pharm) was charged into a side-arm eggplant flask, and purged with nitrogen. Under nitrogen gas stream, 10 mL of dehydrate DMF and 5 mL of DIEA were added, and stirred at room temperature. In 1 mL of dehydrate DMF and 1 mL of DIEA, dissolved was 2,5-dichlorobenzoic acid (309.3 mg, 1.62 mmol, 1 eq, Code No. AK-47665, Ark Pharm), which was then added to the reaction solution, and stirred at room temperature for 20 minutes. PyBOP (1.02 g, 1.96 mmol, 1.2 eq, Code No. 8.51009.0005, Novabiochem, Merck) was dissolved in 1 mL of dehydrate DMF, and then added to the reaction solution, and stirred at room temperature for 3 hours. The reaction solution was diluted with water and aqueous sodium hydrogen carbonate, and extracted twice with ethyl acetate/hexane (= 4/1). After dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. Separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (hexane/chloroform = 1/1 to 0/1, gradient) to obtain a compound 8 (531.0 mg, 1.75 mmol, 103%).
- The compound 8 (212.4 mg, 0.70 mmol) was charged into an eggplant flask, and 5 mL of dichloromethane was then added. This was stirred at room temperature for 5 minutes, and then 5 mL of TFA was added, and stirred at room temperature for 1 hour. After evaporating the solvent under reduced pressure, vacuum drying was performed to obtain a compound 9 (190.7 mg, quant.).
- The compound 9 (190.7 mg, 0.77 mmol, 1 eq) and H-Leu-OtBu·HCl (175.8 mg, 0.79 mmol, 1 eq, Code No. 14G110356, Watanabe Chemical Industries, Ltd.) were charged into a side-arm eggplant flask, and purged with nitrogen. Under nitrogen gas stream, 5 mL of dehydrate DMF and 5 mL of DIEA were added, and stirred at room temperature for 20 minutes. PyBOP (886.7 mg, 1.70 mmol, 2.2 eq, Code No. 8.51009.0005, Novabiochem, Merck) was dissolved in 1.5 mL of dehydrate DMF, and added to the reaction solution, and stirred at room temperature for 3 hours. The reaction solution was diluted with water and aqueous sodium hydrogen carbonate, and extracted twice with ethyl acetate/hexane (= 4/1). After dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. Separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (hexane/chloroform = 1/1 to 0/1, gradient) to obtain a compound 10 (244.2 mg, 0.58 mmol, 76%).
- The compound 10 (240.8 mg, 0.58 mmol) was charged into an eggplant flask, and 5 mL of dichloromethane was added. This was stirred at room temperature for 5 minutes, and then 5 mL of TFA was added, and stirred at room temperature for 1 hour. After evaporating the solvent under reduced pressure, vacuum drying was performed to obtain a compound 11 (MLN-COOH) (214.7 mg, 0.59 mmol, 100%).
- The compound 11 (MLN-COOH) (210.3 mg, 0.58 mmol, 1 eq) was charged into a side-arm eggplant flask, and purged with nitrogen. TMP-NH2 synthesized separately (Long, M. J. et al., Chem. Biol., 2012, 19 (5), 629-637) (207.6 mg, 0.48 mmol, 0.8 eq) was dissolved in 5 mL of dehydrate DMF, and added to the reaction solution. To this, 5 ml of DIEA was added, and stirred at room temperature for 20 minutes. PyBOP (765.2 mg, 1.47 mmol, 2.5 eq, Code No. 8.51009.0005, Novabiochem, Merck) was dissolved in 1.5 mL of dehydrate DMF, and then added to the reaction solution, and stirred at room temperature for 18 hours. The reaction solution was diluted with water and aqueous sodium hydrogen carbonate, and extracted twice with ethyl acetate. After dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (chloroform/methanol = 20/1 to 4/1, gradient). Subsequently, separation and purification treatment was performed using a TLC silica gel 60 (Code No. HX264817, Merck) (chloroform/methanol = 10/1) to obtain a compound 12 (TMP-CiKD_MLN) (20.2 mg, 0.026 mmol, 5%, isolated yield).
- In Example 12, degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN was added was evaluated by FACS analysis.
- HeLa cells were prepared as in Example 2. A plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was introduced into HeLa cells as in Example 2, and then seeded on a 24-well plate.
- TMP-CiKD_MLN was added to HeLa cells as in Example 2 except that TMP-CiKD_MLN was used in place of TMP-CiKD_Bortezomib. Further, an experiment group where a DMSO solution containing TMP-CiKD_MLN and bortezomib was added was also prepared in addition to an experiment group where a DMSO solution containing TMP-CiKD_MLN was added. A DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_MLN.
- The efficiency of target degradation (knockdown) by TMP-CiKD_MLN was determined as in Example 2 except that TMP-CiKD_MLN or TMP-CiKD_MLN and bortezomib were used in place of TMP-CiKD_Bortezomib.
-
Fig. 8A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN was added. Further,Fig. 8B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. Moreover,Fig. 8C shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_MLN and bortezomib were added. As can be seen inFig. 8A , when TMP-CiKD_MLN (80 µM) was added, the graph was found to be significantly shifted to the left as compared with that of the control (DMSO), indicating that the target protein (E. coli DHFR) was degraded. The degradation efficiency estimated from the amount of a shift was about 60% to 70%. In contrast, as can be seen inFig. 8B , when TMP (80 µM) was added, the graph was found to be overlapped with that of the control (DMSO), indicating that the target protein was not degraded. Moreover, as shown inFig. 8C , when TMP-CiKD_MLN (80 µM) and bortezomib (1.5 µM) were added, degradation of the target protein was more significantly inhibited than a case where TMP-CiKD_MLN (80 µM) was added. These results suggest that TMP-CiKD_MLN enabled the target protein to lead to degradation by the proteasome. - In Example 13, MTX-CiKD_MLN as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme. As a protein-degradation inducing tag, used was MLN-COOH (CiKD_MLN) in which the boronic acid ester moiety or boronyl group as the active site of MLN9708 and MLN2238 was replaced with a carboxy group. As a protein binding molecule, used was an MTX derivative (MTX-NH2) in which a functional group including an amino group was introduced into MTX as a dihydrofolate reductase inhibitor capable of binding to DHFR. Then, MLN-COOH was linked to MTX-NH2 to synthesize MTX-CiKD_MLN as a protein-degradation inducing molecule.
- The method of synthesizing MTX-CiKD_MLN is described in detail as follows.
- The compound 13 was allowed to react with triphenylphosphine dibromide in DMA to obtain a compound 14. The compound 14 was dissolved in DMA under nitrogen gas stream, and then the
compound 15 and DIEA were added and reacted to obtain a compound 16 (yield: 69%). Subsequently, the compound 16 and the compound 17 were dissolved in DMSO under nitrogen gas stream, and condensation reaction was performed with a BOP reagent to obtain a compound 18 (yield: 46%). Subsequently, the compound 18 and the compound 19 were dissolved in DMA under nitrogen gas stream, and condensation reaction was performed with HATU to obtain a compound 20 (yield: 69%). Then, thecompound 20 was dissolved in dichloromethane, and deprotection was performed with TFA to obtain a compound 21 (MTX-NH2). - The compound 21 (MTX-NH2) and the
compound 11 used for synthesis of the compound 12 (TMP-CiKD_MLN) were dissolved in DMF under nitrogen gas stream, and a condensation reaction was performed with PyBOP (at room temperature for 3 hours). The reaction solution was diluted with water and aqueous sodium hydrogen carbonate, and extracted with ethyl acetate for 3 times. After dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and separation and purification treatment was performed by silica gel chromatography (chloroform/methanol = 20/1 to 4/1, gradient). Subsequently, separation and purification treatment was performed using a TLC silica gel 60 (chloroform/methanol = 85/15) to obtain a compound 22 (MTX-CiKD_MLN) (isolated yield: 8%). - In Example 14, the affinity of MTX-CiKD_MLN with an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN was added was evaluated by thermal shift assay.
- HeLa cells were prepared as in Example 2. The cell solution collected after trypsin treatment was seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 104 cells/800 µL/well, and then cultured under conditions of 37°C and 5 vol% CO2 for 16 hours.
- MTX-CiKD_MLN was added to HeLa cells as follows 16 hours after cell seeding. As a medium, used was a serum free medium (37°C) in which a 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.). It is noted that the L-glutamine solution was added immediately before use. A DMSO solution containing MTX-CiKD_MLN was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well where the pre-culture medium had been removed at 500 µL/well, and cultured under conditions of 37°C and 5 vol% CO2. It is noted that a DMSO solution containing MTX or DMSO was used as a control in place of the DMSO solution containing MTX-CiKD_MLN.
- The medium was removed 3 hours after addition of MTX-CiKD_MLN (40 µM) or MTX (40 µM), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 1 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA·4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 200 µL/well, and cultured under conditions of 37°C and 5 vol% CO2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No. AYG161516, HyClone) and 1 mass% PenStrep (100 U/mL sodium penicillin G and 100 µg/mL streptomycin sulfate) (Code No. 168-23191, Wako Pure Chemical Industries, Ltd.) were added to D-MEM (low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.) was added to each well at 0.8 mL/well, and suspended, and then a cell solution was collected in a 15 mL tube.
- The cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C). The cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 170 µL of a CETSA buffer (cOmplete™ Mini, EDTA-free (Roche) as a protease inhibitor was added to TBS just before use) was added, and then suspended. The cell solution after suspension was dispensed to nine 1.5 mL tubes at 20 µL per tube, and allowed to stand at room temperature for 30 minutes. After allowed to stand, the 9 tubes were heat-treated for 3 minutes, one each at 38°C, 42°C, 46°C, 50°C, 54°C, 58°C, 62°C, 66°C, or 70°C, and allowed to stand at room temperature for 3 minutes. After allowed to stand, the cell solution was flash frozen in liquid nitrogen, and thawed on ice. After repeating this freeze-thaw cycle for 3 times, the cell solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- The cell extract collected was subjected to Western blot analysis. An SDS-PAGE gel (14 wells) was prepared using TGX™ FastCast™ Acrylamide Kit, 12% (Bio-Rad). Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 17 µL/well. Precision Plus Protein™ Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 60 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- After electrophoresis, proteins were transferred to a PVDF membrane (Immobion™-P, Millipore) under conditions of 100 V and 2 hours using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol). The membrane after transfer was shaken and blocked in 5% skim milk/TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T. As a primary antibody, anti-DHFR antibody (sc-377091, SantaCruz) diluted 500 times was used. After shaken at 4°C overnight, the membrane was washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. After the primary antibody reaction, a secondary antibody reaction was performed in 2% skim milk/TBS-T. As a secondary antibody, anti-mouse IgG (H+L) antibody (A90-116P-33, BETHYL) diluted 10000 times was used. The membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
-
Fig. 9 shows results from the thermal shift assay of an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN or MTX was added. As shown inFig. 9 , human DHFR was able to be detected only up to about 42°C for the control (DMSO) while human DHFR was able to be detected up to about 50°C by virtue of interaction between human DHFR and MTX-CiKD_MLN when MTX-CiKD_MLN (40 µM) was added. These results indicate that MTX-CiKD_MLN, in which MTX-NH2 was linked to CiKD_MLN, had an affinity with human DHFR. - In Example 15, degradation (knockdown) of an endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN was added was evaluated by Western blot analysis.
- HeLa cells were prepared, and seeded on a 24-well plate as in Example 14.
- MTX-CiKD_MLN was added to HeLa cells as in Example 14. A DMSO solution containing MTX or DMSO was used as a control in place of the DMSO solution containing MTX-CiKD_MLN.
- The medium was removed 16 hours after addition of MTX-CiKD_MLN (50 µM, 100 µM, or 200 µM) or MTX (50 µM, 100 µM, or 200 µM), and then PBS (Wako Pure Chemical Industries, Ltd.) at 4°C was added to each well at 1 mL/well to wash the cells. After removing PBS, a mixed solution of a cell lysis buffer (CelLytic™ M, Sigma) and a protease inhibitor (cOmplete™ Mini, EDTA-free (
REF 11 836 170 001), Roche) was added to each well at 27 µL/well. After allowed to stand at 4°C for 15 minutes, cells were detached with a pipette tip (P1000) on ice. A cell solution was collected in a 1.5 mL tube, and flash frozen in liquid nitrogen, and then thawed on ice. After thawed, the cell solution was centrifuged (at 12000 rpm x 15 minutes, 4°C), and the supernatant (cell extract) was collected. - The cell extract collected was subjected to Western blot analysis. An SDS-PAGE gel (14 wells) was prepared using TGX™ FastCast™ Acrylamide Kit, 12% (Bio-Rad). Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 20 µL/well. Precision Plus Protein™ Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 65 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- After electrophoresis, proteins were transferred to a PVDF membrane (Immobion™-P, Millipore) under conditions of 100 V and 2 hours using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol). The Membrane was split into two at the position of a 25 kDa marker. The membrane after transfer was shaken and blocked in 5% skim milk/TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T. As a primary antibody, anti-DHFR antibody (sc-14780, SantaCruz, diluted 500 times) and anti-GAPDH antibody (sc-32233, SantaCruz, diluted 20000 times) were used. After shaken at room temperature for 90 minutes (anti-DHFR antibody) or for 45 minutes (anti-GAPDH antibody), the membranes were washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. After the primary antibody reaction, a secondary antibody reaction was performed in 2% skim milk/TBS-T. The membranes were shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membranes were washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membranes were treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation). Detected bands were quantified with an image processing software ImageJ (NIH).
-
Fig. 10A shows results from quantification of bands detected in the Western blot analysis of the endogenously expressed target protein (human DHFR) in HeLa cells to which MTX-CiKD_MLN or MTX was added.Fig. 10B shows the detected bands. As can be seen inFigs. 10A and 10B , the amount of the target protein (human DHFR) was decreased in a concentration dependent manner when MTX-CiKD_MLN was added. In contrast, when MTX was added, a decrease in the amount of the target protein (human DHFR) was not observed even at a concentration of 200 µM. - In Example 16, degradation (knockdown) of an endogenously expressed target protein (mouse DHFR) in mouse individuals to which MTX-CiKD_MLN was administered was evaluated by Western blot analysis.
- DMSO, 10 mg/kg of MTX, 50 mg/kg of MTX-CiKD_MLN, or 100 mg/kg of MTX-CiKD_MLN was administered to C57BL/6J wild type mice (7 weeks old, male) (CLEA Japan, Inc.) for 24 hours (n = 3). MTX-CiKD_MLN and MTX were dissolved in DMSO, and then dissolved in corn oil (Code No. 25606-55, Nacalai Tesque, Inc.) so that the concentration of DMSO was 10 vol%, and then administered intraperitoneally. The mice were kept under an environment of ad libitum access to food and water. The mice were dissected under deep Somnopentyl anesthesia (serial number: 3214101, Kyoritsuseiyaku Corporation) 24 hours after administration. The liver, kidney, spleen, heart, and lung were excised, and flash freeze in liquid nitrogen.
- The frozen liver (40 mg) was triturated, and then 980 µL of 1x TKM tissue lysis buffer (50 mM triethanolamine (pH 7.8), 50 mM KCl, 5 mM MgCl2, 0.25 M sucrose, 1 mM PMSF, Protein Inhibitors Cocktail-EDTA free (Code No. 03969-21, Nacalai Tesque, Inc.), 1 mM DTT,
recombinant RNase inhibitor 5 µL/mL (40 U/µL, Cat No. 2313A, Lot No. K8402DA, TAKARA) were added, and rotated for 15 minutes (1 rpm, 25°C). After centrifugation (at 3000 rpm x 15 minutes, 4°C), the supernatant (liver tissue extract) was collected. The concentration of extracted proteins was quantified with a spectrophotometer. - The liver tissue extract collected was subjected to Western blot analysis. An SDS-PAGE gel (14 wells) was prepared using TGX™ FastCast™ Acrylamide Kit, 12% (Bio-Rad) . Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 5 minutes. The electrophoresis samples prepared were applied at 100 µg/20 µL/well (for detection of DHFR) or 50 µg/10 µL/well (for detection of GAPDH). Precision Plus Protein™ Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 60 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- After electrophoresis, proteins were transferred to a PVDF membrane (Immobion™-P, Millipore) under conditions of 100 V and 90 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol). The membrane after transfer was shaken and blocked in 5% skim milk/TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6) at room temperature for 30 minutes. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T. As a primary antibody, anti-DHFR antibody (sc-14780, SantaCruz, diluted 500 times) and anti-GAPDH antibody (sc-32233, SantaCruz, diluted 20000 times) were used. The membrane was shaken at room temperature for 60 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. After the primary antibody reaction, a secondary antibody reaction was performed in 1% skim milk/TBS-T. The membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 10 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
-
Fig. 11 shows results from the Western blot analysis of an endogenous expressed target protein (mouse DHFR) in a liver tissue extract from a mouse individual to which MTX-CiKD_MLN or MTX was administered. As can be seen inFig. 11 , when 50 mg/kg or 100 mg/kg of MTX-CiKD_MLN was administered to mice for 24 hours, the amount of the target protein (mouse DHFR) in the liver tissue was decreased in a concentration dependent manner. These results show that about 70% to 80% of the target protein (mouse DHFR) was degraded as fast as one day in the mouse individuals. In contrast, when 10 mg/kg of MTX was administered to mice for 24 hours, the amount of the target protein (mouse DHFR) in the liver tissue was increased as compared with that of the control (DMSO). - In Example 17, TMP-CiKD_DMT as a protein-degradation inducing molecule was synthesized according to the following synthesis scheme. As a protein-degradation inducing tag, used was a compound (DMT) in which R1 and R2 in the aforementioned formula (I) were each a methoxy group. DMT is a compound which is not derived from a proteasome inhibitor, but has an affinity with a proteasome. As a protein binding molecule, TMP-NH2 was used as in Example 1. Then, DMT was linked to TMP-NH2 to synthesize TMP-CiKD_DMT as a protein-degradation inducing molecule.
- The method of synthesizing TMP-CiKD_DMT is described in detail as follows.
- TMP-NH2 (Long, M. J. et al., Chem. Biol., 2012, 19 (5), 629-637) (31.7 mg, 0.073 mmol) was charged into an eggplant flask, and 0.3 mL of dehydrate DMF was added. After stirred at room temperature for 10 minutes, 0.1 mL of DIEA was added, and stirred at room temperature for 10 minutes. DMT-MM (33.6 mg, 0.12 mmol, 1.6 eq, Code No. 329-53751, Wako Pure Chemical Industries, Ltd.) was directly added to the reaction solution, and stirred at room temperature for 18 hours. The reaction solution was diluted with water and aqueous sodium hydrogen carbonate, and extracted with chloroform for 5 times. After dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure. Separation and purification treatment was performed by silica gel chromatography (Code No. 30511-35, Nacalai Tesque, Inc.) (chloroform/methanol = 92/8) to obtain TMP-CiKD_DMT (25.8 mg, 0.045 mmol, 62%, isolated yield).
- In Example 18, the proteasome inhibitory activity of TMP-CiKD_DMT and the affinity of TMP-CiKD_DMT with a proteasome were evaluated as in Example 4 except that 10 µM or 100 µM of TMP-CiKD_DMT was used in place of TMP-CiKD_Bortezomib. As a positive control, used was MG-132 as a proteasome inhibitor.
-
Figs. 12A to 12C show the proteasome activities against β1 (caspase-like activity), β2 (trypsin-like activity), and β5 (chymotrypsin-like activity), respectively. As can be seen inFigs. 12A to 12C , TMP-CiKD_DMT was found to have a significantly lower proteasome inhibitory activity as compared with MG-132. Moreover, the inhibitory activity of TMP-CiKD_DMT was increased in a concentration dependent manner against any of β1, β2, and β5, suggesting that TMP-CiKD_DMT has a moderate affinity with a proteasome. That is, DMT was evaluated to have an affinity with a proteasome, but does not inhibit degradation. - In Example 19, the 50% inhibition concentration (IC50) of TMP-CiKD_DMT against each of the proteasome activities of β1, β2, and β5 of 20S proteasome was measured as in Example 5 except that TMP-CiKD_DMT was used in place of TMP-CiKD_Bortezomib. As a positive control, used was MLN2238 as a proteasome inhibitor.
- The 50% inhibition concentrations (IC50) of TMP-CiKD_DMT and MLN2238 are shown in the following Table 87.
[Table 87] IC50 (µM) β1 β2 β5 TMP-CiKD_DMT > 100 > 100 90.5 MLN2238 0.0079 6.4 0.043 - As can be seen in Table 87, TMP-CiKD_DMT was found to have a significantly lower proteasome inhibitory activity as compared with MLN2238.
- In Example 20, the affinity of TMP-CiKD_DMT with a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added was evaluated by thermal shift assay.
- HeLa cells were prepared as in Example 2.
- A plasmid was introduced into HeLa cells to transiently overexpress ecDHFR as a target protein (specifically, a fusion protein of ecDHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- The plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) (Long, M. J. et al., "Inhibitor mediated protein degradation." Chem. Biol., 2012, 19 (5), 629-637). The plasmid was amplified in E. coli, and then purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFectA™ (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells. A dilution buffer of ScreenFect™ A was added to two 1.5 mL tubes at 250 µL per tube. Then, 12 µL of a transfection reagent of ScreenFect™ A was added to one tube (a solution A), and 6 µg of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes. The solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C). The solution C was mixed in a cell solution of 6 x 105 cells/12 mL collected by trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, and Nippon Genetics Co., Ltd.) at a cell density of 4 x 104 cells/800 µL/well, and then cultured under conditions of 37°C and 5 vol% CO2 for 40 hours.
- Culture was performed for 40 hours after introduction of the plasmid, and then TMP-CiKD_DMT was added to HeLa cells as follows. As a medium, used was a serum free medium (37°C) in which 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.). It is noted that the L-glutamine solution was added immediately before use. A DMSO solution containing MTX-CiKD_DMT was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well at 300 µL/well where the pre-culture medium had been removed, and cultured under conditions of 37°C and 5 vol% CO2. It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_DMT.
- The medium was removed 3 hours after addition of TMP-CiKD_DMT (28 µM) or TMP (40 µM), and then PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 1 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA·4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 300 µL/well, and cultured under conditions of 37°C and 5 vol% CO2 for 1 minutes. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No. AYG161516, HyClone) and 1 mass% PenStrep (100 U/mL sodium penicillin G and 100 µg/mL streptomycin sulfate) (Code No. 168-23191, Wako Pure Chemical Industries, Ltd.) were added to D-MEM (low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.) was added to each well at 1 mL/well, and suspended, and then a cell solution was collected in a 15 mL tube.
- The cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C). The cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 180 µL of a CETSA buffer (complete™ Mini, EDTA-free (Roche) as a protease inhibitor was added to TBS immediately before use) was added and suspended. The cell solution after suspension was dispensed to nine 1.5 mL tubes at 20 µL per tube, and allowed to stand at room temperature for 30 minutes. After allowed to stand, the 9 tubes were heat-treated for 3 minutes, one each at 38°C, 42°C, 46°C, 50°C, 54°C, 58°C, 62°C, 66°C, or 70°C, and allowed to stand at room temperature for 3 minutes. After allowed to stand, the cell solution was flash frozen in liquid nitrogen, and thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected.
- The cell extract collected was subjected to Western blot analysis. An SDS-PAGE gel (14 wells) was prepared using TGX™ FastCast™ Acrylamide Kit, 12% (Bio-Rad). Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 17 µL/well. Precision Plus Protein™ Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 150 V for 40 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- After electrophoresis, proteins were transferred to a PVDF membrane (Immobion™-P, Millipore) under conditions of 100 V and 40 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol). The membrane after transfer was shaken and blocked at room temperature for 30 minutes in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6). After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T. With regard to antibody, anti-HA-peroxidase, high-affinity (3F10) rat monoclonal antibody (25 U/mL) (Roche) diluted 1000 times was used. The membrane was shaken at room temperature for 90 minutes, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
-
Fig. 13 shows results from the thermal shift assay of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT or TMP was added. E. coli DHFR was able to be detected only up to about 50°C for the control (DMSO) while E. coli DHFR was able to be detected up to about 54°C for TMP (40 µM) and up to about 62°C for TMP-CiKD_DMT (28 µM). These results show that TMP-CiKD_DMT, in which TMP-NH2 is linked to DMT, has a higher affinity with E. coli DHFR than TMP. - In Example 21, degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added was evaluated by FACS analysis.
- HeLa cells were prepared as in Example 2.
- A plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- The plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) (Long, M. J. et al., "Inhibitor mediated protein degradation." Chem. Biol., 2012, 19 (5), 629-637). The plasmid was amplified in E. coli, and purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFect™ A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells. A dilution buffer of ScreenFect™ A was added to two 1.5 mL tubes at 960 µL per tube. Then, 40 µL of a transfection reagent of ScreenFect™ A was added to one tube (a solution A), and 16 µg of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes. The solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C). The solution C was mixed with a cell solution of 2.7 x 105 cells/18 mL collected from trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 6 x 104 cells/400 µL/well, and then cultured under conditions of 37 °C and 5 vol% CO2 for 40 hours.
- TMP-CiKD_DMT was added to HeLa cells as follows. Culture was performed for 40 hours after introduction of the plasmid, and then the preculture medium was removed. Then, a serum-free medium (37°C) in which 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, and sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.) was added to each well at 297 µL/well. It is noted that the L-glutamine solution was added immediately before use. A DMSO solution containing a predetermined concentration of TMP-CiKD_DMT was added to each well at 3 µL/well, and cultured under conditions of 37°C and 5 vol% CO2. It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_DMT.
- The medium was removed 24 hours after addition of TMP-CiKD_DMT (56 µM or 112 µM) or TMP (80 µM), PBS (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 1 mL/well to wash the cells. After removing PBS, trypsin (0.25 w/v% trypsin-1 mmol/L EDTA·4 Na solution with phenol red) (Wako Pure Chemical Industries, Ltd.) at 37°C was added to each well at 300 µL/well, and cultured under conditions of 37°C and 5 vol% CO2 for 1 minute. After culturing, a medium where 10 mass% FBS (Code No. SH30910.03, Lot. No. AYG161516, HyClone) and 1 mass% PenStrep (100 U/mL sodium penicillin G and 100 µg/mL streptomycin sulfate) (Code No. 168-23191, Wako Pure Chemical Industries, Ltd.) were added to D-MEM (low D-glucose, L-glutamine, phenol red (Code No. 041-29775, Wako Pure Chemical Industries, Ltd.)) was added to each well at 500 µL/well, and suspended, and then a cell solution was collected in a 15 mL tube.
- The cell solution collected was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then suspended in 2 ml of PBS (37°C). The cell solution after suspension was centrifuged (at 1000 rpm x 5 minutes, 4°C), and the supernatant was removed, and then 500 µL of an FACS buffer (1 mass% FBS/PBS) at 4°C was added, and allowed to stand on ice.
- A BD FACSCanto™ II (BD Biosciences) was used for flow cytometry, and the expression levels of GFR and DsRed in the cells were quantified. The cell solution was passed through a mesh with a pore size of 32 µm, and transferred to an FACS tube immediately before FACS analysis. The GFR/DsRed ratio per cell was computed using an analysis software FLOWJO™ (TOMY Digital Biology Co., Ltd.), and the efficiency of target degradation (knockdown) by TMP-CiKD_DMT was determined from a shift in a graph of target degradation.
-
Fig. 14A shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT (56 µM) was added.Fig. 14B shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT (112 µM) was added. Further,Fig. 14C shows results from the FACS analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP was added. As can be seen fromFigs. 14A and14B , when TMP-CiKD_DMT was added, the amounts of a shift to the left in the graphs were found to be increased as compared with the control (DMSO) in a concentration dependent manner, indicating that the target protein (E. coli DHFR) was degraded. The degradation efficiency estimated from the amount of a shift was about 60% to 70%. In contrast, as can be seen inFig. 14C , the graph was found to be overlapped with that of the control (DMSO) when TMP was added, indicating that the target protein was not degraded. - In Example 22, degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT was added was evaluated by Western blot analysis.
- HeLa cells were prepared as in Example 2.
- A plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- The plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) (Long, M. J. et al., "Inhibitor mediated protein degradation." Chem. Biol., 2012, 19 (5), 629-637). The plasmid was amplified in E. coli, and purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFect™ A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells. A dilution buffer of ScreenFect™ A was added to two 1.5 mL tubes at 250 µL per tube. Then, 12 µL of a transfection reagent of ScreenFect™ A was added to one tube (a solution A), and 4.8 µg of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes. The solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C). The solution C was mixed with a cell solution of 7.7 x 104 cells/7.7 mL collected from trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 104 cells/400 µL/well, and then cultured under conditions of 37°C and 5 vol% CO2 for 40 hours.
- Culture was performed for 40 hours after introduction of the plasmid, and then TMP-CiKD_DMT was added to HeLa cells as follows. As a medium, used was a serum free medium (37°C) in which 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.)). It is noted that the L-glutamine solution was added immediately before use. A DMSO solution containing TMP-CiKD_DMT was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well at 300 µL/well where the pre-culture medium had been removed, and cultured under conditions of 37°C and 5 vol% CO2. Further, an experiment group where a DMSO solution containing TMP-CiKD_DMT and bortezomib was added was also prepared in addition to an experiment group where a DMSO solution containing TMP-CiKD_DMT was added. Cycloheximide as a protein synthesis inhibitor was added to the medium so as to give a concentration of 50 µg/
mL 12 hours after addition of TMP-CiKD_DMT or TMP-CiKD_DMT and bortezomib. It is noted that a DMSO solution containing TMP or DMSO was used as a control in place of the DMSO solution containing TMP-CiKD_DMT. - The medium was removed 24 hours after addition of TMP-CiKD_DMT or TMP-CiKD_DMT and bortezomib, and 1 mL of PBS (Wako Pure Chemical Industries, Ltd.) at 4°C was added to each well to wash the cells. After removing PBS, a mixed solution of a cell lysis buffer (CelLytic™ M, Sigma) and a protease inhibitor (complete™ Mini, EDTA-free (
REF 11 836 170 001), Roche) was added to each well at 55 µL/well. After allowed to stand at 4°C for 15 minutes, cells were detached with a pipette tip (P1000) on ice. A cell solution was collected in a 1.5 mL tube, and flash frozen in liquid nitrogen, and then thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13000 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected. - The cell extract collected was subjected to Western blot analysis. An SDS-PAGE gel (8 wells) was prepared using TGX™ FastCast™ Acrylamide Kit, 12% (Bio-Rad). Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 40 µL/well. Precision Plus Protein™ Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 150 V for 50 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- After electrophoresis, proteins were transferred to a PVDF membrane (Immobion™-P, Millipore) under conditions of 100 V and 40 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol). The membrane after transfer was shaken and blocked at room temperature for 30 minutes in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6). After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T. With regard to antibody, anti-HA-peroxidase, high-affinity (3F10) rat monoclonal antibody (25 U/mL) (Roche) diluted 1000 times was used. The membrane was shaken at room temperature for 1 hour, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- Next, a reaction for detecting GAPDH as a control was performed using the same membrane. The membrane was washed with TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6), and blocked by shaking at room temperature for 30 minutes in 5% skim milk/TBS-T. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T. As a primary antibody, anti-GAPDH antibody (sc-32233, SantaCruz, diluted 20000 times) was used. The membrane was shaken at room temperature for 60 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. After the primary antibody reaction, a secondary antibody reaction was performed in 2% skim milk/TBS-T. As a secondary antibody, anti-mouse IgG (H+L) antibody (A90-116P-33, BETHYL) diluted 20000 times was used. The membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation). Detected bands were quantified with an image processing software ImageJ (NIH).
-
Fig. 15A shows results from quantification of bands detected in the Western blot analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT or TMP-CiKD_DMT and bortezomib were added.Fig. 10B shows the detected bands. As can be seen inFigs. 15A and 15B , the degradation efficiency was about 60% relative to the control (DMSO) when TMP-CiKD_DMT (112 µM) was added. In contrast, degradation of the target protein was inhibited when TMP-CiKD_DMT (112 µM) and bortezomib (1 µM) were added. These results suggest that TMP-CiKD_DMT enabled the target protein to be led to degradation by a proteasome. - In Example 23, degradation (knockdown) of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib were added was evaluated by Western blot analysis.
- HeLa cells were prepared as in Example 2.
- A plasmid was introduced into HeLa cells to transiently overexpress E. coli DHFR as a target protein (specifically, a fusion protein of E. coli DHFR and GFP through a HA tag) or DsRed for comparison in the cells, and the effects of TMP-CiKD_DMT on the target protein were evaluated.
- The plasmid (pMIR DsRed-IRES-ecDHFR-HA-GFP) was provided by Professor Lizbeth Hedstrom at Brandeis University (the United States) (Long, M. J. et al., "Inhibitor mediated protein degradation." Chem. Biol., 2012, 19 (5), 629-637). The plasmid was amplified in E. coli, and purified with Miniprep Kit (Code No. 27106, QIAGEN).
- ScreenFect™ A (Code No. 297-73201, Wako Pure Chemical Industries, Ltd.) as a transfection reagent was used to introduce the plasmid into HeLa cells. A dilution buffer of ScreenFect™ A was added to two 1.5 mL tubes at 400 µL per tube. Then, 20 µL of a transfection reagent of ScreenFect™ A was added to one tube (a solution A), and 10.3 µg of the plasmid was added to the other tube (a solution B), and each tube was lightly pipetted, and then allowed to stand at room temperature for 2 minutes. The solution A was lightly mixed with the solution B, and allowed to stand at room temperature for 30 minutes (a solution C). The solution C was mixed in a cell solution of 8 x 105 cells/16 mL collected by trypsin treatment, and seeded on a 24-well plate (Code No. TR5002, TrueLine, Nippon Genetics Co., Ltd.) at a cell density of 4 x 104 cells/800 µL/well, and then cultured under conditions of 37°C and 5 vol% CO2 for 40 hours.
- Culture was performed for 40 hours after introduction of the plasmid, and then TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib was added to HeLa cells as follows. As a medium, used was a serum free medium (37°C) in which a 1 mass% L-glutamine solution (Code No. G7513, Sigma-Aldrich) was added to D-MEM (high D-glucose, phenol red, sodium pyruvate (Code No. 045-32245, Wako Pure Chemical Industries, Ltd.)). It is noted that the L-glutamine solution was added immediately before use. A DMSO solution containing TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib was mixed with the medium so that the concentration of DMSO was 1 vol%, and added to each well at 300 µL/well where the pre-culture medium had been removed, and cultured under conditions of 37°C and 5 vol% CO2. It is noted that a DMSO solution containing TMP or DMSO was used as a control.
- The medium was removed 24 hours after addition of TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib, and PBS (Wako Pure Chemical Industries, Ltd.) at 4°C was added to each well at 1 mL/well to wash the cells. After removing PBS, a mixed solution of a cell lysis buffer (CelLytic™ M, Sigma) and a protease inhibitor (complete™ Mini, EDTA-free (
REF 11 836 170 001), Roche) was added to each well at 30 µL/well. After allowed to stand at 4°C for 10 minutes, cells were detached with a pipette tip (P1000) on ice. A cell solution was collected in a 1.5 mL tube, and flash frozen in liquid nitrogen, and then thawed on ice. After repeating this freeze-thaw cycle for 3 times, the solution was centrifuged (at 13500 rpm x 20 minutes, 4°C), and the supernatant (cell extract) was collected. - The cell extract collected was subjected to Western blot analysis. An SDS-PAGE gel (12 wells) was prepared using TGX™ FastCast™ Acrylamide Kit, 12% (Bio-Rad). Electrophoresis samples were prepared in a 6x SDS-PAGE sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol, 0.25% BPB), and placed on a heat block at 95°C for 4 minutes. The electrophoresis samples prepared were applied to each well at 20 µL/well. Precision Plus Protein™ Dual Color Standards (Bio-Rad) were used as electrophoresis markers. Electrophoresis was performed at 160 V for 45 minutes (electrophoresis buffer; 195 mM glycine, 25 mM Tris).
- After electrophoresis, proteins were transferred to a PVDF membrane (Immobion™-P, Millipore) under conditions of 100 V and 35 minutes using a tank-type blotting device and a transfer buffer (25 mM Tris-HCl, 195 mM glycine, 0.01% SDS, 15% methanol). The membrane after transfer was shaken and blocked at room temperature for 30 minutes in 5% skim milk/high-salt TBS-T (100 mM Tris-HCl, 500 mM NaCl, 0.2% Tween-20, pH 7.6). After blocking, the membrane was rinsed with high-salt TBS-T, and an antibody reaction was performed in 1% skim milk/high-salt TBS-T. With regard to antibody, anti-HA-peroxidase, high-affinity (3F10) rat monoclonal antibody (25 U/mL) (Roche) diluted 500 times was used. The membrane was shaken at room temperature for 2 hours, and then washed with high-salt TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with high-salt TBS (100 mM Tris-HCl, 500 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation).
- Next, a reaction for detecting GAPDH as a control was performed using the same membrane. The membrane was washed with TBS-T (100 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.6), and blocked by shaking in 5% skim milk/TBS-T at room temperature for 30 minutes. After blocking, a primary antibody reaction was performed in 5% skim milk/TBS-T. As a primary antibody, anti-GAPDH antibody (sc-32233, SantaCruz, diluted 10000 times) was used. The membrane was shaken at room temperature for 60 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. After the primary antibody reaction, a secondary antibody reaction was performed in 2% skim milk/TBS-T. As a secondary antibody, anti-mouse IgG (H+L) antibody (A90-116P-33, BETHYL) diluted 20000 times was used. The membrane was shaken at room temperature for 30 minutes, and then washed with TBS-T for 5 minutes. It is noted that washing was performed for 3 times. Further, the membrane was washed with TBS (100 mM Tris-HCl, 150 mM NaCl, pH 7.6) for 5 minutes. Subsequently, the membrane was treated with a chemiluminescence reagent Immobilon™ Western (Millipore), and then chemiluminescence was detected using a lumino image analyzer LAS-3000 (FUJIFILM Corporation). Detected bands were quantified with an image processing software ImageJ (NIH).
-
Fig. 16 shows results from the Western blot analysis of a forcedly expressed target protein (E. coli DHFR) in HeLa cells to which TMP-CiKD_DMT, TMP-CiKD_MLN, TMP-CiKD_ALLN, or TMP-CiKD_Bortezomib was added. As can be seen inFig. 16 , when TMP-CiKD_DMT was added in an amount of 80 µM or 160 µM, the degradation efficiency relative to the control (DMSO) was 72% or 91%, respectively. Moreover, the degradation efficiencies of TMP-CiKD_MLN, TMP-CiKD_ALLN, and TMP-CiKD_Bortezomib at 160 µM was 82%, 45%, and 28%, respectively. - The disclosures of Japanese Patent Application No.
2015-123740 filed on June 19, 2015 2016-078324 filed on April 8, 2016 -
- |1| A protein-degradation inducing tag, which is a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease.
- |2| The protein-degradation inducing tag according to embodiment |1|, wherein the protein-degradation inducing tag has a structure where a protease inhibitory activity of a protease inhibitor is inactivated.
- |3| The protein-degradation inducing tag according to embodiment |1|, wherein the protease is a proteasome.
- |4| The protein-degradation inducing tag according to embodiment |3|, wherein the protein-degradation inducing tag has a structure where a proteasome inhibitory activity of a proteasome inhibitor is inactivated.
- |5| The protein-degradation inducing tag according to embodiment |4|, wherein the proteasome inhibiting activity is an inhibitory activity against at least one selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity.
- |6| A method of screening for a protein-degradation inducing tag, the method including a step of selecting a molecule having an affinity with a protease without inhibiting degradation of a protein by the protease from candidate molecules.
- |7| The method of screening for a protein-degradation inducing tag according to embodiment |6|, wherein the protease is a proteasome.
- |8| A method of manufacturing a protein-degradation inducing tag, the method including a step of modifying a structure of an active site of a protease inhibitor to inactivate a protease inhibitory activity.
- |9| The method of manufacturing a protein-degradation inducing tag according to embodiment |8|, the method further including a step of selecting, as the protease inhibitor, a molecule having an affinity with a protease and inhibiting degradation of a protein by the protease from candidate molecules.
- |10| A library of protein-degradation inducing tags, comprising two or more types of protein-degradation inducing tags, each of the two or more types of protein-degradation inducing tags being the protein-degradation inducing tag according to any one of embodiments |1| to |5|.
- |11| A protein-degradation inducing molecule, which is a conjugate of at least one protein-degradation inducing tag and at least one protein binding molecule capable of binding to a protein, the at least one protein-degradation inducing tag being the protein-degradation inducing tag according to any one of embodiments |1| to |5|.
- |12| A library of protein-degradation inducing molecules, comprising two or more types of protein-degradation inducing molecules, each of the two or more types of protein-degradation inducing molecules being the protein-degradation inducing molecule according to embodiment |11|.
- |13| A pharmaceutical composition, comprising the protein-degradation inducing tag according to any one of embodiments |1| to |5| or the protein-degradation inducing molecule according to embodiment |11|.
- |14| A method of degrading a target protein, the method comprising a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of embodiments |1| to |5| or the protein-degradation inducing molecule according to embodiment |11|.
- |15| A method of performing functional analysis on a target protein, the method comprising a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of embodiments |1| to |5| or the protein-degradation inducing molecule according to embodiment |11|.
- |16| A method of identifying a target protein, the method comprising a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of embodiments |1| to |5| or the protein-degradation inducing molecule according to embodiment |11|, and
a step of identifying a protein subjected to degradation induced by the protein-degradation inducing tag or the protein-degradation inducing molecule. - |17| A method of identifying a pathway molecule through a target protein, the method comprising a step of inducing degradation of the target protein using the protein-degradation inducing tag according to any one of embodiments |1| to |5| or the protein-degradation inducing molecule according to embodiment |11|, and
a step of identifying a protein showing an altered activity or expression, the protein being different from the target protein. - |18| A method of screening for a protein-degradation inducing tag or a protein-degradation inducing molecule, the method comprising a step of introducing the protein-degradation inducing tag according to any one of embodiments |1| to |5|, the library of protein-degradation inducing tags according to embodiment |10|, the protein-degradation inducing molecule according to embodiment |11|, or the library of protein-degradation inducing molecules according to claim 12 into a system including a target protein, and selecting a protein-degradation inducing tag or protein-degradation inducing molecule which has induced degradation of the target protein.
- |9| The method of screening for a protein-degradation inducing tag or a protein-degradation inducing molecule according to embodiment |18|, wherein the target protein is a disease causative agent, and the protein-degradation inducing tag or the protein-degradation inducing molecule which has induced degradation of the target protein is selected as a candidate ingredient for preventing or treating a disease.
- |20| A method of screening for a candidate ingredient for preventing or treating a disease, the method comprising a step of introducing the protein-degradation inducing tag according to any one of embodiments |1| to |5|, the library of protein-degradation inducing tags according to embodiment |10|, the protein-degradation inducing molecule according to embodiment |11|, or the library of protein-degradation inducing molecules according to claim 12 into a disease model system, and selecting a protein-degradation inducing tag or a protein-degradation inducing molecule which improves a condition of the disease.
- |21| A method of screening for a candidate ingredient for preventing or treating a disease, the method comprising a step of introducing the protein-degradation inducing tag according to any one of embodiments |1| to |5|, the library of protein-degradation inducing tags according to embodiment |10|, the protein-degradation inducing molecule according to embodiment |11|, or the library of protein-degradation inducing molecules according to claim 12 into a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which aggravates a condition of the disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
- |22| A method of specifying a disease-related protein, the method comprising a step of introducing the protein-degradation inducing tag according to any one of embodiments |1| to |5|, the library of protein-degradation inducing tags according to embodiment |10|, the protein-degradation inducing molecule according to embodiment |11|, or the library of protein-degradation inducing molecules according to claim 12 into a disease model system, and extracting a protein-degradation inducing tag or a protein-degradation inducing molecule which has altered a condition of a disease, and selecting a protein subjected to degradation induced by the extracted protein-degradation inducing tag or the extracted protein-degradation inducing molecule.
Claims (14)
- A method of degrading a target protein, the method comprising the step of inducing degrada-tion of the target protein using a protein-degradation inducing tag, wherein the protein-degradation inducing tag is a molecule having an affinity with a protease without inhibiting degradation of the protein by the protease, wherein the protein-degradation inducing tag can lead the target protein to degradation by a protease without ubiquitination of the target protein and wherein the protein-degradation in-ducing tag has a molecular weight within the range of 50 to 5000 g/mol.
- The method according to claim 1, wherein the protein-degradation inducing tag does not bind to the degradation active site of the protease via a covalent bonding.
- The method according to claim 1 or 2, wherein the protein-degradation inducing tag has the structure of a protease inhibitor in which the protease inhibitory activity of a protease in-hibitor is attenuated or is completely elimi-nated.
- The method according to anyone of claims 1 to 3, wherein the protease is a proteasome.
- The method according to claim 4, wherein the proteasome inhibiting activity is an inhibitory activity against at least one selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity.
- The method according to anyone of claims 1 to 5, wherein the protein-degradation inducing tag has been obtained by replacing the active site of a protease inhibitor with another structural moiety to inactivate the protease inhibitory activity.
- The method according to anyone of claims 1 to 6, wherein the protein-degradation inducing tag has a structure represented by following formu-la (I):
- The method according to anyone of claims 1 to 7, wherein the protein-degradation tag is a proteasome activator.
- The method according to anyone of claims 1 to 8, wherein the protein-degradation inducing tag is capable of binding to the target protein.
- The method according to anyone of claims 1 to 8, wherein the protein-degradation inducing tag is incapable of binding to the target protein and wherein the protein-degradation inducing tag is conjugated to a protein binding molecule that is capable of binding to the target pro-tein.
- The method according to claim 10, wherein the protein binding molecule is selected from the group consisting of an antibody, a peptide, a cytokine, a growth factor, a hormone, a natural product, a metabolite, a plant ingredient and a food ingredient.
- The method according to claim 10 or 11, wherein the protein-degradation inducing tag and the protein binding molecule are configured to be linked to each other.
- The method according to anyone of claims 1 to 12, wherein the protein-degradation inducing tag is added to an in vitro cell free protease degradation system or to a medium in which cells, a tissue or an organ is cultured, where-in the cells, the tissue or the organ have been derived from an eukaryote or a prokaryote which have a protease.
- The method according to claim 13, wherein the method further comprises- the step of analyzing the function of the target protein in the in vitro cell free protease degradation system, in the cells, in the tissue or in the organ after the protein-degradation inducing tag has been added,- the step of identifying a protein subjected to degradation induced by the protein-degradation inducing tag after the protein-degradation inducing tag has been added, or- the step of identifying a protein showing an altered activity or expression, the pro-tein being different from the target pro-tein, after the protein-degradation induc-ing tag has been added.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015123740 | 2015-06-19 | ||
JP2016078324 | 2016-04-08 | ||
PCT/JP2016/067852 WO2016204197A1 (en) | 2015-06-19 | 2016-06-15 | Protein degradation inducing tag and usage thereof |
EP16811671.3A EP3312273B1 (en) | 2015-06-19 | 2016-06-15 | Protein degradation inducing tag and usage thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16811671.3A Division EP3312273B1 (en) | 2015-06-19 | 2016-06-15 | Protein degradation inducing tag and usage thereof |
EP16811671.3A Division-Into EP3312273B1 (en) | 2015-06-19 | 2016-06-15 | Protein degradation inducing tag and usage thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3868878A2 true EP3868878A2 (en) | 2021-08-25 |
EP3868878A3 EP3868878A3 (en) | 2022-01-05 |
Family
ID=57545313
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16811671.3A Active EP3312273B1 (en) | 2015-06-19 | 2016-06-15 | Protein degradation inducing tag and usage thereof |
EP20215603.0A Pending EP3868878A3 (en) | 2015-06-19 | 2016-06-15 | Protein degradation inducing tag and usage thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16811671.3A Active EP3312273B1 (en) | 2015-06-19 | 2016-06-15 | Protein degradation inducing tag and usage thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US10976306B2 (en) |
EP (2) | EP3312273B1 (en) |
JP (1) | JP6954619B2 (en) |
KR (1) | KR20180021080A (en) |
CN (1) | CN107922927A (en) |
AU (1) | AU2016279493B2 (en) |
BR (1) | BR112017027246A2 (en) |
CA (1) | CA2988379A1 (en) |
HK (1) | HK1249546A1 (en) |
IL (1) | IL256217A (en) |
SG (1) | SG11201710272VA (en) |
WO (1) | WO2016204197A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107922927A (en) | 2015-06-19 | 2018-04-17 | 学校法人东京理科大学 | Breaks down proteins induction label and application thereof |
WO2018092723A1 (en) * | 2016-11-15 | 2018-05-24 | 学校法人東京理科大学 | Ras PROTEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION |
BR112019009565A2 (en) * | 2016-11-15 | 2019-10-08 | Univ Tokyo Science Found | molecular kinetics evaluation method and tracking method |
AU2017361157A1 (en) * | 2016-11-15 | 2019-06-06 | Tokyo University Of Science Foundation | p53 degradation inducing molecule and pharmaceutical composition |
CA3103185A1 (en) | 2018-06-13 | 2019-12-19 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
CN109761970B (en) * | 2019-01-26 | 2020-06-09 | 中国药科大学 | Protein targeted degradation chimeric molecule, preparation method and application |
CN114644682A (en) * | 2022-03-30 | 2022-06-21 | 海南双成药业股份有限公司 | Preparation method of bortezomib |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
WO2008123266A1 (en) | 2007-03-19 | 2008-10-16 | Reverse Proteomics Research Institute Co., Ltd. | Target protein and target gene for drug discovery, and screening method |
WO2012003281A2 (en) | 2010-06-30 | 2012-01-05 | Brandeis University | Small-molecule-targeted protein degradation |
JP2013056837A (en) | 2011-09-07 | 2013-03-28 | Japan Health Science Foundation | Apoptosis inhibitory protein ligand-estrogen receptor ligand hybrid compound, estrogen receptor decomposition inducing agent utilizing the same, and prophylactic and therapeutic agent for breast cancer, cervical cancer or ovarian cancer |
JP2015123740A (en) | 2013-12-27 | 2015-07-06 | キヤノン株式会社 | Ink set, and inkjet recording method |
JP2016078324A (en) | 2014-10-16 | 2016-05-16 | 株式会社呉竹 | Pen and refill for pen |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882941A (en) | 1994-05-04 | 1999-03-16 | Massachusette Institute Of Technology | Programmable genotoxic agents and uses therefor |
AU2864100A (en) * | 1999-02-01 | 2000-08-18 | Cytovia, Inc. | Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products |
US7371539B2 (en) * | 2003-12-03 | 2008-05-13 | President And Fellows Of Harvard College | Targeted polypeptide degradation |
ATE437185T1 (en) | 2005-03-25 | 2009-08-15 | Univ Ramot | HUMAN SYNTHETIC SINGLE CHAIN ANTIBODIES DIRECTED AGAINST THE COMMON EPITOPE OF MUTANT P53 AND APPLICATIONS THEREOF |
JP2009149524A (en) | 2006-03-16 | 2009-07-09 | Kyushu Univ | Prophylactic and therapeutic agent for alzheimer's disease |
US20100292129A1 (en) | 2007-05-24 | 2010-11-18 | Daniel Finley | Methods and Compositions for Enhancing Proteasome Activity |
JP5605658B2 (en) | 2009-04-30 | 2014-10-15 | 国立大学法人大阪大学 | Proteolytic induction method in mammalian cells |
WO2012078559A2 (en) * | 2010-12-07 | 2012-06-14 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
EP2802608A4 (en) * | 2012-01-12 | 2015-08-05 | Univ Yale | Compounds&methods for the enhanced degradation of targeted proteins&other polypeptides by an e3 ubiquitin ligase |
JP2013177444A (en) | 2013-05-18 | 2013-09-09 | Isao Kajisa | ORAL IMMORTALIZATION DRUG 5 FOR HUMAN iPS T CELL REDIFFERENTIATION AND REJUVENATION OF TELOMERE FOR ELIMINATION OF INFLAMMATORY AGING AND DECOMPOSITION OF P53 AND RB |
US10017540B2 (en) | 2015-03-11 | 2018-07-10 | California Institute Of Technology | Cyclic peptide binder against oncogenic K-Ras |
CN107922927A (en) | 2015-06-19 | 2018-04-17 | 学校法人东京理科大学 | Breaks down proteins induction label and application thereof |
BR112019009565A2 (en) | 2016-11-15 | 2019-10-08 | Univ Tokyo Science Found | molecular kinetics evaluation method and tracking method |
AU2017361157A1 (en) | 2016-11-15 | 2019-06-06 | Tokyo University Of Science Foundation | p53 degradation inducing molecule and pharmaceutical composition |
-
2016
- 2016-06-15 CN CN201680048166.8A patent/CN107922927A/en active Pending
- 2016-06-15 JP JP2017525270A patent/JP6954619B2/en active Active
- 2016-06-15 EP EP16811671.3A patent/EP3312273B1/en active Active
- 2016-06-15 BR BR112017027246-6A patent/BR112017027246A2/en not_active Application Discontinuation
- 2016-06-15 KR KR1020187001420A patent/KR20180021080A/en not_active Application Discontinuation
- 2016-06-15 US US15/736,089 patent/US10976306B2/en active Active
- 2016-06-15 WO PCT/JP2016/067852 patent/WO2016204197A1/en active Application Filing
- 2016-06-15 EP EP20215603.0A patent/EP3868878A3/en active Pending
- 2016-06-15 SG SG11201710272VA patent/SG11201710272VA/en unknown
- 2016-06-15 CA CA2988379A patent/CA2988379A1/en active Pending
- 2016-06-15 AU AU2016279493A patent/AU2016279493B2/en active Active
-
2017
- 2017-12-10 IL IL256217A patent/IL256217A/en unknown
-
2018
- 2018-07-12 HK HK18109054.4A patent/HK1249546A1/en unknown
-
2020
- 2020-12-02 US US17/109,187 patent/US20210088504A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
WO2008123266A1 (en) | 2007-03-19 | 2008-10-16 | Reverse Proteomics Research Institute Co., Ltd. | Target protein and target gene for drug discovery, and screening method |
WO2012003281A2 (en) | 2010-06-30 | 2012-01-05 | Brandeis University | Small-molecule-targeted protein degradation |
JP2013056837A (en) | 2011-09-07 | 2013-03-28 | Japan Health Science Foundation | Apoptosis inhibitory protein ligand-estrogen receptor ligand hybrid compound, estrogen receptor decomposition inducing agent utilizing the same, and prophylactic and therapeutic agent for breast cancer, cervical cancer or ovarian cancer |
JP2015123740A (en) | 2013-12-27 | 2015-07-06 | キヤノン株式会社 | Ink set, and inkjet recording method |
JP2016078324A (en) | 2014-10-16 | 2016-05-16 | 株式会社呉竹 | Pen and refill for pen |
Non-Patent Citations (11)
Title |
---|
DEMIZU, Y. ET AL.: "Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy.", BIOORG. MED. CHEM. LETT., vol. 15, 2012, pages 1793 - 1796 |
HINES, J. ET AL.: "Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs", PROC. NATL. ACAD. SCI. U.S.A., vol. 110, no. 22, 2013, pages 8942 - 8947, XP055709194, DOI: 10.1073/pnas.1217206110 |
ITOH, Y. ET AL.: "Development of target protein-selective degradation inducer for protein knockdown", BIOORG. MED. CHEM., vol. 19, 2011, pages 3229 - 3241, XP028384646, DOI: 10.1016/j.bmc.2011.03.057 |
KAISER, M. ET AL., CHEM. BIO. CHEM., vol. 5, 2004, pages 1256 - 1266 |
KISSELEV, A. F. ET AL., CHEMISTRY BIOLOGY, vol. 19, 2012, pages 99 - 115 |
KISSELEV, A.F. ET AL., CHEMISTRY & BIOLOGY, vol. 19, 2012, pages 99 - 115 |
LONG, M. J. ET AL.: "Inhibitor mediated protein degradation", CHEM. BIOL., vol. 19, no. 5, 2012, pages 629 - 637, XP055119226, DOI: 10.1016/j.chembiol.2012.04.008 |
LONG, M. J. ET AL.: "Inhibitor mediated protein degradation.", CHEM. BIOL., vol. 19, no. 5, 2012, pages 629 - 637, XP055119226, DOI: 10.1016/j.chembiol.2012.04.008 |
NEKLESA, T.K. ET AL.: "Greasy tags for protein removal.", NATURE, vol. 487, 2012, pages 308 - 309 |
SCIENCE, vol. 265, 1994, pages 1234 - 1237 |
SCIENCE, vol. 316, 2007, pages 1349 - 1353 |
Also Published As
Publication number | Publication date |
---|---|
EP3312273A1 (en) | 2018-04-25 |
AU2016279493A1 (en) | 2017-12-14 |
WO2016204197A1 (en) | 2016-12-22 |
AU2016279493B2 (en) | 2022-08-11 |
JP6954619B2 (en) | 2021-10-27 |
HK1249546A1 (en) | 2018-11-02 |
SG11201710272VA (en) | 2018-01-30 |
KR20180021080A (en) | 2018-02-28 |
US10976306B2 (en) | 2021-04-13 |
IL256217A (en) | 2018-02-28 |
JPWO2016204197A1 (en) | 2018-05-31 |
CN107922927A (en) | 2018-04-17 |
US20210088504A1 (en) | 2021-03-25 |
EP3312273B1 (en) | 2024-07-24 |
BR112017027246A2 (en) | 2018-08-28 |
CA2988379A1 (en) | 2016-12-22 |
US20180164289A1 (en) | 2018-06-14 |
EP3868878A3 (en) | 2022-01-05 |
EP3312273A4 (en) | 2019-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210088504A1 (en) | Protein degradation inducing tag and usage thereof | |
US11007269B2 (en) | P53 degradation inducing molecule and pharmaceutical composition | |
US20190369111A1 (en) | Molecular kinetics evaluation method and screening method | |
TWI811197B (en) | Ras proteolysis-inducing molecules and medicinal compositions | |
US20150273010A1 (en) | High-throughput assays for hiv-1 envelope maturation and novel peptide inhibitors against hiv-1 | |
Lundblad | Biochemistry and molecular biology compendium | |
Kaminska | New activity-based probes to detect matrix metalloproteases | |
Lukasiak | Elucidating the cause of FAT10 over-expression in liver and colon carcinomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AC | Divisional application: reference to earlier application |
Ref document number: 3312273 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 5/00 20060101ALI20211129BHEP Ipc: C12Q 1/02 20060101ALI20211129BHEP Ipc: C07D 239/49 20060101ALI20211129BHEP Ipc: A61K 38/00 20060101ALI20211129BHEP Ipc: C12N 9/00 20060101AFI20211129BHEP Ipc: A61P 43/00 20060101ALI20211129BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220608 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220715 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240326 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |